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General Introduction and Outline 
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Introduction 
Patients frequently have to make decisions in a vulnerable, emotionally laden state in a 
theatre that is undesirable, without having a comprehensive understanding of the treatment 
or screening options available and what they entail [1]. Considering this perspective, how 
can researchers support a framework for exploring opportunities to level power structures 
in healthcare delivery systems, build connections between patients, clinicians, and 
administrators and strengthen long-term solutions in various settings? 
 
The quality and pattern of communication is an essential variable in the complex patient-
clinician relationship that has evolved over time [1]. Seminal work in social sciences 
research indicates that the traditional role and expectation of the clinician is to determine 
the patient’s course of action based on their medical expertise, with the patient accepting a 
more passive role in the clinical encounter [2-4]. However, this communication style or 
model of care is generally not preferred by patients who increasingly expect their clinician 
to communicate the advantages and disadvantages of each treatment option related to their 
health condition, particularly when there is a preference-sensitive decision at stake [1]. It is 
a process known as shared decision making (SDM) which is a model that promotes patient-
centered care [1].  
 
Patient decision aids have been developed to facilitate the SDM process, but many gaps in 
the literature exist regarding the outcomes associated with their use on the internet and in 
the clinical encounter and the barriers and facilitators to their implementation in practice 
settings. The following section will introduce SDM and patient decision aids as a segue 
into the research studies that address the gaps in the literature.  
 
Shared decision-making (SDM) 
 
 What is it? 
 
Katz used the term ‘SDM’ in a 1984 book titled The Silent World of Doctor and Patient in 
which he challenges the paternalistic nature of patient-clinician relationships [5]. Since 
then, various authors have tried to define SDM with a considerable degree of overlap 
[1,6,7]. A recent definition taken from the second edition of Elwyn and Edwards’ book 
provides nuance and considers the patient perspective: SDM is ‘involving the patient in 
decision-making, to the extent that they desire [1]. Clinicians need to be able to gauge the 
patient’s preferred level of involvement, and then employ skills and competencies to 
achieve the preferred level of involvement, whether a clinician-led, shared, or patient-led 
decision’ [1]. Considering the patient’s desire for involvement in the decision-making 
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process, certain medical situations arise where the ‘best’ course of treatment action is 
unclear. In these situations of equipoise, information provision by the clinician can help 
patients consider the benefits and harms of various treatment or screening options, so they 
can make a decision that aligns with their preferences [6]. The sharing of information 
between patient and clinician mitigates the power asymmetry and provides an opportunity 
to elicit the patient’s preferences [7-9]. This process of mutuality is known as SDM.  
 
Researchers have developed various models to help clinicians conceptualize and 
operationalize SDM [10]. Early research drew distinctions between different 
communication styles, including paternalism versus SDM, to clarify the patient’s role [11]. 
Once SDM was conceptualized and the role of the patient clarified, a model was proposed 
by Charles et al. to help clinicians practice SDM: information exchange, deliberation, and 
treatment decision [6]. At the same time, Towle et al. listed a set of competencies for both 
clinicians and patients that encompassed the key components of establishing a relationship 
by defining roles and preferences, sharing and evaluating information, and a final 
negotiation prior to the decision [12]. In 2006, a systematic review investigated the 
commonalities among the existing models and identified the nine essential elements of the 
SDM process: define and explain the problem, present the options, discuss the pros and 
cons, discuss patient preferences and self-efficacy, clinician recommendation, check 
patient understanding, make or defer medical decision, and arrange follow-up [10]. A 
recent ‘three-talk’ model by Elwyn et al. encompasses these elements: team talk, option 
talk, and decision talk. It serves as a ‘primer, a reminder, and a guide’ to practice SDM and 
has emerged as the prominent model due to its simplicity and flexible approach to active 
listening and deliberation while keeping the core elements of prior SDM mechanisms [13].  
 
 Why is it an important approach to consider? 
 
The patient-clinician interaction has been predominantly paternalistic [14,15]. The 
paternalistic model limits the patient’s role in the decision-making process by having the 
clinician dictate the medical course of action and the amount of information provided to 
the patient [5,14]. The balance of authority is heavily in favor of the clinician who assumes 
that the patient will ‘passively acquiesce’ to decisions being made [16]. The foundation of 
this model is based on many assumptions or expectations: (i) the clinician always acts in 
the best interest of the patient, without the need to elicit their values; (ii) clinicians possess 
knowledge of the most up-to-date clinical evidence, and the experience to evaluate the 
trade-offs between treatment options dismissing the need for patient input; (iii) patients do 
not want decisional responsibility [15]. These factors, in combination with the desire to be 
viewed as a ‘good patient,’ leave many patients facing a decision with a lack of knowledge 
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and a reluctance to voice their opinion and concerns in the encounter [16]. Hence, ethical 
issues revolving around autonomy and consent have many patients and health professionals 
questioning the validity of the paternalistic model, with many calling for a paradigm shift 
to a more patient-centered approach, such as SDM. A patient not exposed to all 
information regarding the benefits and drawbacks of treatment options when a preference-
sensitive decision is required cannot be fully informed [17,18]. Ethicists argue that 
informed consent is not realized in paternalistic medicine [19,20]. Furthermore, 
paternalism de-emphasizes patient autonomy [20]. The lack of consumer protection leaves 
patients vulnerable and may lead to ‘acting without understanding’ [14].  
 
SDM is a critical approach to consider because it addresses the ethical gaps of the 
paternalistic model [21]. SDM requires preference elicitation and information provision to 
enable patients to be more knowledgeable and prepared to make a decision [21,22]. There 
is also the element of ‘checking understanding,’ thus ensuring that patients receive and 
understand information [22]. The principle of beneficence is respected, but so is the 
patient’s autonomy. Not only is SDM considered the pinnacle of ethical medical care, but 
this patient-centered concept also improves outcomes such as knowledge, risk perception, 
satisfaction, and participation in the decision-making process [23-25]. Ethnographic data 
supports the assertion that the respect for agency that comes with SDM makes patients feel 
respected by their health professional, which improves the sense of comfort with the 
treatment decision [26]. Ultimately, most patients prefer informed, active involvement in 
the decision-making process as opposed to the paternalistic approach [27,28]. SDM is an 
essential approach to consider because it is ethically sound, improves patient-clinician 
communication, and meets the patient desire to be involved in the decision-making process 
[18,20]. 
 
 What can help facilitate SDM? 
 
Following the emergence of the SDM approach was the development of tools, in particular, 
patient decision aids, to facilitate its practice [25,29]. Patient decision aids are tools 
designed to provide evidence-based information, in a balanced fashion, of the available 
treatment or screening options with the aim of helping users ‘construct, clarify, and 
communicate’ their preferences [30]. They can help guide decision-making by presenting 
alternatives without leading a patient to a certain decision [30]. The knowledge gained 
from these tools can increase the quality of decision-making and improve communication 
with a clinician. It is important to note, however, that these tools are not designed or meant 
General introduction and outline | 11 
to replace the actual patient-clinician conversation [31]. Nor does it signify that SDM 
occurs only when decision aids are administered [31].  
 
Development of patient decision aids began in the 1980s and has since intensified [25]. 
The development of the International Patient Decision Aids Standards (IPDAS) ensured 
the quality and safety of these tools [30]. This checklist aims to ensure that the information, 
and the format in which it is presented, is high-quality and not affected by competing 
interests [30]. In 2003, the first IPDAS Collaboration was established and identified a 74-
item checklist to inform the Delphi process that would later take place [32]. The checklist 
was validated and deemed reliable to assess the quality of decision support technologies 
and was condensed to a 47-item checklist [30,32-34]. Recently, efforts have been made to 
develop minimum standards to certify patient decision aids (based on IPDAS) if they meet 
qualifying, certification, and quality criteria [35]. These standards have been adopted and 
are currently being used by the Washington State Healthcare Authority to certify patient 
decision aids. A process for certification at the national level in the US is currently taking 
place following the formation of a multi-stakeholder panel by the National Quality Forum 
in 2016, but has not, as of 2018, been implemented [35]. 
 
Patient decision aids 
 
 Effects of these tools on patients/users 
 
A Cochrane systematic review and meta-analysis of the effects of patient decision aids has 
been periodically updated over the past 17 years [23-25]. Results of this review, which 
include over 100 randomized trials, indicate that compared to usual care, patient decision 
aids increase ‘patient knowledge of options and risks, accuracy of risk perceptions, and 
congruency between informed values and care choices’ [25]. Use of these tools also 
significantly decrease decisional conflict, indecision about personal values, and the level of 
acquiescence in the decision-making process [25]. Patients also tend to feel more satisfied 
with the decision-making process and the quality of communication with their clinician 
and more prepared to make a decision [25]. Users of decision aids also tend to shift their 
preference to more risk-averse treatment options [25,36]. For example, there was a 
reduction in the number of patients choosing elective invasive surgery or the prostate-
specific antigen (PSA) test when using decision aids versus usual care. Additionally, there 
are no adverse outcomes associated with using these tools [25]. 
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Patient decision support interventions are classified into three different categories: 
encounter-based interventions, tools that can be used independently by patients outside the 
clinical encounter, and interactive, web-based interventions [29]. As part of the Cochrane 
review of patient decision aids, a subgroup analysis was conducted comparing two types of 
tools – traditional patient decision aids (designed for independent use) versus encounter 
patient decision aids [25]. These pre- or post-encounter patient decision aids are typically 
longer and more complex compared to tools designed for the clinical encounter [25].  
 
Encounter tools are not as comprehensive but are ‘designed to encourage and directly 
support’ the patient-clinician conversation [31]. Regardless of type, they also aim to 
provide outlines to patients on treatment or screening options relevant to their condition 
[31]. Ideally, more detailed tools prepare patients for SDM, whereas encounter tools 
facilitate a discussion of the treatment options in the clinic visit and elicitation and 
integration of patient preferences [25,31]. In the Cochrane systematic review analysis, 
there were no significant differences in terms of patient outcomes between the two types of 
tools; however, there have been far fewer randomized trials with encounter patient decision 
aids as the intervention compared to tools designed for independent use [25]. It is also 
important to consider the potential advantages of web-based patient decision aids which 
are increasingly studied and which could potentially be used to bypass some of the barriers 
to clinical implementation of these tools. 
 
 Barriers to implementation in clinical settings 
 
Supported by the evidence that patient decision aids have a positive effect on patient 
outcomes and the decision-making process, some healthcare organizations have attempted 
to implement these tools in the hopes of creating a more patient-centered experience for 
their clients [37-39]. Examples of organizations include the Dartmouth-Hitchcock Medical 
Center (DHMC) and Massachusetts General Hospital in the US and the National Health 
Service (NHS) in the United Kingdom who have made financial and political commitments 
to integrate decision aids in the clinic workflow patterns. According to a recent editorial, 
many more Western countries have crafted policies, or are considering legislation 
promoting SDM and the use of decision aids in clinical settings [40]. Despite the political 
thrust to use decision aids to support patient-centered care, implementation challenges 
persist. 
 
The authors of a book published in 2013, ‘Are we there yet?’ which consisted of a series of 
case studies, highlighted the barriers and facilitators to implementation of patient decision 
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aids [41]. There is a significant reluctance on the part of clinicians to adopt these tools as 
‘adjuncts’ to the clinical conversation [41]. Many clinicians feel that patient decision aids 
are seldom applicable to their patients and their respective clinical situations [42-44]. In 
particular, the content and format of these tools make them incompatible for patients with 
low health literacy skills [45-47]. Disagreement with the content of patient decision aids 
and the numerous competing priorities that clinicians face impose considerable barriers to 
their implementation [45-47]. Also, clinicians often project that many of their patients do 
not want ‘decisional responsibility’ [42-44]. The most frequently cited barrier, however, is 
the perceived time pressures that using decision aids add to the duration of encounters. All 
of these barriers affect the clinician’s willingness to adopt these tools routinely in their 
practice [42-47].  
 
Logistical barriers and infrastructure challenges are also present in organizations which 
hinder implementation: the process of identifying a patient candidate to receive the 
appropriate decision aid, the individual who will provide the tool, and the timing of 
dissemination all require efficient communication among the clinical staff. This system-
level change requires a coherent grassroots strategy backed by organizational support to 
provide training on why and how these tools are used [37,38,48]. Creating an SDM culture 
within the clinic to foster a more positive attitude among clinicians regarding the use of 
patient decision aids can address some of the systemic issues with implementation 
[37,38,42-44]. A scoping review conducted by Scholl et al. re-iterated and categorized 
these organizational and systemic barriers to decision aid implementation [49]. Having 
information dissemination strategies and scheduling routines so that each professional in 
the health system understands his or her role in the implementation of the tool is critical 
[49]. Implementing financial incentives for using decision aids, creating policies and 
guidelines promoting decision aid use, and trying to cultivate a culture of healthcare 
delivery that is accepting of these tools through education are all system-level strategies 
that have resulted in varying degrees of success [49]. Despite this body of evidence, more 
research is needed to explore the barriers and facilitators to different strategies to 
implement patient decision aids across different cultural and clinical settings. 
 
 Can web-based patient decision aids represent a solution to implementation struggles? 
 
Millions of Americans use the internet to search for health information related to their 
condition. The public need for freely accessible, evidence-based information in 
combination with the increasing movement toward creating online content has led decision 
aid developers to create another mode of delivery – web-based decision aids [50]. Results 
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of randomized controlled trials (RCTs) using online tools as the intervention indicate that 
they have a similar impact on patient outcomes (i.e., increase in patient knowledge and 
reduction in decisional conflict) as paper-based decision aids [51-54]. Due to the novelty of 
these tools, a paucity of data exists regarding the usability and acceptability of these tools 
with patient populations with varying health literacy levels [55]. Also, researchers have yet 
to explore the impact these tools have on the decision-making process (what information is 
associated with preference shift), and whether unsolicited, independent use is associated 
with similar outcomes to traditional patient decision aids. These gaps have obvious 
implementation implications which could lead to a better understanding of whether online 
tools represent a solution to the current struggle of routine adoption.  
 
 Option Grid patient decision aids 
 
Variations of encounter patient decision aids have been developed and used in practice. 
Examples include the Mayo Clinic issue cards, Université de Laval Decision Boxes 
(Dboxes), and Option GridTM patient decision aids [56-59]. The issue cards and the 
DBoxes provide brief, evidence-based information on the pros and cons for various 
treatments of different health conditions or screening tests [58,59]. Option Grid presents 
evidence-based answers to frequently asked questions (FAQs) for various treatment or 
screening options of different health conditions in a tabular format [56]. They are brief 
tools designed for use in the clinical encounter and are available in paper or on the web – 
the interactive version [56]. The interactive Option Grid enables users to identify their 
preference for a treatment option or screening test before and after viewing the FAQs [36]. 
For each FAQ, the patient identifies their preference-leaning based on the evidence-based 
information provided and rates how important that information is in formulating their 
preference [36]. This thesis focused on these tools, which are examples of comparison 
tables.  
 
Several studies were conducted to assess the impact associated with Option Grid use in the 
clinical encounter, and their feasibility to be implemented in practice [56,57,60-62]. A 
stepped wedge trial that used the knee osteoarthritis Option Grid collected observational 
data which demonstrated the tools’ facilitation of SDM without significantly increasing 
encounter duration [57]. Published qualitative evidence also indicates that patients and 
clinicians highly value Option Grid decision aids to explain the existence of options and 
increase patient involvement in the decision-making process [56,62]. However, despite 
these positive outcomes, Tsulukidze et al. and the Wood et al. studies, which assess the 
impact of using an Option Grid with an interpreter in the encounter, shows that training is 
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needed on how to appropriately use the tool to achieve “optimal levels of SDM” core 
concepts [60,61].  
 
We used Option Grid patient decision aids instead of other encounter tools, not only 
because they were developed by the Preference Laboratory where research for this thesis 
was conducted, but because some healthcare organizations across different clinical and 
cultural contexts have chosen to adopt these tools in clinical practice due to their brief, 
practical design. Their availability in the paper-based and interactive formats, therefore, 
enabled examination of the research gaps (see section below) on the effects of encounter 
tools on decision-making processes and their implementation in clinical settings. It is 
important to note, however, that since the completion of this doctoral work, Option Grid 
decision aids are no longer available for public viewing but will return to be freely 
available in the future.  
 
Study rationale and research objectives 
 
 Objective 1: Determine the effect associated with the use of encounter patient decision 
aids by conducting a meta-analysis of RCTs, and a narrative synthesis of non-
randomized studies to determine the feasibility, utility, and integration into clinic 
workflow from different stakeholder perspectives. 
 
Research on the effects of patient decision aids has focused primarily on tools designed for 
independent use (outside the clinical encounter). Fewer randomized trials have been 
conducted with patient decision aids designed for the clinical encounter – encounter patient 
decision aids. With an increasing focus on patient-centered care in recent years, some 
healthcare organizations are beginning to implement encounter tools to facilitate SDM to 
try and improve patient outcomes and experience. There is little known about the effects of 
these encounter tools or how they impact clinic workflow patterns. For this reason, we 
decided to conduct the first comprehensive, systematic review of encounter patient 
decision aids. We assessed all randomized trials to determine the effects of encounter tools, 
and conducted a narrative synthesis of non-randomized studies to better understand their 
implementation from different stakeholder perspectives. 
 
 Objective 2: Determine if using the interactive Option Grid patient decision aids led to a 
pre-post shift in preferences; which FAQs led to preference shifts; which FAQs were 
rated as the most important as users compared options. 
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Randomized trials indicate that patient decision aids lead to patients having different 
preferences and making different choices. They also have a positive impact on patient 
outcomes such as increased knowledge of risks and benefits of different treatment options, 
reduction in decisional conflict, and more accurate risk perception, but little is known 
about the active ingredients in these tools that shift preference. We have a poor 
understanding of the impact of these tools on patient preference and the type of 
information that is highly valued by individuals who use these tools. To address this gap in 
the research, we set out to analyze data from the most highly used web-based, interactive 
Option Grid decision aids to better understand information that shifts user preference and 
identify the most valued information in these tools.  
 
 Objective 3: Determine the impact of publicly available web-based PSA Option Grid 
patient decision aids on preference shift, knowledge, and decisional conflict; identify 
which FAQs are associated with preference shift; explore the possible relationships 
between these outcomes. 
 
Patient outcomes have always been measured in a study context, often with incentives for 
participation. Seldom are studies conducted to measure patient outcomes from an 
unsolicited sample of individuals who search for health information independent of any 
invitation. Do the results mirror those found in randomized trials? To address this gap, we 
conducted a cross-sectional analysis from a longitudinal sample derived from the Option 
Grid website where patients had a choice of using pdf or interactive versions to determine 
if using this web-based tool increased knowledge, reduced decisional conflict, and shifted 
user preference. Similar to the previous study, we wanted to identify which FAQs shifted 
preference to see if a pattern emerged. 
 
 Objective 4: User-test the ‘PSA test: yes or no?’ web-based, interactive Option Grid 
patient decision aid to determine the usability, acceptability, and feasibility with men of 
higher and lower health literacy. 
 
Part of the IPDAS criteria advises developers of patient decision aids to user-test their 
interventions with the target audience ahead of publication, yet this seldom occurs, 
particularly for web-based tools. With only 12% of the US adult population possessing 
proficient health literacy, developers of web-based patient decision aids may be publishing 
tools that are not usable by large sections of the population. Those that do conduct user-
testing often exclude vulnerable populations such as individuals with low health or 
computer literacy. Primary reasons include insufficient financial resources and access to 
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these populations. In the context of web-based tools for the PSA test, only one has been 
user-tested; and it did not include any vulnerable populations. Therefore, prior to studying 
the patient outcomes associated with the interactive, web-based Option Grid patient 
decision aids, we chose to user-test the ‘PSA test: yes or no?’ tool to determine if it was 
usable, feasible, and acceptable to individuals with high and low health literacy skills.   
 
 Objective 5: Examine the use of Option Grid patient decision aids in a sample of clinics 
in Warsaw, Poland, and measure their impact on SDM. 
 
The known positive effects of SDM have made many policymakers in Western countries 
promote its practice. In contrast, Eastern European countries have yet to consider the 
implementation of this rather novel clinical approach. Some evidence suggests that SDM 
would be incompatible with patient expectations in this part of the world. Furthermore, 
clinicians are not introduced to this approach in their medical education; so, there’s no 
indication that SDM or the use of patient decision aids is at all practiced in Eastern Europe. 
We know the implementation challenges at various levels in healthcare systems, but these 
have generally been studied in Western countries. We conducted an implementation study 
of encounter patient decision aids (we used Option Grid) in a sample of clinics in Warsaw, 
Poland to determine their impact on SDM.  
 
 Objective 6: Use the Normalization Process Theory (NPT) to explore how and why two 
separate healthcare organizations in the United States (US) had spontaneously adopted 
Option Grid patient decision aids in routine clinical practice and investigate the factors 
that have facilitated routine use. 
 
Implementation of patient decision aids in clinical practice faces many challenges. Time 
constraints, lack of training on how to use these tools, misunderstanding of these tools’ 
values and how they can help practice SDM, clinician attitude toward their 
implementation, and disagreement with their content have all been cited barriers to routine 
integration of decision aids into clinic workflow patterns. Despite legislation promoting the 
use of tools to facilitate SDM, very few healthcare organizations have made financial and 
political commitments in the US to implement encounter patient decision aids to practice 
SDM. We became aware of two organizations – HealthPartners in Minnesota and Capital 
Care in New York – that used contrasting strategies to routinely implement Option Grid 
encounter patient decision aids. This provided us with a unique opportunity to conduct two 
case studies to better understand the systemic mechanisms used to implement encounter 
tools. 
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Abstract 
 
Objective: To determine the effect of encounter patient decision aids (PDAs) as evaluated 
in randomized controlled trials (RCTs) and conduct a narrative synthesis of non-
randomized studies assessing feasibility, utility and their integration into clinical 
workflows. 
 
Methods: Databases were systematically searched for RCTs of encounter PDAs to enable 
the conduct of a meta-analysis. We used a framework analysis approach to conduct a 
narrative synthesis of non-randomized studies. 
 
Results: We included 23 RCTs and 30 non-randomized studies. Encounter PDAs 
significantly increased knowledge (SMD= 0.42; 95% CI 0.30, 0.55), lowered decisional 
conflict (SMD= -0.33; 95% CI -0.56, -0.09), increased observational-based assessment of 
shared decision making (SMD= 0.94; 95% CI 0.40, 1.48) and satisfaction with the 
decision-making process (OR= 1.78; 95% CI 1.19, 2.66) without increasing visit durations 
(SMD= -0.06; 95% CI -0.29, 0.16). The narrative synthesis showed that encounter tools 
have high utility for patients and clinicians, yet important barriers to implementation exist 
(i.e. time constraints) at the clinical and organizational level. 
 
Conclusion: Encounter PDAs have a positive impact on patient-clinician collaboration, 
despite facing implementation barriers. 
 
Practical implications: The potential utility of encounter PDAs requires addressing the 
systemic and structural barriers that prevent adoption in clinical practice.  
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Introduction 
Most research on patient decision aids (PDAs) has focused on interventions designed to be 
used independently by patients, before or after the clinical encounter. Recently, there has 
been increasing interest in tools that are brief, and designed to facilitate collaboration 
between patients and clinicians in clinical encounters – the term encounter PDAs has 
become widely recognized [1,2]. Interest in these tools arose partly due to the difficult task 
of implementing pre-encounter decision aids [3], which were typically more 
comprehensive and complex [4-7]. We should acknowledge however that the idea of using 
tools to stimulate collaboration in clinical encounters has been present for decades, as 
exampled by Whelan’s decision boards [8,9] and Elwyn and Edwards’ risk communication 
tools [10,11]. Nevertheless, there has been more interest in encounter PDAs over the last 
decade, given their potential to change conversations, and that they might prove easier to 
introduce into practice workflows. 
 
A systematic review of PDAs indicates that tools designed for independent use by patients 
increase patient knowledge, understanding of risk, preparedness to make decisions, and 
reduce decisional conflict [12]. There is no doubt that the information embedded in PDAs 
enables users to be better informed and develop more ‘accurate expectations of benefits 
and harms’ [12]. The use of a PDA also significantly increases participation in decision-
making processes [12], as reported by patients. When outcomes for patients exposed to 
PDAs before or during encounters were compared, no difference in knowledge gained or 
accuracy of their risk perception scores were observed [12]. Variation in how studies were 
evaluated preclude comparison on other outcomes [12].  
 
Variability exists in the outcome measures used in randomized controlled trials (RCTs) of 
PDAs [8-10,13-32]. Most outcomes are measured using self-report (patient-reported 
outcome measures (PROMs)); some studies also used observational measures [8-10,13-
33]. Observational measures have mostly been used in trials of encounter PDAs to measure 
the process of shared decision making (SDM), whereas trials with pre-encounter tools have 
typically used PROMs of perceived SDM [14,17,19,22,23,25,26,31]. Arguably, data from 
observational measures allow more objective conclusions about the effects of PDAs on 
SDM and patient-clinician communication.   
 
The implementation of PDAs in clinic workflows remains a challenge [34-36]. From the 
clinician’s perspective, time constraints, competing priorities, lack of training on how to 
use PDAs, and distrust in the content are cited as barriers [2,35,37-39]. Some clinicians 
also report that many patients shun decisional responsibility [35,40]. Clinicians are often 
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wary of using PDAs [41,35,42,43]. At the organizational level, the absence of clear 
advantages to the use of PDAs impedes implementation [41,44]. Given these challenges, 
might it be easier to implement encounter PDAs, which are briefer and, arguably, allow 
more flexible use? No reviews to date have focused on encounter PDAs [12]. Furthermore, 
little is known about the feasibility, utility and integration of encounter PDAs into routine 
workflows. Despite a decade or more of work on encounter PDAs, none of this research 
has been summarized, so we therefore conducted a systematic review of the relevant 
literature. 
 
The systematic review aimed to: 1) determine the effect associated with the use of 
encounter PDAs by conducting a meta-analysis of RCTs, and 2) conduct a narrative 
synthesis of non-randomized studies to determine the feasibility, utility and integration into 
clinical workflow from different stakeholder perspectives. 
 
Methods 
The PRISMA guidelines guided our approach to data collection and analysis (see 
Appendix 1). The study protocol was developed before the search was conducted 
(PROSPERO – registration # CRD42018084732).  
 
Inclusion criteria 
For aim 1, we included only identified RCT designs. The population, intervention, control, 
outcomes, study design (PICOS) criteria were used to assess study eligibility. We did not 
impose a population-type restriction. We defined encounter PDAs as tools designed for use 
by clinicians and patients during clinical encounters. Studies of PDAs not designed for 
collaborative use during clinical encounters were excluded. We considered three types of 
control arm conditions: 1) usual care without an encounter PDA; 2) the use of a pre-
encounter PDA for use independently by patients; and 3) other types of educational content 
(pamphlets, guidelines, booklets) provided to patients before, during, or after their visit, but 
not defined as an encounter PDA. We included primary and secondary study-specified 
outcomes. 
 
For aim 2, we included non-randomized study designs that presented empirical data where 
an encounter PDA was the intervention. We excluded editorials and commentaries. We 
included studies where stakeholders’ (patient, healthcare provider, healthcare 
professionals, and others) perspectives regarding the feasibility, utility, and integration of 
these tools into clinic workflows was examined.  
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Data sources and search strategy 
An electronic search strategy, developed by an information scientist (TM), was adapted for 
the following databases: Medline, PsycINFO, Web of Science, CINAHL, and the Cochrane 
Library from inception to November 16, 2017. We identified articles that assessed the 
impact (aim 1) and/or feasibility, utility, and integration of encounter PDAs in clinic 
workflows (aim 2). The search strategy included a combination of key words and medical 
subject headings (MeSH) terms related to “clinical encounter”, “patient decision aids”, and 
“patient-provider communication/shared decision making”. See Appendix 2 for the 
complete search strategy used in Medline. We adapted our search to ensure efficient 
coverage [45]. We did not impose restrictions on date of publication or language for aim 1 
and aim 2. To avoid duplication, we excluded systematic reviews. We also searched 
Google Scholar using each keyword and MeSH term and screened the first 50 results. To 
increase sensitivity, we manually reviewed citations in the included studies. Abstracts from 
scientific meetings and conferences (i.e. International Shared Decision Making 
conferences, Annual North American Meeting of the Society for Medical Decision 
Making, and the International Conference on Communication in Healthcare & Health 
Literacy Annual Research conference) were reviewed (2000-November 16, 2017), and 
checked whether relevant abstracts had led to publications.  
 
Study selection 
After removing duplicate publications, the titles and abstracts of included studies were 
independently screened by two researchers (PS and JB). Disagreements about inclusion 
were resolved by discussion with a third researcher (GE), see Figure 1. Full-text articles 
were reviewed by three study authors (PS, JB, NP) to check if inclusion criteria were met. 
Where doubt remained, the studies were reviewed by GE, and authors contacted.   
 
Data extraction 
 
For randomized controlled trials 
The data extraction sheet collected the following information: author, publication date, 
country, practice setting, patient characteristics (age, sex, race, ethnicity, education), level 
of clinician training on how to use the encounter PDAs, the intervention, the control group, 
duration of follow-up, decisional outcomes, and clinical outcomes.  
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Figure 1.  PRISMA flow diagram detailing the studies included. 
 
 
 
 
For non-randomized studies 
The data extraction sheet for non-randomized studies was identical, and in addition 
included fields for study type, methods, and study outcomes focused on the feasibility, 
utility and integration of the encounter PDAs. 
 
Assessment of risk of bias and publication bias in included RCTs 
The Cochrane ‘risk of bias’ tool was used by PS and JB to assess studies [46]. For each 
study, we justified the risk assignment, and created funnel plots by plotting standardized 
mean differences (SMD) against the standard error of the SMD (vertical axis), where 
asymmetry denotes high publication bias [46]. We contacted study authors during data 
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extraction to obtain data where it was absent. Funnel plot interpretation requires the 
inclusion of data from a minimum of 10 studies, which places limits on analyses if 
homogenous outcome measurement across studies is not available [46]. An Egger 
regression was conducted to confirm publication bias (STATA 13.1). 
 
Methodological quality assessment in non-randomized studies 
To assess the methodological quality of qualitative studies, we used the Critical Appraisal 
Skills Program (CASP) Checklist (see Appendix 3) [47]. The Newcastle-Ottawa Quality 
Assessment scale was used to assess the quality of observational studies (case-control, 
cohort, and cross-sectional studies (see Appendix 4) [48]. We used the National Heart, 
Lung, and Blood Institute (NHLBI) quality assessment tool to evaluate pre-post studies 
with no control group (see Appendix 5) [49]. The Downs and Black checklist tool was 
used to assess the quality of quasi-experimental studies (see Appendix 6) [50]. 
 
Analysis 
 
For randomized controlled trials 
After pooling data, we added the study outcomes into RevMan 5.2. We calculated the 
SMD for studies reporting outcomes as continuous variables, and pooled the effect 
estimate. A mean difference of 0.2 was considered a ‘small’ effect size, 0.5 was considered 
‘moderate’, and 0.8 was considered ‘large’. For studies with dichotomous outcomes, we 
calculated odds ratios. We adopted the inverse variance statistical method and selected the 
conservative random effects model to conduct the meta-analysis. We generated forest plots 
for outcomes where we had data for the SMD (continuous), odds ratio (dichotomous), 
associated 95% confidence interval, and conducted subgroup analyses to determine the 
effects on specific health conditions (i.e. depression or osteoporosis). Z-scores were used to 
provide a test for overall effect, and heterogeneity between studies was determined using 
the I2 statistic, where >50% indicates substantial heterogeneity. If heterogeneity was 
present, we would conduct a sensitivity analysis by removing studies at a high risk of bias. 
 
For non-randomized studies 
We used a framework approach based on our pre-specified perspectives of feasibility, 
utility, and integration to qualitatively analyze the integration of encounter PDAs into 
practice of non-randomized studies [51]. We had coded key sections of each article 
pertaining to those three issues. We also created codes for other topics related to 
implementation that were present in the articles. After applying the framework, we 
determined the emergent themes and possible relationships between themes. Three 
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reviewers (NP, JB, and PS) independently coded the data and reached agreement on the 
primary themes. We discussed the emergent themes with co-authors (GE and MAD) to 
consider alternative explanations for the identified themes.  
 
Results 
 
Study characteristics 
The search strategy identified 2969 articles. After removing duplicates and screening titles 
and abstracts, we retrieved 248 articles for full-text review. After applying the inclusion 
and exclusion criteria, and after GE’s verification with study authors that the tools could be 
considered encounter PDAs, we included 23 RCTs in our meta-analysis, and 30 non-
randomized studies in the narrative synthesis (see Figure 1). 
 
For randomized controlled trials 
Most RCTs had been conducted in the United States (n=13), United Kingdom (n=3), 
Germany (n=2), Canada (n=2), Greece (n=1), Spain (n=1), and Australia (n=1). Encounter 
PDAs covered a wide range of health topics including: diabetes medication (3 studies), 
statin choice (3 studies), surgical management, treatment or prevention of breast cancer (3 
studies), osteoporosis (2 studies), depression (2 studies), labor versus elective repeat 
caesarian section (1 study), cardiovascular disease risk (1 study), chest pain (1 study), pre-
natal diagnosis for down’s syndrome (1 study), warfarin treatment for atrial fibrillation (1 
study), obstructive sleep apnea (1 study), percutaneous coronary intervention for stable 
artery disease (1 study), tooth extraction or root canal therapy (1 study), and smoking (1 
study). One study covered a range of health topics including atrial fibrillation, prostatism, 
menorrhagia, and menopausal symptoms. The control arms were either a routine 
consultation or usual care (n=18), educational package such as a booklet, pamphlet, or 
guidelines (n=4), or a risk communication tool (n=1). Tools were provided to patients in 
the paper-based format (n=20) or through a digital interface (n=3). A total of 15 RCTs 
reported that participating clinicians in their study received training on how to use PDAs. 
We qualitatively report the training methods used for those studies in table 1. Table 1 
provides further details on the included RCTs.  
 
For non-randomized studies 
Our narrative synthesis included 30 studies: 21 qualitative, 4 observational, 3 pre-post, and 
2 quasi-experimental [4,6,44,52-78]. Over half of the non-randomized studies (n=16) were 
conducted in the United States. Table 2 provides details. 
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Risk of bias and publication bias 
Figure 2 shows the risk of bias results (23 RCTs). Approximately 25% of the studies 
scored ‘low risk’ of bias on all seven domains. Risks of selection and detection bias were 
low for almost 75% of the included studies in our meta-analysis. Appendix 7 provides 
details to support the risk judgments.  
 
Knowledge and decisional conflict were the two continuous outcome measures reported by 
more than ten studies, enabling publication bias analyses. According to the Egger test, 
there was no publication bias for knowledge (bias=0.67, 95% CI -2.90, 4.24; p=0.70). See 
appendix 8a for the funnel plot for the knowledge outcome. There was also no publication 
bias for the 16 studies reporting the same measure of decision conflict outcome (bias= -
2.37, 95% CI -6.86, 2.12; p=0.28). See appendix 8b for the funnel plot.  
 
Methodological quality assessment 
Of the 21 qualitative studies, 16 were deemed to be of ‘high’ quality according to our use 
of the CASP checklist. Two of the observational studies were of ‘good’ quality, and two 
were of ‘fair’ quality based on our evaluation using the Newcastle-Ottawa scoring system. 
All three pre-post studies in our narrative review were ‘good’ quality, and the two quasi-
experimental studies were of ‘high’ quality. In our analysis, we included all non-
randomized studies regardless of quality. We believe that removing the studies that were 
not of ‘high’ quality would have had no impact on our narrative synthesis results, so we 
opted to include them in the analysis. See table 2 for details. 
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l 2
00
4,
 
C
an
ad
a,
 H
am
ilt
on
, 
O
tta
w
a,
 a
nd
 o
th
er
 
co
m
m
un
iti
es
 in
 O
nt
ar
io
 
[9
] 
20
1 
In
te
rv
en
tio
n:
 
~5
7+
/-*
 C
on
tro
l: 
~5
7+
/-*
 
10
0 
A
 v
id
eo
 o
ut
lin
ed
 h
ow
 th
e 
in
st
ru
m
en
t s
ho
ul
d 
be
 
ad
m
in
is
te
re
d.
 T
he
 su
rg
eo
n 
pr
ac
tic
ed
 w
ith
 a
 v
ol
un
te
er
. 
D
ec
is
io
n 
B
oa
rd
 fo
r t
he
 
su
rg
ic
al
 tr
ea
tm
en
t o
f 
br
ea
st
 c
an
ce
r 
U
su
al
 c
ar
e 
 K
no
w
le
dg
e 
 D
ec
is
io
na
l c
on
fli
ct
 
 P
at
ie
nt
 sa
tis
fa
ct
io
n 
 
A
nx
ie
ty
 
 
 *S
ta
nd
ar
d 
de
vi
at
io
n 
no
t r
ep
or
te
d.
 D
A
 =
 d
ec
is
io
n 
ai
d;
 N
/A
 =
 n
ot
 a
va
ila
bl
e.
 
=
In
te
rv
en
tio
n 
si
gn
ifi
ca
nt
ly
 im
pr
ov
ed
 o
ut
co
m
e;
 =
In
te
rv
en
tio
n 
si
gn
ifi
ca
nt
ly
 w
or
se
ne
d 
ou
tc
om
e;
 
=n
o 
di
ff
er
en
ce
 b
et
w
ee
n 
in
te
rv
en
tio
n 
an
d 
co
nt
ro
l f
or
 th
at
 o
ut
co
m
e.
 
              
  Ta
bl
e 
2.
  
C
ha
ra
ct
er
is
tic
s o
f n
on
-r
an
do
m
iz
ed
 st
ud
ie
s i
nc
lu
de
d 
in
 th
e 
na
rr
at
iv
e 
re
vi
ew
 (n
=3
0)
. 
 S
tu
dy
, Y
ea
r,
 
C
ou
nt
ry
 
In
te
rv
en
tio
n 
Sa
m
pl
e 
Se
tt
in
g/
C
on
te
xt
 
R
es
ul
ts
  
St
ud
y 
Ty
pe
 
Q
ua
lit
y 
A
la
m
 e
t a
l 
20
16
, U
SA
 [5
1]
Ea
rly
 st
ag
e 
br
ea
st
 
ca
nc
er
 O
pt
io
n 
G
rid
 
PD
A
 
10
 w
om
en
 o
f l
ow
 
so
ci
oe
co
no
m
ic
 
st
at
us
 a
nd
 5
 h
ea
lth
 
pr
of
es
si
on
al
s 
D
ar
tm
ou
th
-H
itc
hc
oc
k 
M
ed
ic
al
 C
en
te
r &
 
C
he
ls
ea
 H
ea
lth
C
ar
e 
C
en
te
r 
Pa
tie
nt
s i
nd
ic
at
ed
 th
at
 th
e 
pi
ct
ur
es
 w
er
e 
us
ef
ul
 
in
 te
rm
s o
f p
re
pa
rin
g 
ne
w
ly
 d
ia
gn
os
ed
 w
om
en
 
w
ith
 lo
w
 h
ea
lth
 li
te
ra
cy
 to
 a
sk
 q
ue
st
io
ns
. 
Tr
ea
tm
en
t c
os
t a
nd
 re
co
ve
ry
 ti
m
e 
w
er
e 
ke
y 
su
bj
ec
ts
 in
 th
e 
in
te
rv
en
tio
n.
 
Su
rv
ey
 +
 se
m
i-
st
ru
ct
ur
ed
 
in
te
rv
ie
w
s 
H
ig
h 
 
(C
A
SP
* 
sc
or
e:
 
5)
 
B
oe
hm
er
 2
01
4,
 
U
SA
 
[5
2]
 
D
ec
is
io
n 
ai
ds
 
37
 p
at
ie
nt
s 
A
n 
an
al
ys
is
 o
f 
re
co
rd
in
gs
 m
ad
e 
du
rin
g 
th
e 
co
nd
uc
t o
f 5
 R
C
Ts
 
of
 D
A
s*
 v
er
su
s u
su
al
 
ca
re
 a
t t
he
 M
ay
o 
C
lin
ic
‘T
he
 u
se
 o
f e
ff
ec
tiv
e 
de
ci
si
on
 a
id
s d
id
 n
ot
 
ap
pe
ar
 to
 a
ff
ec
t t
he
 m
an
ne
r o
r m
ag
ni
tu
de
 o
f 
ca
re
gi
ve
r e
ng
ag
em
en
t i
n 
th
e 
en
co
un
te
r’
. 
 
Se
co
nd
ar
y 
da
ta
 
an
al
ys
is
 o
f v
id
eo
 
re
co
rd
in
gs
 
H
ig
h 
 
(C
A
SP
 S
co
re
: 7
) 
B
rin
km
an
 e
t a
l 
20
13
, U
SA
 
[5
3]
 
A
tte
nt
io
n-
de
fic
it 
hy
pe
ra
ct
iv
ity
 
di
so
rd
er
 (A
D
H
D
) 
M
ed
ic
at
io
n 
C
ho
ic
e 
C
ar
ds
 
7 
cl
in
ic
ia
ns
 
5 
pr
ac
tic
es
 in
 th
e 
gr
ea
te
r C
in
ci
nn
at
i 
R
eg
io
n 
Pa
re
nt
s i
n 
th
e 
in
te
rv
en
tio
n 
gr
ou
p 
w
er
e 
si
gn
ifi
ca
nt
ly
 m
or
e 
in
vo
lv
ed
 in
 S
D
M
, m
or
e 
kn
ow
le
dg
ea
bl
e,
 a
nd
 le
ss
 c
on
fli
ct
ed
 a
bo
ut
 
tre
at
m
en
t o
pt
io
ns
 c
om
pa
re
d 
to
 th
e 
co
nt
ro
l. 
V
is
it 
du
ra
tio
n 
di
d 
no
t s
ig
ni
fic
an
tly
 in
cr
ea
se
.  
 
Pr
e-
po
st 
G
oo
d 
 
(N
H
LB
I*
 S
ca
le
: 
6)
 
B
rin
km
an
 e
t a
l 
20
17
, U
SA
 &
 
C
an
ad
a 
[5
4]
 
Ju
ve
ni
le
 id
io
pa
th
ic
 
ar
th
rit
is
 (J
IA
) 
m
ed
ic
at
io
n 
ch
oi
ce
 
ca
rd
s 
17
1 
su
rv
ey
s f
ro
m
 
pa
re
nt
s w
ho
 
re
po
rte
d 
th
at
 th
e 
vi
si
t i
nv
ol
ve
d 
ta
lk
 
of
 st
ar
tin
g 
or
 
sw
itc
hi
ng
 m
ed
ic
in
e
11
 si
te
s i
n 
th
e 
U
ni
te
d 
St
at
es
 a
nd
 C
an
ad
a.
  
JI
A
 c
ar
ds
 w
er
e 
us
ed
 in
 3
5%
 o
f v
is
its
. P
ar
en
ts
 
w
er
e 
m
or
e 
in
vo
lv
ed
 in
 th
e 
di
sc
us
si
on
 a
nd
 h
ad
 
le
ss
 d
ec
is
io
na
l c
on
fli
ct
 w
he
n 
th
e 
ca
rd
s w
er
e 
us
ed
. B
uy
-in
 fr
om
 c
lin
ic
ia
ns
 o
n 
va
lu
e 
of
 S
D
M
, 
tra
in
in
g 
an
d 
fa
m
ili
ar
ity
 w
ith
 th
e 
ca
rd
s, 
an
d 
re
m
in
de
rs
 to
 u
se
 th
em
 fa
ci
lit
at
ed
 
im
pl
em
en
ta
tio
n.
  
Im
pl
em
en
ta
tio
n 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 6
) 
B
rit
o 
et
 a
l, 
U
SA
 
20
15
 
[5
5]
 
G
ra
ve
s’
 D
is
ea
se
 
C
ho
ic
e 
(G
D
 C
ho
ic
e)
 
68
 p
at
ie
nt
s 
Th
yr
oi
d 
C
lin
ic
 w
ith
in
 
th
e 
D
iv
is
io
n 
of
 
en
do
cr
in
ol
og
y 
at
 th
e 
M
ay
o 
C
lin
ic
  
Th
e 
in
te
rv
en
tio
n 
ha
d 
no
 im
pa
ct
 o
n 
en
co
un
te
r 
du
ra
tio
n,
 y
et
 p
at
ie
nt
s i
n 
th
e 
G
D
 C
ho
ic
e 
ar
m
 
re
ce
iv
ed
 m
or
e 
in
fo
rm
at
io
n,
 w
er
e 
m
or
e 
in
vo
lv
ed
 
in
 th
e 
de
ci
si
on
-m
ak
in
g,
 a
nd
 w
er
e 
m
or
e 
lik
el
y 
to
 
m
ak
e 
a 
de
ci
si
on
. 
Pr
e-
po
st 
G
oo
d 
 
(N
H
LB
I S
ca
le
: 
6)
  
C
oy
le
w
rig
ht
 e
t 
al
 2
01
7,
 U
SA
 
[5
6]
 
Pe
rc
ut
an
eo
us
 
co
ro
na
ry
 in
te
rv
en
tio
n 
(P
C
I)
 C
ho
ic
e 
de
ci
si
on
 a
id
 
13
 c
lin
ic
ia
ns
 
M
ay
o 
C
lin
ic
  
C
lin
ic
ia
ns
 w
er
e 
un
ab
le
 to
 d
iff
er
en
tia
te
 p
at
ie
nt
 
ed
uc
at
io
n 
fr
om
 S
D
M
 –
 m
an
y 
re
po
rte
d 
al
re
ad
y 
pr
ac
tic
in
g 
SD
M
. S
om
e 
cl
in
ic
ia
ns
 w
ho
 u
se
d 
th
e 
in
te
rv
en
tio
n 
sa
w
 im
pr
ov
em
en
t i
n 
ve
rb
al
 
co
m
m
un
ic
at
io
n 
an
d 
el
ic
ita
tio
n 
of
 p
at
ie
nt
 
pr
ef
er
en
ce
. C
lin
ic
ia
ns
 w
er
e 
w
or
rie
d 
ab
ou
t t
im
e 
co
ns
tra
in
ts
, a
nd
 h
ad
 d
is
co
m
fo
rt 
us
in
g 
th
e 
to
ol
.  
 
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 6
) 
  S
tu
dy
, Y
ea
r,
 
C
ou
nt
ry
 
In
te
rv
en
tio
n 
Sa
m
pl
e 
Se
tt
in
g/
C
on
te
xt
 
R
es
ul
ts
  
St
ud
y 
Ty
pe
 
Q
ua
lit
y 
M
an
y 
pr
ef
er
re
d 
th
e 
to
ol
 b
e 
de
liv
er
ed
 p
rio
r t
o 
th
e 
en
co
un
te
r. 
Pa
tie
nt
s w
er
e 
m
or
e 
sa
tis
fie
d 
w
he
n 
in
te
rv
en
tio
n 
w
as
 u
se
d.
 
El
w
yn
 e
t a
l 
20
15
, U
K
 
[5
7]
 
K
ne
e 
O
st
eo
ar
th
rit
is
 
O
pt
io
n 
G
rid
 
72
 p
at
ie
nt
s 
Th
e 
Pe
nn
in
e 
M
us
cu
lo
sk
el
et
al
 C
lin
ic
 
Li
m
ite
d 
in
 O
ld
ha
m
, 
G
re
at
er
 M
an
ch
es
te
r, 
U
K
 
In
 p
at
ie
nt
s w
ith
 lo
w
er
 h
ea
lth
 li
te
ra
cy
, t
he
 
in
te
rv
en
tio
n 
in
cr
ea
se
d 
SD
M
, k
no
w
le
dg
e,
 a
nd
 
re
ad
in
es
s t
o 
de
ci
de
. U
se
 o
f t
he
 in
te
rv
en
tio
n 
ha
d 
no
 im
pa
ct
 o
n 
en
co
un
te
r d
ur
at
io
n.
 C
lin
ic
ia
ns
 
w
er
e 
co
nc
er
ne
d 
ab
ou
t t
he
 in
te
rv
en
tio
n’
s 
w
or
ka
bi
lit
y,
 c
on
te
nt
 a
nd
 fo
rm
at
 –
 so
m
e 
pa
tie
nt
s 
m
ig
ht
 re
ac
t n
eg
at
iv
el
y 
to
 it
s i
m
pl
em
en
ta
tio
n.
 
C
lin
ic
ia
ns
 n
ee
de
d 
tim
e 
to
 a
dj
us
t t
o 
us
in
g 
th
e 
to
ol
 
in
 th
e 
en
co
un
te
r b
ut
 p
er
so
na
liz
in
g 
th
e 
to
ol
 a
nd
 
gi
vi
ng
 p
at
ie
nt
s t
im
e 
to
 re
ad
 h
el
pe
d.
 
St
ep
pe
d-
w
ed
ge
 
tri
al
 
H
ig
h 
 
(D
ow
ns
 a
nd
 
B
la
ck
 c
he
ck
lis
t: 
20
) 
El
w
yn
 e
t a
l 
20
18
, U
K
 [5
8]
 
K
ne
e 
O
st
eo
ar
th
rit
is
 
O
pt
io
n 
G
rid
 
6 
pa
tie
nt
s 
Th
e 
Pe
nn
in
e 
M
us
cu
lo
sk
el
et
al
 C
lin
ic
 
Li
m
ite
d 
in
 O
ld
ha
m
, 
G
re
at
er
 M
an
ch
es
te
r, 
U
K
 
C
lin
ic
ia
ns
 w
er
e 
co
nc
er
ne
d 
ab
ou
t t
im
e 
co
ns
tra
in
ts
, t
he
 c
on
te
nt
 a
nd
 fo
rm
at
 o
f t
he
 to
ol
, 
an
d 
th
at
 p
at
ie
nt
s w
er
e 
no
t e
xp
ec
tin
g 
de
ci
si
on
al
 
re
sp
on
si
bi
lit
y.
 C
lin
ic
ia
ns
 n
ee
de
d 
tim
e 
an
d 
ex
pe
rie
nc
e 
to
 a
dj
us
t. 
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 5
) 
En
ge
le
n 
et
 a
l 
20
16
, B
el
gi
um
  
[5
9]
 
Ea
rly
 d
et
ec
tio
n 
of
 
pr
os
ta
te
 c
an
ce
r 
de
ci
si
on
 a
id
 
16
 c
lin
ic
ia
ns
; 4
3 
pa
tie
nt
s  
So
ci
oc
ul
tu
ra
l c
lu
bs
 a
nd
 
so
ci
et
ie
s i
n 
Fl
an
de
rs
 
Pa
tie
nt
s e
xp
ec
te
d 
th
ei
r c
lin
ic
ia
n 
to
 p
ro
ac
tiv
el
y 
te
st
, w
hi
le
 c
lin
ic
ia
ns
 d
id
 n
ot
 se
e 
th
e 
be
ne
fit
s i
n 
te
st
in
g.
 C
on
tra
st
in
g 
at
tit
ud
es
 le
d 
to
 d
iv
er
ge
nt
 
ex
pe
ct
at
io
ns
. B
ot
h 
st
ak
eh
ol
de
rs
 n
ee
de
d 
su
pp
or
t 
de
sp
ite
 th
es
e 
at
tit
ud
es
. L
ac
k 
of
 e
xp
er
ie
nc
e 
an
d 
tim
e 
pr
es
su
re
s a
re
 b
ar
rie
rs
 to
 in
te
rv
en
tio
n 
us
e.
 
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 5
) 
Fa
y 
et
 a
l 2
01
5,
 
U
SA
 
[4
] 
C
irc
um
ci
si
on
 O
pt
io
n 
G
rid
 P
D
A
 
4 
cl
in
ic
ia
ns
; 3
2 
se
ts
 
of
 p
ar
en
ts
 
co
ns
id
er
in
g 
ci
rc
um
ci
si
on
 
N
ew
bo
rn
 c
ar
e 
un
it 
at
 
D
ar
tm
ou
th
 H
itc
hc
oc
k 
M
ed
ic
al
 C
en
te
r  
Th
e 
in
te
rv
en
tio
n 
en
ab
le
d 
co
lla
bo
ra
tio
n 
an
d 
co
nf
er
re
d 
ag
en
cy
 to
 th
e 
pa
tie
nt
. C
lin
ic
ia
ns
 
ne
ed
ed
 to
 g
ai
n 
ex
pe
rie
nc
e 
to
 fe
el
 c
om
fo
rta
bl
e 
us
in
g 
th
e 
to
ol
. G
re
at
er
 w
ill
in
gn
es
s f
or
 c
lin
ic
ia
ns
 
to
 m
od
ify
 th
ei
r c
om
m
un
ic
at
io
n 
pa
tte
rn
s. 
U
si
ng
 
th
e 
to
ol
 c
ou
ld
 a
ct
ua
lly
 sa
ve
 ti
m
e.
 
A
na
ly
si
s o
f 
vi
de
o 
re
co
rd
in
gs
 
+ 
se
m
i-
st
ru
ct
ur
ed
 
in
te
rv
ie
w
s 
M
od
er
at
e 
 
(C
A
SP
 sc
or
e:
 4
) 
G
ig
ue
re
 e
t a
l 
20
14
, C
an
ad
a 
[6
0]
 
Th
e 
in
te
rv
en
tio
n 
co
ns
is
te
d 
of
 8
 
ev
id
en
ce
-b
as
ed
 
de
ci
si
on
 b
ox
es
 
(D
bo
xe
s)
 o
n 
co
m
m
on
 
pr
im
ar
y 
ca
re
 
in
te
rv
en
tio
ns
 w
rit
te
n 
10
1 
cl
in
ic
ia
ns
 
6 
cl
in
ic
s l
oc
at
ed
 in
 4
 
ci
tie
s i
n 
C
an
ad
a 
81
%
 o
f c
lin
ic
ia
ns
 w
er
e 
sa
tis
fie
d 
w
ith
 th
e 
in
te
rv
en
tio
n,
 o
ve
r h
al
f l
ea
rn
ed
 so
m
et
hi
ng
. 
B
ar
rie
rs
 a
cc
or
di
ng
 to
 c
lin
ic
ia
ns
: i
nf
o 
w
as
 to
o 
co
m
pl
ex
 fo
r p
at
ie
nt
s, 
tim
e 
co
ns
tra
in
ts
 (s
ho
ul
d 
be
 
pr
ov
id
ed
 b
ef
or
e 
th
e 
en
co
un
te
r)
, a
nd
 ti
m
e 
to
 
fa
m
ili
ar
iz
e 
th
em
se
lv
es
 w
ith
 th
e 
to
ol
. S
om
e 
pe
rc
ei
ve
d 
th
e 
to
ol
s e
as
ie
r t
o 
im
pl
em
en
t i
n 
Su
rv
ey
 +
 se
m
i-
st
ru
ct
ur
ed
 fo
cu
s 
gr
ou
p 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 6
) 
  S
tu
dy
, Y
ea
r,
 
C
ou
nt
ry
 
In
te
rv
en
tio
n 
Sa
m
pl
e 
Se
tt
in
g/
C
on
te
xt
 
R
es
ul
ts
  
St
ud
y 
Ty
pe
 
Q
ua
lit
y 
in
 b
ot
h 
Fr
en
ch
 a
nd
 
En
gl
is
h.
 
pr
iv
at
e 
pr
ac
tic
e 
or
 te
ac
hi
ng
 c
lin
ic
s c
om
pa
re
d 
to
 
ho
sp
ita
ls
. 
H
aj
iz
ad
eh
 e
t a
l 
20
13
, U
SA
 
[6
1]
 
C
om
pu
te
riz
ed
 
de
ci
si
on
 a
id
 
10
 c
lin
ic
ia
ns
; 1
8 
pa
tie
nt
s 
O
ut
pa
tie
nt
 p
ul
m
on
ar
y 
cl
in
ic
 a
t t
he
 B
el
le
vu
e 
H
os
pi
ta
l, 
N
ew
 Y
or
k 
C
ity
 
C
lin
ic
ia
ns
 te
nd
ed
 to
 m
ak
e 
th
e 
fin
al
 d
ec
is
io
ns
. 
Pa
tie
nt
s w
er
e 
no
t e
nc
ou
ra
ge
d 
to
 p
ar
tic
ip
at
e 
in
 
th
e 
fin
al
 d
ec
is
io
n-
m
ak
in
g 
pr
oc
es
s. 
C
lin
ic
ia
ns
 
ex
pr
es
se
d 
lit
tle
 to
 n
o 
ex
pe
rie
nc
e 
w
ith
 
co
m
pu
te
riz
ed
 d
ec
is
io
n 
ai
d 
pr
og
ra
m
s, 
bu
t 
pa
tie
nt
s w
an
te
d 
th
ei
r c
lin
ic
ia
n 
to
 sh
ar
e 
th
e 
sc
re
en
. M
os
t f
el
t c
om
pu
te
riz
ed
 d
ec
is
io
n 
ai
d 
pr
og
ra
m
s w
ou
ld
 b
e 
an
 a
ss
et
 –
 p
at
ie
nt
s c
an
 a
sk
 
m
or
e 
qu
es
tio
ns
. T
im
e 
co
ns
tra
in
ts
 w
as
 a
 b
ar
rie
r. 
Q
ua
lit
at
iv
e 
M
od
er
at
e 
 
(C
A
SP
 sc
or
e:
 2
) 
H
ar
ris
on
 e
t a
l 
20
09
, A
us
tra
lia
 
[6
2]
 
Th
re
e 
D
A
 fo
rm
at
s f
or
 
ad
ju
va
nt
 tr
ea
tm
en
t 
fo
r r
ec
ta
l c
an
ce
r 
w
er
e 
ev
al
ua
te
d:
 a
 
co
m
pu
te
r d
ec
is
io
n 
ai
d,
 d
ec
is
io
n 
bo
ar
d,
 
an
d 
A
nn
al
is
a 
in
te
ra
ct
iv
e 
de
ci
si
on
 
su
pp
or
t &
 
co
m
m
un
ic
at
io
n 
pa
ck
ag
e 
20
 c
ol
or
ec
ta
l 
su
rg
eo
ns
 
C
ol
or
ec
ta
l s
ur
ge
on
s 
w
ho
 w
er
e 
m
em
be
rs
 o
f 
th
e 
C
ol
or
ec
ta
l S
ur
gi
ca
l 
So
ci
et
y 
of
 A
us
tra
lia
 
an
d 
N
ew
 Z
ea
la
nd
 
at
te
nd
in
g 
co
nt
in
ui
ng
 
m
ed
ic
al
 e
du
ca
tio
n 
(C
M
E)
 se
ss
io
ns
  
Su
rg
eo
ns
 su
pp
or
t a
 c
ol
la
bo
ra
tiv
e 
ap
pr
oa
ch
 to
 
de
ci
si
on
-m
ak
in
g.
 A
ll 
fo
rm
at
s w
er
e 
co
ns
id
er
ed
 
us
ef
ul
. T
he
 d
ec
is
io
n 
bo
ar
d 
w
as
 m
os
t l
ik
el
y 
to
 b
e 
us
ed
 b
ec
au
se
 o
f t
he
 d
ia
gr
am
s u
se
d.
 B
ar
rie
rs
 
fr
om
 th
e 
cl
in
ic
ia
n 
pe
rs
pe
ct
iv
e:
 ti
m
e 
co
ns
tra
in
ts
, 
pe
rs
on
al
 a
nd
 c
lin
ic
al
 c
ha
ra
ct
er
is
tic
s o
f t
he
 
pa
tie
nt
 (t
oo
 e
m
ot
io
na
lly
 b
ur
de
ns
om
e 
to
 p
ro
vi
de
 
su
ch
 d
et
ai
le
d 
in
fo
 th
at
 is
 h
ar
d 
to
 u
nd
er
st
an
d)
, 
co
nt
en
t (
am
ou
nt
 o
f i
nf
o 
is
 o
ve
rw
he
lm
in
g)
, a
nd
 
co
nc
er
ns
 a
bo
ut
 th
e 
im
pa
ct
 o
n 
pa
tie
nt
-c
lin
ic
ia
n 
re
la
tio
ns
hi
p 
(to
ol
 w
ou
ld
 ta
ke
 a
w
ay
 th
e 
re
la
tio
ns
hi
p)
.  
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 7
) 
H
en
sh
al
l e
t a
l 
20
17
, E
ng
la
nd
 
[6
3]
 
W
eb
-b
as
ed
, 
co
m
pu
te
riz
ed
 c
lin
ic
al
 
de
ci
si
on
 su
pp
or
t 
in
te
rv
en
tio
n 
fo
r 
m
en
ta
l h
ea
lth
 
di
so
rd
er
s 
12
 c
on
su
lta
nt
 
ps
yc
hi
at
ris
ts
, 1
1 
pr
im
ar
y 
ca
re
 
cl
in
ic
ia
ns
 
(in
cl
ud
in
g 
5 
nu
rs
es
) 
an
d 
8 
w
er
e 
pa
tie
nt
s 
or
 c
ar
eg
iv
er
s 
O
xf
or
d,
 U
ni
te
d 
K
in
gd
om
 
M
aj
or
ity
 re
po
rte
d 
th
at
 it
 w
as
 a
 u
se
fu
l t
oo
l (
fo
r 
cl
in
ic
ia
ns
 w
ith
 a
 v
ar
ie
ty
 o
f e
xp
er
ie
nc
e)
 th
at
 
pr
om
ot
ed
 d
is
cu
ss
io
n 
w
ith
 th
e 
pa
tie
nt
. M
os
t 
co
ns
ul
ta
nt
s v
ie
w
ed
 it
 a
s a
 g
oo
d 
w
ay
 to
 
st
an
da
rd
iz
e 
pr
es
cr
ib
in
g 
pr
ac
tic
es
. T
he
 to
ol
 
pr
om
ot
ed
 p
er
so
na
liz
ed
 c
ar
e.
 T
he
 c
om
pl
ex
ity
 o
f 
th
e 
co
nt
en
t w
as
 a
 b
ar
rie
r f
or
 u
se
.  
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 7
) 
H
irs
ch
 e
t a
l, 
G
er
m
an
y,
 2
01
2 
[6
4]
 
ar
rib
a 
lib
 
19
2 
pa
tie
nt
s 
Pr
im
ar
y 
ca
re
 c
lin
ic
ia
ns
 
in
 th
e 
G
er
m
an
 fe
de
ra
l 
la
nd
s o
f N
or
th
 R
hi
ne
-
W
es
tp
ha
lia
 a
nd
 H
es
se
 
 
Th
e 
de
fin
iti
on
 o
f t
he
 p
ro
bl
em
 w
as
 d
is
cu
ss
ed
 in
 
le
ss
 d
et
ai
l c
om
pa
re
d 
to
 th
e 
ot
he
r s
te
ps
 a
nd
 th
at
 
th
e 
in
di
vi
du
al
 ri
sk
 a
nd
 tr
ea
tm
en
t o
pt
io
ns
 w
er
e 
di
sc
us
se
d 
m
os
t t
ho
ro
ug
hl
y.
 9
%
 o
f c
lin
ic
ia
ns
 sa
id
 
th
e 
en
co
un
te
r w
as
 ‘t
oo
 lo
ng
’. 
  
C
ro
ss
-s
ec
tio
na
l 
Fa
ir 
 
(N
ew
ca
st
le
-
O
tta
w
a:
 6
) 
  S
tu
dy
, Y
ea
r,
 
C
ou
nt
ry
 
In
te
rv
en
tio
n 
Sa
m
pl
e 
Se
tt
in
g/
C
on
te
xt
 
R
es
ul
ts
  
St
ud
y 
Ty
pe
 
Q
ua
lit
y 
H
ol
m
es
-R
ov
ne
r 
et
 a
l 2
01
5,
 U
SA
[6
5]
 
Pr
os
ta
te
 c
an
ce
r 
de
ci
si
on
 a
id
 
45
 c
lin
ic
ia
ns
; 2
52
 
pa
tie
nt
s 
Pa
tie
nt
s w
er
e 
re
cr
ui
te
d 
fr
om
 4
 V
A
 H
ea
lth
 
Sy
st
em
s (
A
nn
 A
rb
or
, 
M
ic
hi
ga
n;
 D
ur
ha
m
, 
N
or
th
 C
ar
ol
in
a;
 
Pi
tts
bu
rg
h,
 
Pe
nn
sy
lv
an
ia
; a
nd
 S
an
 
Fr
an
ci
sc
o,
 C
al
ifo
rn
ia
) 
C
om
pl
et
e 
di
sc
us
si
on
 o
f t
re
at
m
en
t o
pt
io
ns
 
oc
cu
rr
ed
 in
 5
9%
, b
en
ef
its
 a
nd
 ri
sk
s i
n 
21
%
, a
nd
 
pr
ef
er
en
ce
s i
n 
30
%
 o
f t
he
 v
is
its
. H
ig
h-
qu
al
ity
 
SD
M
 o
cc
ur
re
d 
w
ith
 2
9%
 o
f c
lin
ic
ia
ns
. 
 
A
na
ly
si
s o
f 
au
di
o 
re
co
rd
in
gs
 
of
 c
lin
ic
al
 
en
co
un
te
rs
 
H
ig
h 
 
(C
A
SP
 sc
or
e:
 6
) 
H
ol
m
es
-R
ov
ne
r 
et
 a
l 2
01
8,
 U
SA
[6
6]
 
Pr
os
ta
te
 c
an
ce
r 
de
ci
si
on
 a
id
 
45
 c
lin
ic
ia
ns
; 2
52
 
pa
tie
nt
s 
R
ec
ru
itm
en
t f
ro
m
 4
 V
A
 
H
ea
lth
 S
ys
te
m
s (
A
nn
 
A
rb
or
, M
ic
hi
ga
n;
 
D
ur
ha
m
, N
or
th
 
C
ar
ol
in
a;
 P
itt
sb
ur
gh
, 
Pe
nn
sy
lv
an
ia
; a
nd
 S
an
 
Fr
an
ci
sc
o,
 C
al
ifo
rn
ia
) 
Th
e 
de
ci
si
on
 a
id
 w
as
 re
fe
re
nc
ed
 m
os
t f
re
qu
en
tly
 
du
rin
g 
th
e 
di
sc
us
si
on
 o
f t
re
at
m
en
t o
pt
io
ns
 
(3
6%
). 
So
m
e 
pa
tie
nt
s u
se
d 
th
e 
bo
ok
le
t t
o 
ex
pl
ai
n 
th
ei
r w
or
ry
 a
bo
ut
 th
ei
r p
ro
st
at
e 
ca
nc
er
 
or
 sp
ec
ifi
c 
tre
at
m
en
ts
. T
he
 D
A
 w
as
 e
ith
er
 a
 to
ol
 
fo
r r
ea
ss
ur
an
ce
 o
r t
o 
ex
pr
es
s c
on
ce
rn
 to
 th
e 
cl
in
ic
ia
n.
 C
lin
ic
ia
ns
 w
er
e 
le
ss
 li
ke
ly
 to
 u
se
 th
e 
to
ol
 w
ith
 p
at
ie
nt
s w
ho
 h
ad
 a
 h
ig
he
r e
du
ca
tio
n.
 
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 S
co
re
: 7
) 
H
ua
ng
 e
t a
l 
20
16
, C
hi
na
 
[6
7]
 
St
at
in
 c
ho
ic
e 
de
ci
si
on
 a
id
 
7 
cl
in
ic
ia
ns
; 8
0 
pa
tie
nt
s 
Tw
o 
te
ac
hi
ng
 h
os
pi
ta
ls
 
in
 N
or
th
er
n 
C
hi
na
. 
M
os
t C
hi
ne
se
 c
lin
ic
ia
ns
 w
er
e 
ab
le
 to
 
su
cc
es
sf
ul
ly
 p
ra
ct
ic
e 
SD
M
. T
he
re
 w
as
 a
 tr
en
d 
to
w
ar
d 
be
tte
r S
D
M
 w
he
n 
cl
in
ic
ia
ns
 h
ad
 m
or
e 
ex
pe
rie
nc
e 
us
in
g 
th
e 
de
ci
si
on
 a
id
. 
Pr
os
pe
ct
iv
e,
 
fe
as
ib
ili
ty
 
G
oo
d 
 
(N
ew
ca
st
le
-
O
tta
w
a:
 6
.5
) 
In
se
lm
an
 e
t a
l 
20
16
, U
SA
 
[6
8]
 
St
at
in
/A
sp
iri
n 
ch
oi
ce
 
de
ci
si
on
 a
id
 
49
7 
cl
in
ic
ia
ns
; 
29
86
 p
at
ie
nt
s 
 
M
ay
o 
C
lin
ic
 p
rim
ar
y 
ca
re
 p
ra
ct
ic
es
  
U
se
 o
f d
ec
is
io
n 
ai
ds
 w
as
 fe
as
ib
le
 c
on
si
de
rin
g 
th
e 
to
ol
 w
as
 a
cc
es
se
d 
63
12
 ti
m
es
, o
f w
hi
ch
 4
51
6 
co
rr
es
po
nd
ed
 to
 u
ni
qu
e 
cl
in
ic
al
 e
nc
ou
nt
er
s i
n 
w
hi
ch
 th
e 
de
ci
si
on
 a
id
 w
as
 u
se
d.
 1
6%
 
do
cu
m
en
te
d 
th
e 
us
e 
of
 th
e 
in
te
rv
en
tio
n 
in
 th
e 
m
ed
ic
al
 re
co
rd
.  
R
et
ro
sp
ec
tiv
e 
an
al
ys
is
 
G
oo
d 
 
(N
ew
ca
st
le
-
O
tta
w
a:
 6
.5
) 
K
in
se
y 
et
 a
l 
20
17
, U
K
 
[6
9]
 
K
ne
e 
os
te
oa
rth
rit
is
 
O
pt
io
n 
G
rid
 d
ec
is
io
n 
ai
d 
72
 p
at
ie
nt
s 
M
us
cu
lo
sk
el
et
al
 
se
rv
ic
e 
th
at
 p
ro
vi
de
s 
in
te
gr
at
ed
 se
rv
ic
es
 to
 
th
e 
lo
ca
l p
op
ul
at
io
n 
in
 
O
ld
ha
m
, G
re
at
er
 
M
an
ch
es
te
r, 
U
K
 
Pa
rti
ci
pa
nt
s w
ho
 re
ce
iv
ed
 th
e 
O
pt
io
n 
G
rid
 
ap
pe
ar
ed
 to
 d
em
on
st
ra
te
 a
 g
re
at
er
 a
w
ar
en
es
s 
th
at
 th
er
e 
w
er
e 
a 
nu
m
be
r o
f o
pt
io
ns
 a
va
ila
bl
e.
 
Th
e 
in
fo
rm
at
io
n 
in
 th
e 
to
ol
 w
as
 c
le
ar
 a
nd
 u
se
fu
l 
to
 p
at
ie
nt
s. 
 
Q
ua
lit
at
iv
e 
M
od
er
at
e 
 
(C
A
SP
 S
co
re
: 4
) 
O
os
te
nd
or
p 
et
 
al
 2
01
5,
 
N
et
he
rla
nd
s 
[7
0]
  
D
ec
is
io
n 
A
id
s f
or
 
Pa
lli
at
iv
e 
C
he
m
ot
he
ra
py
 
11
 n
ur
se
s, 
13
 
on
co
lo
gi
st
s 
R
ad
bo
ud
 U
ni
ve
rs
ity
 
M
ed
ic
al
 C
en
tre
 
Th
e 
co
nt
en
t, 
fo
rm
at
 a
nd
 e
ff
ec
t o
f t
he
 to
ol
 is
 a
 
ba
rr
ie
r –
 p
re
se
nt
in
g 
nu
m
er
ic
al
 in
fo
rm
at
io
n 
th
at
 
is
 g
ro
up
-b
as
ed
 is
 n
ot
 a
lw
ay
s h
el
pf
ul
 fo
r p
at
ie
nt
s. 
N
ur
se
s f
el
t t
he
y 
di
d 
no
t h
av
e 
en
ou
gh
 e
xp
er
ie
nc
e 
us
in
g 
th
e 
to
ol
 a
nd
 w
er
e 
no
t s
ur
e 
ab
ou
t t
he
 v
al
ue
 
Q
ua
lit
at
iv
e 
M
od
er
at
e 
 
(C
A
SP
 S
co
re
: 3
) 
  S
tu
dy
, Y
ea
r,
 
C
ou
nt
ry
 
In
te
rv
en
tio
n 
Sa
m
pl
e 
Se
tt
in
g/
C
on
te
xt
 
R
es
ul
ts
  
St
ud
y 
Ty
pe
 
Q
ua
lit
y 
th
ey
 a
dd
. O
nc
ol
og
is
ts
 w
an
te
d 
to
 ta
ilo
r t
he
 
in
te
rv
en
tio
n 
to
 th
e 
pa
tie
nt
s. 
R
es
ou
rc
es
, l
og
is
tic
s, 
an
d 
so
ci
al
 se
tti
ng
 re
pr
es
en
t o
rg
an
iz
at
io
na
l 
ba
rr
ie
rs
 to
 im
pl
em
en
ta
tio
n.
 
R
en
zi
 e
t a
l 
20
06
, I
ta
ly
 
[7
1]
 
Ps
or
ia
si
s D
ec
is
io
n 
B
oa
rd
 
11
6 
ps
or
ia
si
s 
ou
tp
at
ie
nt
s a
nd
 1
15
 
in
pa
tie
nt
s 
 
Is
tit
ut
o 
D
er
m
op
at
ic
o 
de
ll’
Im
m
ac
ol
at
a 
R
om
e,
 
Ita
ly
 
Pa
tie
nt
s i
n 
th
e 
co
nt
ro
l a
rm
 w
an
te
d 
to
 b
e 
m
or
e 
in
vo
lv
ed
 in
 th
e 
de
ci
si
on
-m
ak
in
g 
pr
oc
es
s. 
C
lin
ic
ia
ns
 fe
lt 
th
e 
to
ol
 w
as
 h
el
pf
ul
 fo
r h
al
f o
f 
th
e 
in
pa
tie
nt
 v
is
its
. P
at
ie
nt
s i
n 
th
e 
in
te
rv
en
tio
n 
ar
m
 h
ad
 sl
ig
ht
ly
 h
ig
he
r k
no
w
le
dg
e 
an
d 
sa
tis
fa
ct
io
n.
 
Q
ua
si
- 
Ex
pe
rim
en
ta
l 
H
ig
h 
 
(D
ow
ns
 a
nd
 
B
la
ck
 c
he
ck
lis
t: 
21
) 
Sc
al
ia
 e
t a
l 
20
17
, U
SA
 
[4
4]
 
O
pt
io
n 
G
rid
 
7 
cl
in
ic
ia
ns
, 7
 
nu
rs
es
, 4
 m
ed
ic
al
 
as
si
st
an
ts
, 2
 
m
an
ag
er
s, 
3 
ot
he
r 
st
af
f m
em
be
rs
. 
C
ap
ita
lC
ar
e 
M
ed
ic
al
 
G
ro
up
 in
 A
lb
an
y,
 N
Y
 
&
 
tw
o 
H
ea
lth
Pa
rtn
er
s i
n 
M
in
ne
so
ta
. 
C
ap
ita
lC
ar
e 
or
ga
ni
za
tio
n 
im
pl
em
en
te
d 
a 
to
p-
do
w
n 
ap
pr
oa
ch
 b
y 
us
in
g 
fin
an
ci
al
 in
ce
nt
iv
es
 fo
r 
cl
in
ic
ia
ns
 u
si
ng
 O
pt
io
n 
G
rid
. H
ea
lth
Pa
rtn
er
s h
ad
 
a 
ch
am
pi
on
 c
lin
ic
ia
n 
th
at
 se
t t
he
 e
xa
m
pl
e 
fo
r 
co
lle
ag
ue
s. 
N
ur
se
s p
la
ye
d 
a 
pi
vo
ta
l r
ol
e 
in
 
ro
ut
in
e 
ad
op
tio
n 
of
 th
e 
to
ol
s. 
O
pt
io
n 
G
rid
 a
ls
o 
he
lp
ed
 st
ru
ct
ur
e 
co
nv
er
sa
tio
ns
, b
ut
 p
at
ie
nt
s w
ith
 
lo
w
er
 h
ea
lth
 li
te
ra
cy
 m
ay
 h
av
e 
is
su
es
 u
si
ng
 th
e 
to
ol
s. 
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 S
co
re
: 7
) 
Si
m
m
on
s e
t a
l 
20
17
, A
us
tra
lia
 
[7
2]
 
O
nl
in
e 
de
ci
si
on
 a
id
 
fo
r y
ou
th
 d
ep
re
ss
io
n 
48
 c
lie
nt
s 
H
ea
ds
pa
ce
 c
en
te
rs
 
(e
nh
an
ce
d 
pr
im
ar
y 
ca
re
 
se
rv
ic
es
) w
ith
 a
 fo
cu
s 
on
 y
ou
th
 m
en
ta
l h
ea
lth
 
fo
r y
ou
ng
 p
eo
pl
e 
ag
ed
 
12
‐2
5 
ye
ar
s i
n 
th
e 
no
rth
er
n 
su
bu
rb
s o
f 
M
el
bo
ur
ne
, A
us
tra
lia
  
Pa
tie
nt
s w
er
e 
m
or
e 
lik
el
y 
to
 m
ak
e 
a 
de
ci
si
on
 
th
at
 w
as
 g
ui
de
lin
e-
co
nc
or
da
nt
 a
nd
 a
ll 
w
ho
 u
se
d 
th
e 
in
te
rv
en
tio
n 
m
ad
e 
de
ci
si
on
s t
ha
t a
lig
ne
d 
w
ith
 th
ei
r n
ee
ds
 a
nd
 p
re
fe
re
nc
es
. T
ho
se
 w
ho
 
us
ed
 th
e 
to
ol
 w
er
e 
al
so
 m
or
e 
in
vo
lv
ed
 in
 th
e 
de
ci
si
on
-m
ak
in
g 
pr
oc
es
s a
nd
 h
ad
 le
ss
 d
ec
is
io
na
l 
co
nf
lic
t. 
C
lin
ic
ia
ns
 w
er
e 
al
so
 h
ig
hl
y 
sa
tis
fie
d 
w
ith
 th
e 
in
te
rv
en
tio
n.
  
C
oh
or
t 
Fa
ir 
(N
ew
ca
st
le
-
O
tta
w
a:
 4
.5
) 
Sm
ith
 e
t a
l 
20
08
, U
K
 
[7
3]
 
Fa
ec
al
 o
cc
ul
t b
lo
od
 
te
st
in
g 
(F
O
B
T)
 
de
ci
si
on
 a
id
 
33
 p
at
ie
nt
s 
G
ov
er
nm
en
t-f
un
de
d 
ad
ul
t b
as
ic
 e
du
ca
tio
n 
lit
er
ac
y 
cl
as
se
s h
el
d 
at
 
fu
rth
er
 e
du
ca
tio
n 
co
lle
ge
s (
TA
FE
) i
n 
Sy
dn
ey
, A
us
tra
lia
 &
 
U
ni
ve
rs
ity
 o
f S
yd
ne
y’
s 
C
on
tin
ui
ng
 E
du
ca
tio
n 
Pr
og
ra
m
 
Pa
tie
nt
s o
f h
ig
h 
an
d 
lo
w
 h
ea
lth
 li
te
ra
cy
 
in
di
ca
te
d 
th
at
 th
e 
to
ol
 w
as
 c
le
ar
 a
nd
 e
as
y 
to
 
re
ad
. L
ow
er
 li
te
ra
cy
 p
at
ie
nt
s h
ad
 d
iff
ic
ul
ty
 w
ith
 
th
e 
m
ed
ic
al
 ja
rg
on
, b
ut
 a
pp
re
ci
at
ed
 th
e 
vi
su
al
s 
em
be
dd
ed
 in
 th
e 
de
ci
si
on
 a
id
. 
     
Q
ua
lit
at
iv
e 
H
ig
h 
 
(C
A
SP
 S
co
re
: 6
) 
  S
tu
dy
, Y
ea
r,
 
C
ou
nt
ry
 
In
te
rv
en
tio
n 
Sa
m
pl
e 
Se
tt
in
g/
C
on
te
xt
 
R
es
ul
ts
  
St
ud
y 
Ty
pe
 
Q
ua
lit
y 
Ta
pp
 H
 e
t a
l 
20
14
, U
SA
 
[7
4]
 
A
st
hm
a 
de
ci
si
on
 a
id
 
10
8 
pr
ov
id
er
s;
 2
06
6
pa
tie
nt
s 
Si
x 
pr
ac
tic
es
: t
hr
ee
 
pr
im
ar
y 
ca
re
/fa
m
ily
 
m
ed
ic
in
e,
 o
ne
 in
te
rn
al
 
m
ed
ic
in
e,
 a
nd
 tw
o 
pe
di
at
ric
 c
om
m
un
ity
 
am
bu
la
to
ry
 c
lin
ic
s 
Im
pl
em
en
ta
tio
n 
of
 th
e 
to
ol
 w
as
 e
ff
ec
tiv
e 
w
ith
 
ov
er
 9
0%
 o
f p
at
ie
nt
s f
ee
lin
g 
lik
e 
th
e 
tre
at
m
en
t 
de
ci
si
on
 w
as
 sh
ar
ed
, a
nd
 a
lm
os
t 8
0%
 fe
el
in
g 
th
at
 th
ei
r i
nf
lu
en
ce
 o
n 
th
e 
fin
al
 tr
ea
tm
en
t c
ho
ic
e 
w
as
 e
qu
al
 to
 th
e 
pr
ov
id
er
. T
he
 n
um
be
r o
f 
cl
in
ic
ia
ns
 u
si
ng
 th
e 
to
ol
 c
on
tin
ue
s t
o 
ex
pa
nd
 
be
yo
nd
 th
e 
cl
in
ic
ia
n 
ch
am
pi
on
s. 
Fa
ci
lit
at
or
s:
 th
e 
im
pl
em
en
ta
tio
n 
w
as
 ta
ilo
re
d 
to
 th
e 
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Figure 2.  Risk of bias summary for RCTs (n=23): judgments about risk of bias items. 
 
 
 
Meta-analysis 
 
Knowledge  
Figure 3a illustrates the calculated SMDs for the 18 studies that compared knowledge. The 
pooled effect estimate indicates a ‘moderate’ effect size indicate that patients who used 
encounter PDAs had significantly higher knowledge compared to those in the control 
group (SMD= 0.50; 95% CI 0.33, 0.67). However, there was a high level of statistical 
heterogeneity (chi2= 67.32; df= 17; p<0.00001; I2= 75%). The heterogeneity score was 
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lowered significantly by removing four studies [16,20,22,29] with high risk of bias (chi2= 
19.37; df= 13; p=0.11; I2= 33%) without effecting the pooled effect estimate (SMD= 0.42; 
95% CI 0.30, 0.55). See figure 3b for details. 
 
Figure 3a.  Forest plot comparing knowledge scores for patients who used an encounter patient decision aid 
versus controls. 
 
 
 
Figure 3b.  Forest plot comparing knowledge scores for patients who used an encounter patient decision aid 
versus controls excluding studies that have a high risk of bias. 
 
 
 
Decision conflict scale score 
All studies measuring decisional conflict used O’Connor’s validated, 16-item Decisional 
Conflict Scale (DCS). Figure 4 shows the effect estimate for each of the 15 studies where 
we had sufficient data to estimate the SMD. We were unable to estimate the SMD based on 
the study published by Thomson et al., and contact with the author did not yield more data. 
The pooled SMD indicates a ‘moderate’ effect size, and significantly favors the control 
which indicates that patients who did not have a PDA in the encounter had higher DCS 
compared to patients who used an encounter PDA (SMD= -0.33; 95% CI -0.56, -0.09). 
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Heterogeneity was statistically high (chi2= 88.54; df= 14; p<0.00001; I2= 84%) and 
remained high after removal of the four studies [16,20,22,29] that have a high risk of bias 
(chi2= 69.26; df= 14; p<0.00001; I2= 86%). Appendix 9 shows the effect size for the 
individual subscales of the DCS.  
 
Figure 4.  Forest plot comparing decisional conflict scores for patients who used an encounter patient 
decision aid versus controls. 
 
 
 
Patient involvement 
Figure 5 illustrates the effect estimate and confidence interval for each of the 9 studies 
reporting the patient involvement in the decision-making process using the Observer 
OPTION scale. Eight of the nine studies reported the use of Observer OPTION-12 
[10,15,17,22,23,25,26,31], and one study [19] used the more recent Observer OPTION-5 
scale. We were unable to estimate the SMD based on the study published by Coylewright 
et al., and contact with the author did not yield more data. In studies where an encounter 
PDA was used, patients had a higher level of involvement compared to the control, a large 
effect size (SMD= 0.94; 95% CI 0.40, 1.48). Significant heterogeneity was present (chi2= 
188.86; df= 8; p<0.00001; I2= 96%). There was no significant difference in perceived 
involvement where studies used a PROM [14,24].  
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Figure 5.  Forest plot comparing patient involvement for patients who used an encounter patient decision 
aid versus controls. 
 
 
 
Duration of consultation 
Figure 6 illustrates the effect estimate and confidence interval for each study reporting 
encounter duration time. We excluded the Whelan et al study because we were unable to 
estimate the SMD based on the information provided. The pooled SMD indicates no 
statistically significant difference in consultation time when comparing encounters that 
included the PDA, and those that did not (SMD= -0.06; 95% CI -0.29, 0.16). Significant 
heterogeneity was present (chi2= 20.30; df= 7; p<0.005; I2= 66%) and remained significant 
despite the removal of the studies [16,22] that have a high risk of bias (chi2= 15.32; df= 5; 
p<0.009; I2= 67%).   
 
Figure 6.  Forest plot comparing time durations when using encounter PDAs versus controls. 
 
 
 
Compared to the control, the use of encounter PDAs significantly increased patient 
satisfaction (when reported as a dichotomous outcome), but did not have an effect on 
patient trust or anxiety (see Appendix 10a through 12 for details). 
 
Subgroup analysis 
We analyzed the RCTs reporting a clinical outcome for four health conditions: diabetes 
mellitus, cholesterol, depression, and osteoporosis. Three studies used the Diabetes 
Medication Choice encounter PDA. There was no statistically significant decrease in blood 
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sugar (HbA1c) between the intervention and control arm  (SMD= -0.28;  p= 0.35;  95% CI 
-0.60, 0.03) [20,26], nor in the percentage of patients where blood sugar was lowered 
(intervention= 44% vs control= 50%, p=0.57) [15]. For the Statin Choice encounter PDA 
there was no statistically significant difference between the intervention and control group 
regarding adherence to statin medication (OR= 1.64; p= 0.35; 95% CI 0.58, 4.64). In the 
two studies that assessed depressive symptom severity reduction [23,24] – there was no 
statistically significant mean reduction in PHQ-D scores between intervention and the 
control groups (SMD= 0.08; p= 0.44; 95% CI -0.12, 0.28). When we pooled the odds ratio 
for the two studies that used the Osteoporosis Choice encounter PDA, there was no 
statistically significant difference between intervention and control group in terms of the 
number of patients who started bisphosphonates (OR= 1.39; p= 0.31; 95% CI 0.74, 2.60).  
 
Narrative review 
 
Our analysis identified the following three major themes – see Box 1:  
 
Box 1. Major themes of the non-randomized studies of encounter PDAs. 
 
 The high utility of encounter PDAs as judged by both patients and clinicians 
 Identifiable barriers to integration of encounter PDAs into clinic workflows 
 Encounter PDAs are feasible to implement if certain conditions are met 
 
The high utility of encounter PDAs as judged by both patients and clinicians 
22 of the 30 non-randomized studies reported data about the utility of encounter PDAs. 
Overall, encounter PDAs were judged to be highly useful by patients in two ways: 
improving knowledge and awareness of treatment options, and communication with their 
clinician. In four different qualitative studies, patients described their perception that 
encounter tools foster communication about treatment or screening options by enabling the 
exchange of information [6,52,60,70]. For example, patients felt that the use of an 
encounter tool for antihyperglycemic agents was useful in getting engaged in the decision-
making process [6]. A reported consequence of encounter PDAs fostering communication 
was that patients ask more questions, as was seen in one qualitative study using an 
encounter PDA for localized prostate cancer [67]. A mixed methods study using an 
electronic library of decision aids (arriba-lib) was useful in practicing the steps of SDM 
according to patient report [65]. Quasi-experimental studies reinforce the evidence that 
encounter tools improve knowledge and patient-clinician communication. An encounter 
tool for psoriasis, the Graves’ Decision choice decision aid and a Decision Board providing 
the benefits and risks of breast-conserving therapy all improved patient knowledge and 
patient-clinician communication [56,72,77]. Parents also reported high levels of perceived 
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SDM with the use of an encounter PDA for juvenile idiopathic arthritis medication choices 
[55]. Patients consider encounter tools to be useful, a finding that is reinforced by 
observational data in non-randomized studies. Analysis of video recordings show that the 
use of encounter tools increases SDM [4,53,54,58]. For example, observational data 
showed that the use of Option GridTM decision aids for neonatal circumcision and knee 
osteoarthritis, not only facilitated SDM, but increased knowledge of the available treatment 
options [4,58]. The same outcomes were also observed using an encounter PDA for 
attention-deficit hyperactivity disorder [54].  
 
From the clinician’s perspective, encounter PDAs were highly useful in changing 
communication patterns and facilitating a SDM process. Semi-structured interviews with 
clinicians indicated that they perceived the encounter PDAs to be useful in helping provide 
information about the treatment options which provoked patients to ask questions 
[6,44,52,59,60,61,63,64,67,75,76]. For example, Decision Boxes were useful to ‘provide 
relevant scientific information’ which empowered clinicians to answer patient questions 
[60]. Information provision ‘prompted more questions’, ‘opened-up discussion about 
possible side-effects of medication’ and helped clinicians ‘to have a better conversation 
with patients’ [6,64,76]. Survey data also indicates that encounter PDAs were found to be 
useful in providing information and discussing the therapeutic options [65,77]. 
Observational data reinforced the perception that encounter tools enabled SDM. Five 
studies, using the Observer OPTION scale to measure SDM, all concluded that encounter 
tools are useful in increasing patient involvement in the decision-making process 
[4,54,56,58,68].  
 
Barriers to integration of encounter PDAs into clinic workflow patterns 
Barriers to integration of encounter PDAs were mentioned in 16 of the 30 non-randomized 
studies. According to clinicians, there are three key barriers to integration of encounter 
tools: 1) time constraints; 2) lack of training on how to use encounter PDAs, and; 3) 
disagreement with the content and format of the tools. In terms of time constraints, 
qualitative evidence indicated that clinicians felt that using encounter PDAs increases the 
duration of encounters [44,59-64,71,76]. For example, colorectal cancer surgeons 
perceived that using encounter PDAs would be too time consuming [63]. Time pressure 
was the most often reported barrier by clinicians to the possible use of PDAs. Nevertheless, 
a pre-post study showed that the median consultation duration was 39 minutes when using 
the Graves’ Decision choice decision aid compared to 40 minutes for the control group 
[56]. In another pre-post study the mean consultation time when using an attention-deficit 
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hyperactive disorder encounter PDA was nearly identical to the control group (41 versus 
42 minutes) [54].  
 
Lack of clinician training on how to use encounter tools is an important barrier. Clinicians 
report a need to be more familiar with encounter PDAs before using them 
[4,6,44,59,60,71,75,76]. For example, clinicians who used Option GridTM PDAs needed 
more experience with the format before feeling comfortable using them with patients [76]. 
Practitioners working in two different healthcare organizations in the United States also 
stated that lack of training and education was a barrier to adoption of encounter PDAs [44]. 
General practitioners in Belgium indicated that they were reluctant to introduce encounter 
PDAs for early detection of prostate cancer due to lack of experience and training [60]. 
The same was true for oncologists in the Netherlands who were ‘insufficiently familiar’ 
with encounter PDAs and how to use them in practice [71]. Clinicians working in an inner-
city outpatient clinic also cited their lack of experience with a computerized encounter 
PDA as a hindrance to routine use [62]. According to clinicians a learning curve needs to 
take place. They need training and experience with encounter PDAs in order to overcome 
their reluctance to adopt them in routine workflows [4,59,78].  
 
Based on the studies analyzed, the content and format of many encounter PDAs is a barrier 
to routine use. Clinicians stated that the content of many encounter tools is too complex 
and poses a cognitive burden on patients, particularly those with lower health literacy skills 
or for those who have language problems. This was the case for some colorectal cancer 
surgeons who felt that the content of the three decision support tools in their study was 
‘overwhelming’ [63]. Similarly, clinicians using various Option GridTM PDAs and 
Decision Box PDAs also voiced concern that the content was too difficult for some 
patients to understand [44,59,61,76]. Patients and clinicians indicated that the content of an 
encounter PDA for psychiatric patients was too ‘medicalized’ and might cause confusion 
[64]. The layout of information was also a commonly reported barrier – many clinicians 
felt that important information was missing, that numerical data was poorly presented, and 
graphical displays absent [44,59,61,63,64,71,76].  
 
Ultimately, disagreement with the content and format of encounter tools, unfamiliarity with 
how to use them in practice, and the perception that they will increase duration of 
consultations influences clinician attitude towards implementing encounter PDAs routinely 
in their practice. 
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Encounter decision aids are feasible to implement if certain conditions are met 
Nine of the 30 non-randomized studies reported data about the feasibility of implementing 
encounter PDAs. To summarize, implementation of encounter PDAs was considered 
feasible provided clinicians agree to their use to improve healthcare delivery, the clinical 
team agrees on the mechanisms to disseminate the tools to patients, and there is a critical 
appraisal process to identify and address barriers as a group. [6,75]. Healthcare 
organizations that wish to promote SDM by using encounter PDAs report the need to 
invest in educating clinicians on the value of these tools and provide training on how to use 
them. Investment in education increases familiarization and can change the perception that 
time is an insurmountable barrier [6,61,71,76]. Organizations also report the need to 
formulate strategies to prevent PDAs disrupting clinic workflows. For example, clinical 
staff who enable patients to view encounter PDAs prior to the consultation found the 
process beneficial [44,52,57-59,61]. HealthPartners organization used this strategy where 
nurses presented the Option GridTM PDAs to patients prior to the encounter [44]. Nurses 
also played a pivotal role in the distribution of the Decision Boxes [61]. Giving patients 
time to read the content and enabling clinicians to personalize the tool during the clinical 
encounter are factors that were reported to increase the feasibility of implementation 
[58,59,71].  
 
Discussion and conclusion 
 
Discussion 
Encounter PDAs significantly increase patient knowledge, reduce Decision Conflict Scores 
and, based on observational data, increase SDM without increasing encounter duration. 
From the perspective of patient’s and clinician’s, these tools have high utility for 
structuring and facilitating conversations. Despite encounter PDAs being shorter, their 
integration into clinic workflow remains challenging given the reported barriers, which 
include: time constraints, lack of education on their purpose, training on how to use them, 
and some clinicians’ concern that the content and formats are unsuited for people with 
lower health literacy. Concerns about time pressures are prominent [34,35], even though 
the evidence indicates that the actual impact on encounter duration is minimal [79]. 
Despite the fact that very few articles describe the implementation strategies of encounter 
tools in their analysis, we can discern that the barriers to implementation of encounter 
PDAs are similar to those found when trying to implement pre-encounter tools. 
Nevertheless, the research so far indicates that encounter PDAs are capable of being 
implemented, provided that healthcare organizations formulate policies that support the use 
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of encounter PDAs to facilitate SDM and invest in strategies (i.e. provide training to 
clinicians) to implement these tools in practice.  
 
The strong aspects of this review are that the research gap arose from our experience in this 
field, our engagement of an information scientist (TM), and adherence to the best practice 
in how to conduct a systematic review, meta-analysis, and narrative review [46]. Narrative 
reviews are viewed as contributing to ‘deepening understanding’ about a specific question 
[80]. Three authors, all with different professional backgrounds, came to agreement on the 
key themes when analyzing the non-randomized studies in the narrative synthesis process. 
Potential limitations are the possible omission of some studies, despite our best efforts, and 
that several outcomes demonstrated statistically high heterogeneity. We therefore caution 
that the pooled effect size and confidence intervals reported should be interpreted as a 
range across conditions [12]. Also, in many RCTs the description of the PDA intervention 
was not comprehensive, often absent details regarding the PDA development process and 
ideal use. Future reports should use the SUNDAE checklist [81]. 
 
Our review differs and adds to the Cochrane review of PDAs [12]. The Cochrane review 
contains a subgroup analysis that compares pre-encounter tools to encounter PDAs. The 
analysis concluded that there was no difference in knowledge scores between the two types 
of tools, and that there were ‘too few studies’ to measure the uninformed or unclear values 
subscales for decisional conflict. In addition, the Cochrane review sub-analysis was unable 
to investigate patient communication, length of consultation, or patient satisfaction [12]. 
The review also did not investigate the effects of encounter PDAs on their own [12]. We 
address these outcomes and found that despite being shorter, these tools increase 
knowledge, increase SDM and satisfaction with the decision-making process, and lead to 
lower DCS scores without increasing encounter durations [12]. In addition, observational 
data indicates that encounter PDAs change communication patterns and increase SDM - a 
novel finding regarding encounter PDAs which addresses a significant gap in the decision 
aid literature which has typically relied on self-report as opposed to observation. These 
results corroborate the findings of Clayman et al which indicated, mainly using patient-
reported perceived involvement in decision-making, that interventions used within medical 
encounters increased patient involvement and participation [82].  
 
There is some indication emerging that as clinicians become familiar with encounter PDAs 
they are less likely to be concerned about the barriers [83]. Yet, this review highlights the 
challenge that faces healthcare organizations when considering how to create climates that 
are conducive to the implementation of these tools [7,41,44,83,84]. As mentioned in a 
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recent editorial by Montori et al, encounter PDAs promote patient-centered conversations 
that align with SDM, and although more evidence is needed to determine the effects of 
these tools on patient care, they can represent an ‘intellectual, emotional, and practical’ 
solution to policy goals [85]. 
 
Conclusion 
In summary, although encounter PDAs are shorter, they have very similar benefits to pre-
encounter PDAs. Notably, observational data indicates that encounter PDAs help 
clinicians’ practice SDM. These tools have high utility according to all stakeholders in the 
clinical setting, but clinicians have concerns about integration. Feasibility may be possible 
provided organizations get buy-in from their clinical teams on implementing encounter 
PDAs to improve healthcare delivery, and if they are provided with an education on how to 
use these tools in practice.  
 
Practical implications 
Based on our results, the positive effects of encounter PDAs should encourage healthcare 
stakeholders who wish to promote patient-centered care to create a pathway that is 
conducive to the implementation of these tools in clinical settings. As we continue to study 
the effects of these interventions, future research should focus on how best to bypass or 
mitigate the barriers to implementation and pay attention to the clinical outcomes 
associated with using encounter PDAs, and their effects on healthcare costs. 
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Appendix 2. Search strategy used for the Medline database. 
 
Search Search Terms 
#1 exp office visits/ or doctor appointment$.af. 
#2 (clinical encounter$ or day-to-day or routine consultation$).af. 
#3 (appointment$ or office visit$ or clinic visit$ or clinical visit$).af. 
#4 (health care encounter$ or health care visit$).af. 
#5 (healthcare encounter$ or healthcare visit$).af. 
#6 medical encounter$.af. or clinical practice.ti,ab. 
#7 or/1-6  
#8 (decision box or option grid$ or issue card$).af. 
#9 (drug fact box$ or shared decision$ or informed decision$).af. 
#10 (informed choice$ or collaborative decision$).af. 
#11 encounter decision aid$.af. 
#12 encounter decision tool$.af. 
#13 or/9-13 
#14 exp decision making/ or exp decision support techniques/ 
#15 (decision making or decision support).af. 
#16 (decision aid$ or decision tool$).af. 
#17 or/17-19 
#18 exp patient preferences/ or exp patient-centered care/ or exp patient participation/ 
#19 exp professional-patient relations/ or exp professional-family relations/ 
#20 (patient participation$ or patient engagement$).af. 
#21 (patient involvement or client participation).af. 
#22 (client engagement or client involvement).af. 
#23 (patient relation$ or patient preferenc$).af. 
#24 (patient centred or patient centered).af. 
#25 or/21-27 
#26 20 and 28 
#27 14 or 29 
#28 7 and 31 
#29 ("22854227" or "26566194" or "27871271" or "21605732" or "26343571" or "22867107" or 
"24708747").ui. 
#30 remove duplicates from 33 
#31 32 or 34 
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Appendix 3. CASP Checklist used to assess methodological quality of qualitative studies included in the 
narrative review. 
 
The Critical Appraisal Skills Program (CASP) Checklist which includes ten questions; 
each question has three possible responses – ‘yes’, ‘can’t tell’, and ‘no’. The first two 
questions on the checklist are screening questions, and both require a ‘yes’ in order to 
proceed to remaining eight questions (see Appendix 2 to view the CASP Checklist). There 
is no scoring system associated with this checklist because it was originally designed for 
education pedagogic tools. Therefore, study authors created a scoring criterion prior to 
starting the quality assessment for each study. Each response was coded (‘yes’= 1, ‘can’t 
tell’= 0, ‘no’= -1), and all study authors determine a priori that a score of 5-10 indicated 
that the study was of high value, 0-4 indicated moderate value, and -10 to -1 indicated low 
value. 
 
Was there a clear statement of the aims of the research? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Is a qualitative methodology appropriate? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Was the research design appropriate to address the aims of the research? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Was the recruitment strategy appropriate to the aims of the research? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Was the data collected in a way that addressed the research issue? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Has the relationship between researcher and participants been considered? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Have ethical issues been taken into consideration? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Was the data analysis sufficiently rigorous? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
Is there a clear statement of findings? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
How valuable is the research? ‘yes’= 1, ‘can’t tell’= 0, ‘no’= -1 
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Appendix 4. Ottawa-Newcastle quality assessment scales to evaluate observational studies included in the 
narrative review. 
 
The Newcastle-Ottawa Quality Assessment scale was used to assess observational studies 
(case-control, cohort, cross-sectional). Each study was evaluated based on three domains: 
the selection of the study groups, the comparability of the groups, and the ascertainment of 
either the exposure or outcome of interest. Developers of the scale used a ‘star system’ to 
judge whether a study was of good, fair, or poor quality. A study can receive a maximum 
of 5 stars for the selection domain, 2 stars for the comparability domain, and 3 stars for the 
outcome domain. A ‘good’ quality study was assigned: 3 or 4 stars in selection domain, 
and 1 or 2 stars in comparability domain and 2 or 3 stars in outcome/exposure domain. A 
‘fair’ quality study was assigned: 2 stars in selection domain and 1 or 2 stars in 
comparability domain, and 2 or 3 stars in outcome domain. Lastly, a poor-quality study 
received: 0 or 1 star in the selection domain, or 0 stars in the comparability domain, or 0 or 
1 stars in the outcome domain.  
 
CASE CONTROL COHORT CROSS-SECTIONAL 
Selection 
1)Is the case definition adequate? 
   a) yes, with independent 
validation* 
   b) yes, e.g. record linkage or self-
report 
   c) no description 
2)Representativeness of the cases 
   a) consecutive/representative 
series* 
   b) potential for selection biases or 
N/A 
3)Selection of controls 
   a) community controls* 
   b) hospital controls 
   c) no description 
4)Definition of controls 
   a) no history of disease (endpoint)* 
   b) no description of source 
Selection 
1)Representativeness of the exposed 
cohort 
   a) truly representative* 
   b) somewhat representative* 
   c) selected group 
   d) no description of the derivation 
2)Selection of the non-exposed 
cohort 
   a) drawn from the same 
community as  the exposed 
cohort* 
   b) drawn from a different source 
   c) no description of the derivation 
of the  non-exposed cohort 
3)Ascertainment of exposure 
   a) secure record (e.g. surgical 
record) * 
   b) structured interview* 
   c) written self-report  
   d) no description 
   e) other 
4)Demonstration that outcome of 
interest was not present at start of 
study 
   a) yes* 
   b) no  
Selection 
1)Representativeness of the exposed 
cohort 
   a) truly representative* 
   b) somewhat representative* 
   c) selected group of users 
   d) no description of sampling 
strategy 
2)Sample size 
   a) justified and satisfactory* 
   b) not justified 
3)Non-respondents 
   a) comparability between 
respondents and non-respondent’s 
characteristics is established, and 
 the response rate is 
satisfactory. * 
   b) the response rate is 
unsatisfactory, or  the comparability 
between respondents and non-
respondents is unsatisfactory. 
   c) no description of the response 
rate or the characteristics of the 
responders and the non-responders. 
4)Ascertainment of exposure (risk 
factor): 
   a) validated measurement tools** 
   b) non-validated measurement tool, 
but  the tool is available* 
   c) no description of the tool 
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CASE CONTROL COHORT CROSS-SECTIONAL 
Comparability 
1)Comparability of cases and 
controls on the basis of design or 
analysis 
   a) study controls for      * 
   b) study controls for an additional 
factor* 
Comparability 
1)Comparability of cohorts on the 
basis of design or analysis controlled 
for confounders 
   a) study controls for age, sex, and 
 marital status* 
   b) study controls for other factors* 
   c) cohorts are not comparable on 
the basis of the design or analysis 
controlled for confounders. 
Comparability (max 2 stars) 
1)The subjects in different outcome 
groups are comparable, based on the 
study design or analysis. 
Confounding factors are controlled. 
   a) the study controls for the most 
important factor* 
   b) study controls for any additional 
factor* 
Exposure 
1)Ascertainment of exposure 
   a) secure record (e.g. surgical 
records) * 
   b) structured interview where blind 
to  case/control status* 
   c) interview not blinded to 
case/control 
   d) written self-report or medical 
record 
   e) no description 
2)Same method of ascertainment for 
cases and controls 
   a) yes* 
   b) no 
3)Non-response rate 
   a) same rate for both group* 
   b) non-respondents described 
   c) rate different and no designation 
Outcome 
1)Assessment of outcome 
   a) independent blind assessment * 
   b) record linkage* 
   c) self-report 
   d) no description 
   e) other 
2)Was follow-up long enough for 
outcomes to occur 
   a) yes* 
   b) no 
3)Adequacy of follow-up cohorts 
   a) complete follow-up* 
   b) subjects lost to follow-up 
unlikely to introduce bias* 
   c) follow-up rate less than 80% and 
no description of those lost 
   d) no statement 
Outcome (max 3 stars) 
1)Assessment of outcome 
   a) independent blind assessment ** 
   b) record linkage** 
   c) self-report* 
   d) no description 
2)Statistical test: 
   a) the statistical test used to 
analyze the data is clearly described 
and appropriate, and the 
measurement of the association is 
presented, including confidence 
intervals and the probability level 
(p value). * 
   b) the statistical test is not 
appropriate, not described or 
incomplete. 
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Appendix 5. NHLBI quality assessment tool used to evaluate pre-post studies included in the narrative review. 
 
The NHLBI quality assessment tool lists 12 dichotomous (yes/no) questions to assess the 
internal validity of each study. For each question we assigned a score of yes (1), no (-1), or 
can’t tell (0). The lowest possible score was -12, and the highest possible score was 12. If 
the study received a score between -12 and -4 it was considered ‘poor’ quality, a  score  of 
-3 to 4 was considered ‘fair’ quality, and a score of >5 ‘good’ quality.  
 
Was the study question objective clearly stated? yes (1), no (-1), or can’t tell (0) 
Were eligibility/selection criteria for the study population prespecified and 
clearly described? yes (1), no (-1), or can’t tell (0) 
Were the participants in the study representative of those who would be eligible 
for the test/service/intervention in the general or clinical population of interest? yes (1), no (-1), or can’t tell (0) 
Were all eligible participants that met the prespecified entry criteria enrolled? yes (1), no (-1), or can’t tell (0) 
Was the sample size sufficiently large to provide confidence in the findings? yes (1), no (-1), or can’t tell (0) 
Was the intervention clearly described and delivered consistently across the 
study population? yes (1), no (-1), or can’t tell (0) 
Were the outcome measures prespecified, clearly defined, valid, reliable, and 
assessed consistently across all study participants? yes (1), no (-1), or can’t tell (0) 
Were the people assessing the outcomes blinded to the participants’ 
exposures/interventions? yes (1), no (-1), or can’t tell (0) 
Was the loss to follow-up after baseline 20% or less? Were those lost to follow-
up accounted for in the analysis? yes (1), no (-1), or can’t tell (0) 
Did the statistical methods examine changes in outcome measures from before 
or after the intervention? Were statistical tests done that provided p values for 
the pre-to-post changes? 
yes (1), no (-1), or can’t tell (0) 
Were outcome measures of interest taken multiple times before the intervention 
and after the intervention? yes (1), no (-1), or can’t tell (0) 
If the intervention was conducted at the group level did the statistical analysis 
take into account, the use of individual-level data to determine effects at the 
group level? 
yes (1), no (-1), or can’t tell (0) 
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Appendix 6. The Downs and Black checklist tool to assess the quality of quasi-experimental studies. 
 
The Downs and Black checklist tool to assess the quality of quasi-experimental studies 
contains five domains: reporting, external validity, internal validity (bias), internal validity 
(selection bias), power. Each domain contains one to ten questions – in total there are 27 
questions in this checklist. Each question can have two possible answers: no (coded as 0), 
yes (coded as 1). The highest possible score is 27. A score of >26 indicates that the study is 
of excellent quality. A score of 20-25 indicates that the study is of good quality, 15-19 
indicates fair quality, and 14 or less indicates poor quality.  
 
Reporting  
Is the hypothesis/aim/objective of the study clearly described? Yes = 1; No = 0 
Are the main outcomes to be measured clearly described in the introduction or methods 
section? If the main outcomes are first mentioned in the Results section, the question should be 
answered no. 
Yes = 1; No = 0 
 
Are the characteristics of the patients included in the study clearly described? In cohort studies 
and trials, inclusion and/or exclusion criteria should be reported. In case-control studies, a case-
definition and the source for controls should be provided. 
Yes = 1; No = 0 
 
Are the interventions of interest clearly described? Treatments and placebo (where relevant) 
that are to be compared should be clearly described. 
Yes = 1; No = 0 
 
Are the distributions of principal confounders in each group of patients to be compared clearly 
described? A list of principal confounders is provided. 
Yes = 1; No = 0 
 
Are the main findings of the study clearly described? Simple outcome data (including 
denominators and numerators) should be reported for all major findings so that the reader can 
check the major analyses and conclusions. (This question does not cover statistical tests that are 
considered below). 
Yes = 1; No = 0 
 
Does the study provide estimates of the random variability in the data for the main outcomes? 
In non-normally distributed data, the inter-quartile range of results should be reported. In 
normally distributed data, the standard error, standard deviation, or confidence intervals should 
be reported. If the distribution of the data is not described, it must be assumed that the 
estimates used were appropriate and the question should be answered yes. 
Yes = 1; No = 0 
 
Have all important adverse events that may be a consequence of the intervention been 
reported? This should be answered yes if the study demonstrates that there was a 
comprehensive attempt to measure adverse events. 
Yes = 1; No = 0 
 
Have the characteristics of patients lost to follow-up been described? This should be answered 
yes where there were no losses to follow-up or where losses to follow-up were so small that 
findings would be unaffected by their inclusion. This should be answered no when a study does 
not report the number of patients lost to follow-up. 
Yes = 1; No = 0 
 
Have actual probability values been reported (e.g., 0.035 rather than < or > specific figures, 
some as equality, e.g. p = 0.034), question should be answered ‘yes’. 
Yes = 1; No = 0 
 
External Validity  
Were the subjects asked to participate in the study representative of the entire population from 
which they were recruited? The study must identify the source population for patients and 
describe how the patients were selected. Patients would be representative if they comprised the 
entire source population, an unselected sample of consecutive patients, or a random sample. 
Random sampling is only feasible where a list of all members of the relevant population exists. 
Where a study does not report the proportion of the source population from which the patients 
are derived, the question should be answered as unable to determine. 
 
 
 
 
Yes = 1; No = 0 
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Were those subjects who were prepared to participate representative of the entire population 
from which they were recruited? The proportion of those asked and agreed to participate should 
be stated. Validation that the sample was representative would include demonstrating that the 
distribution of the main confounding factors was the same in the study sample and the source 
population. 
Yes = 1; No = 0 
 
Were the staff, places, and facilities where the patients were treated representative of the 
treatment the majority of patients receive? For the question to be answered yes the study should 
demonstrate that the intervention was representative of that in use in the source population. The 
question should be answered no if, for example, the intervention was undertaken in a specialist 
center unrepresentative of the hospitals most of the source population would attend. 
Yes = 1; No = 0 
 
Internal Validity - Bias  
Was an attempt made to blind study subjects to the intervention they have received? For studies 
where the patients would have no way of knowing which intervention they received, this 
should be answered yes. 
Yes = 1; No = 0 
 
Was an attempt made to blind those measuring the main outcomes of the intervention? Yes = 1; No = 0 
If any of the results of the study were based on “data dredging,” was this made clear? Any 
analyses that had not been planned at the outset of the study should be clearly indicated. If no 
retrospective unplanned subgroup analyses were reported, then answer yes. 
Yes = 1; No = 0 
 
In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, 
or in case-control studies, is the time period between the intervention and outcome the same for 
cases and controls? Where follow-up was the same for all study patients, the answer should 
yes. If different lengths of follow-up were adjusted, for example, by survival analysis, the 
answer should be yes. Studies where differences in follow-up are ignored should be answered 
no. 
Yes = 1; No = 0 
 
Were the statistical tests used to assess the main outcomes appropriate? The statistical 
techniques used must be appropriate to the data. For example, nonparametric methods should 
be used for small sample sizes. Where little statistical analysis has been undertaken but where 
there is no evidence of bias, the question should be answered yes. If the distribution of the data 
(normal or not) is not described it must be assumed that the estimates used were appropriate 
and the question should be answered yes. 
Yes = 1; No = 0 
 
Was compliance with the intervention(s) reliable? Where there was noncompliance with the 
allocated treatment or where there was contamination of one group, the question should be 
answered no. For studies where the effect of any misclassification was likely to bias any 
association to the null, the question should be answered yes. 
Yes = 1; No = 0 
 
Were the main outcome measures used accurate (valid and reliable)? For studies where the 
outcome measures are clearly described, the question should be answered yes. For studies that 
refer to other work or demonstrates the outcome measures are accurate, the question should be 
answered as yes. 
Yes = 1; No = 0 
 
Internal Validity – Confounding (selection bias)  
Were the patients in different intervention groups (trials and cohort studies) or were the cases 
and controls (case-control studies) recruited from the same population? For example, patients 
for all comparison groups should be selected from the same hospital. The question should be 
answered “unable to determine” for cohort and case control studies where there is no 
information concerning the source of patients included in the study. 
Yes = 1; No = 0 
 
Were study subjects in different intervention groups (trials and cohort studies) or were the 
cases and controls (case-control studies) recruited over the same period of time? For a study 
which does not specify the time period over which patients were recruited, the question should 
be answered as “unable to determine.” 
Yes = 1; No = 0 
 
Were study subjects randomized to intervention groups? Studies that state that subjects were 
randomized should be answered yes except where method of randomization would not ensure 
random allocation. For example, alternate allocation would score 0 because it is predictable. 
 
Yes = 1; No = 0 
 
Was the randomized intervention assignment concealed from both patients and healthcare staff 
until recruitment was complete and irrevocable? All nonrandomized studies should be 
answered no. If assignment was concealed from patients but not from staff, it should be 
answered no. 
Yes = 1; No = 0 
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Was there adequate adjustment for confounding in the analyses from which the main findings 
were drawn? This question should be answered no for trials if: the main conclusions of the 
study were based on analyses of treatment rather than intention to treat; the distribution of 
known confounders in the different treatment groups was not described; or the distribution of 
known confounders differed between the treatment groups but was not taken into account in the 
analyses. In nonrandomized studies, if the effect of the main confounders was not investigated 
or confounding was demonstrated but no adjustment was made in the final analyses, the 
question should be answered as no. 
Yes = 1; No = 0 
 
Were losses of patients to follow-up taken into account? If the numbers of patients lost to 
follow-up are not reported, the question should be answered as “unable to determine.” If the 
proportion lost to follow-up was too small to affect the main findings, the question should be 
answered yes. 
Yes = 1; No = 0 
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Appendix 7. The support for judgment for all risk of bias domains of the Cochrane tool for each included 
randomized controlled trial. 
 
Bias  Authors’ 
judgment 
Support for judgment 
Bekker et al, 2004 
Random sequence generation  Unclear Comment: No information provided. 
Allocation concealment Low Quote: “Participants were randomly allocated to one of two 
consultations using previously numbered, sealed, opaque envelopes.” 
Blinding of participants and 
personnel 
Low Quote: “Participants were not told which consultation was routine.” 
Blinding of outcome assessment Low Comment: No blinding of outcome assessment, but the review authors 
judge that the outcome measurement is not likely to be influenced by 
lack of blinding 
Incomplete outcome data Unclear Comment: Insufficient reporting of attrition/exclusions. 
Selective reporting bias Unclear Comment: Insufficient information. 
Other bias Unclear Comment: Insufficient information to assess whether an important risk 
of bias exists 
Bergeron et al, 2017 
Random sequence generation  Low Quote: “Randomization was carried out using a random number 
generator at the time of presentation to the clinic.” 
Allocation concealment Unclear Comment: Method of concealment is not described. 
Blinding of participants and 
personnel 
Unclear Comment: The study did not mention if/how participants were blinded.
Blinding of outcome assessment Low Quote: “The person administering the decisional conflict measures was 
blinded to the method used for each patient.” 
Incomplete outcome data Low Comment: No missing outcome data. 
Selective reporting bias Low Comment: Study protocol is not available, but the expected outcomes 
are published. 
Other bias Unclear Comment: Insufficient rationale or evidence that an identified problem 
will introduce bias. 
Branda et al, 2013 
Random sequence generation  Low Quote: “Primary care practices were enrolled then matched by size (≤ 2 
clinicians or > 2 clinicians) and randomly allocated by a statistician 
(who was the only team member aware of the composition of the pairs 
of practices).” 
Allocation concealment Unclear Comment: A statistician was the only team member aware of which 
practices were in each trial arm. 
Blinding of participants and 
personnel 
Low Quote: “Patients, who were kept unaware of the study hypotheses...” 
Blinding of outcome assessment Low Quote: “A pair of trained and calibrated investigators working 
independently and reproducibly evaluated video recorded encounters in 
intervention and control groups.” 
Incomplete outcome data Low Comment: Reasons for missing outcome data unlikely to be related to 
true outcome 
Selective reporting bias Low Comment: The study protocol is available and all of the study's pre-
specified outcomes have been reported. 
Other bias Unclear Comment: Insufficient information to assess whether an important risk 
of bias exists 
Coylewright et al, 2013 
Random sequence generation  Low Quote: “The randomization took place on a secure study website using 
a computer-generated allocation sequence, which randomized patients 
in a concealed fashion to decision aid versus usual care.” 
Allocation concealment Unclear Quote: “Blinding was not possible for patients and involved clinicians, 
given physical presence of the decision aid. Per the original study 
design, the principal investigators did not enroll any patients they were 
personally treating to eliminate bias in patient selection and potential 
coercion.” 
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Bias  Authors’ 
judgment 
Support for judgment 
Blinding of participants and 
personnel 
High Comment: Not possible due to the presence of the decision aid in the 
encounter for those in the intervention arm. 
Blinding of outcome assessment Unclear Comment: The study did not address this outcome. 
Incomplete outcome data Low Comment: No missing outcome data. 
Selective reporting bias Low Comment: Outcomes match those found on clinicaltrials.gov 
Other bias Unclear Comment: Insufficient information to assess whether an important risk 
of bias exists. 
Elwyn et al, 2004 
Random sequence generation  Low Quote: “All randomizations were undertaken by random number 
generation…” 
Allocation concealment Low Quote: “…allocations by the trial statistician were concealed from 
those implementing the interventions or assessments.” 
Blinding of participants and 
personnel 
Low Quote: “Both clinicians and patients were informed that the trial was 
investigating ‘communication skills’ but were otherwise ‘blinded’ to 
the decision-making or risk communication focus of the interventions.”
Blinding of outcome assessment Low Quote: “All consultation recordings were intended to be rated by two 
raters and ratings were undertaken blind to study group allocation of 
clinicians or patients.” 
Incomplete outcome data Unclear Insufficient reporting of attrition/exclusion to permit judgment. 
Selective reporting bias Unclear Insufficient information provided 
Other bias Low Study appears to be free of other sources of bias. 
Hess et al, 2012 
Random sequence generation  Low Quote: “Patients were randomized to either usual care or shared 
decision making through a Web-based, computer-generated allocation 
sequence in a 1:1 concealed fashion.” 
Allocation concealment Low Quote: “We used dynamic allocation, a method of sequential treatment 
assignment that minimizes imbalances in selected prognostic factors 
between groups, to generate treatment assignments.” 
Blinding of participants and 
personnel 
Low Comment: Patients and personnel were blinded. 
Blinding of outcome assessment Low Quote: “The principal investigator, blinded to allocation and to patient 
outcome.” 
Incomplete outcome data Unclear Comment: Study did not address this outcome. 
Selective reporting bias Low Comment: The study protocol is available, and all of the pre-specified 
outcomes are present in the current study. 
Other bias Low Comment: The study appears to be free of other sources of bias 
Johnson et al, 2006 
Random sequence generation  Low Quote: “Four computer-generated randomization lists (one for each 
resident) were prepared by the P.I. Each resident used the list to assign 
patients to one of the two groups.” 
Allocation concealment Unclear Quote: “Allocation was concealed from patients.” 
Blinding of participants and 
personnel 
Unclear Comment: Insufficient information. Patients were blinded, but it is 
unclear if residents were blinded as well. 
Blinding of outcome assessment Low Quote: “There were no patient or resident identifiers on the patient 
questionnaire or the envelope. The questionnaire results were therefore 
completely anonymous.” 
Incomplete outcome data Low Comment: Reasons for missing outcome data unlikely to be related to 
true outcome 
Selective reporting bias Unclear Comment: Insufficient information 
Other bias Unclear Comment: Insufficient information to assess whether an important risk 
of bias exists. 
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Bias  Authors’ 
judgment 
Support for judgment 
Jouni et al, 2017 
Random sequence generation  Low Quote: “Randomization was performed by means of a computer-
generated random sequence with stratification for age, gender, and 
positive family history for coronary heart disease...” 
Allocation concealment Unclear Comment: Method of concealment not described in sufficient detail. 
Blinding of participants and 
personnel 
Unclear Comment: Unclear if personnel were blinded since principal 
investigator generated the random allocation sequence and study arm 
assignment. 
Blinding of outcome assessment Unclear Comment: Unclear if personnel were blinded. 
Incomplete outcome data Unclear Comment: Insufficient reporting of attrition to permit judgment of high 
or low risk. 
Selective reporting bias Low Quote: “The study was performed in accordance with relevant 
guidelines and regulations. The MI-GENES study protocol, design, and 
primary outcome have been previously published.” 
Other bias Unclear Comment: Insufficient rationale or evidence that an identified problem 
will introduce bias. 
Karagiannis et al, 2016 
Random sequence generation  Low Quote: “Eligible practices were matched based on level of care 
(primary or secondary) by the study statistician, and were randomly 
allocated within each pair, using a computer-generated allocation 
sequence, to either the use of the Diabetes Medication Choice Decision 
Aid or to usual care.” 
Allocation concealment Low Quote: “...the statistician paired the sites without study team input. This 
seemed appropriate to avoid bias, as the statistician had no contact with 
participating sites and no information on them beyond information for 
randomisation.” 
Blinding of participants and 
personnel 
Unclear Quote: “Owing to the nature of the intervention, clinicians and patients 
were not blinded. However, by virtue of how we designed the informed 
consent procedures, patients were kept masked to the study goals and 
main hypotheses.” 
Blinding of outcome assessment Unclear Comment: Insufficient information to make judgment. 
Incomplete outcome data Low Comment: Missing outcome data balanced in numbers across groups, 
with similar reasons for missing data. 
Selective reporting bias High Quote: “In the study protocol, we report decisional quality as our 
primary outcome, defined as decisional conflict measured with a 
modified 13-item version of the Decisional Conflict Scale. In our 
report, decisional conflict values were inverted to decisional comfort 
values, an approach also adopted in other studies evaluating decision 
aids.” 
Other bias Unclear Comment: Insufficient information. 
Krones et al, 2008 
Random sequence generation  Unclear Comment: Insufficient information. 
Allocation concealment Unclear Quote: “Participating family doctors could not be blinded because of 
the intervention. Patients were informed that different kinds of risk 
communication and decision support would be assessed; they were 
unaware of their physicians’ group allocation, however.” 
Blinding of participants and 
personnel 
Unclear Comment: Insufficient information. 
Blinding of outcome assessment Unclear Comment: Insufficient information to judge. 
Incomplete outcome data Unclear Comment: Insufficient reporting of attrition. 
Selective reporting bias Unclear Comment: Insufficient information. 
Other bias Unclear Comment: Insufficient information. 
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Bias  Authors’ 
judgment 
Support for judgment 
Leblanc et al, 2015 
Random sequence generation  Low Quote: “Patients were the unit of randomization and were allocated 
using a computer-generated sequence that randomized them 1:1:1 in a 
concealed fashion.” 
Allocation concealment Low Quote: “Patients and clinicians were aware of the overall objective, 
presented as improvement in communication between patients and 
clinicians during the clinical encounter, but remained blinded to the 
specific aims.” 
Blinding of participants and 
personnel 
Low Comment: Patients and clinicians were blind to study aims. 
Blinding of outcome assessment Low Quote: “After randomization, only data analysts remained blind to 
allocation.” 
Incomplete outcome data Low Comment: Missing outcome data is balanced across groups. 
Selective reporting bias Unclear Comment: Insufficient information to judge. 
Other bias High Comment: Had potential source of bias related to study design. 
Leblanc et al, 2015 
Random sequence generation  Unclear Quote: “The lead study statistician therefore stratified practices by their 
history of accrual and the presence of the Depression Improvement 
Across Minnesota, Offering a New Direction (DIAMOND) program 
and centrally randomized practices within these strata to either care 
with or without DMC.” 
Allocation concealment Unclear Quote: “Study team-members, practices, and clinicians were aware of 
the assigned arms.” 
Blinding of participants and 
personnel 
Unclear Quote: “Patients were kept unaware of the study hypothesis and nature 
of the intervention.” 
Blinding of outcome assessment Unclear Comment: Insufficient information to judge. 
Incomplete outcome data Low Comment: Similar reasons for missing data + balanced across groups. 
Selective reporting bias Low Comment: Study protocol is published, and pre-specified outcomes are 
reported. 
Other bias Unclear Comment: Insufficient information to assess whether other biases exist.
Loh et al, 2007 
Random sequence generation  Low Quote: “To compare the intervention with usual care, two-thirds of the 
general practitioners (n = 20) were randomly assigned to the 
intervention group by drawing blinded lots under supervision of the 
principal investigator and two researchers...” 
Allocation concealment Low Comment: Drawing blinded lots. 
Blinding of participants and 
personnel 
Unclear Comment: Method of concealment not described in sufficient detail to 
make judgment. 
Blinding of outcome assessment Unclear Comment: Insufficient information provided. 
Incomplete outcome data Unclear Comment: Insufficient reporting of attrition to permit judgment. 
Selective reporting bias Unclear Comment: Insufficient information. 
Other bias Low Comment: Study appears to be free of other sources of bias. 
Montori et al, 2011 
Random sequence generation  Low Quote: ‘A computer-generated allocation sequence randomized patients 
1:1 in a concealed fashion (using a secure study website) to control or 
intervention.” 
Allocation concealment Low Quote: “After randomization, data collectors and data analysts were 
blind to allocation.” 
Blinding of participants and 
personnel 
Unclear Comment: Insufficient information to permit judgment. 
Blinding of outcome assessment Low Comment: Data collectors were blind to allocation. 
Incomplete outcome data Low Comment: No missing outcome data. 
Selective reporting bias Low Comment: Study protocol is available, and pre-specified outcomes are 
reported. 
Other bias Unclear Comment: Insufficient information to make judgment. 
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Bias  Authors’ 
judgment 
Support for judgment 
Mullan et al, 2009 
Random sequence generation  Low Quote: “A computer-generated allocation sequence, unavailable to 
personnel enrolling patients or clinicians, randomized clinicians to 
intervention (decision aid) or usual care and was accessed by the study 
coordinators via telephone. The sequence was stratified by practice 
type (e.g., family medicine or primary care) and practice location, with 
a block size of 4.” 
Allocation concealment Low Quote: “A computer-generated allocation sequence, unavailable to 
personnel enrolling patients or clinicians...” 
Blinding of participants and 
personnel 
Unclear Comment: Insufficient info to judge. 
Blinding of outcome assessment Low Comment: Outcome measurement is not likely to be influenced by lack 
of blinding. 
Incomplete outcome data Unclear Comment: Insufficient info on attrition. 
Selective reporting bias Low Comment: Published report include all expected outcomes. 
Other bias Low Comment: Free of other sources of bias. 
Ozanne et al, 2007 
Random sequence generation  Unclear Comment: Insufficient information provided. 
Allocation concealment Unclear Comment: No information provided on allocation concealment. 
Blinding of participants and 
personnel 
Unclear Comment: Insufficient information provided. 
Blinding of outcome assessment Low Comment: No blinding of outcome assessment, but not likely to be 
influenced by lack of blinding 
Incomplete outcome data Low Comment: No missing outcome data. 
Selective reporting bias Unclear Comment: Insufficient information to judge. 
Other bias Unclear Comment: Insufficient information. 
Perestelo-Perez et al, 2016 
Random sequence generation  Low Quote: “Physicians who consented to participate were randomized to 
intervention or usual care by means of a computer-generated list.” 
Allocation concealment Unclear Comment: Insufficient information provided. 
Blinding of participants and 
personnel 
Unclear Comment: Insufficient information provided. 
Blinding of outcome assessment Low Quote: “Post visit measures were collected immediately after the visit 
by a researcher.” 
Incomplete outcome data Low Comment: Missing outcome data balanced in numbers across groups. 
Selective reporting bias Low Comment: Study protocol is unavailable, but all expected outcomes are 
reported. 
Other bias Unclear Comment: Insufficient information to judge. 
Shorten et al, 2005 
Random sequence generation  Low Quote: “Opaque envelopes containing a random allocation for each 
participant code number were prepared by computer‐based randomized 
generation.” 
Allocation concealment Low Quote: “After recruitment and consent were obtained with the first 
survey, a code number was assigned to the participant. The researcher 
then opened the envelope for the corresponding number and recorded 
the allocation to prevent departures from the schedule by a patient or 
her physician or midwife.” 
Blinding of participants and 
personnel 
Unclear Quote: “Participants were blinded to their allocation, although they all 
expected to receive information about birth options during the 
pregnancy. Midwives and doctors were blinded to both women's 
enrolment and study allocation. However, women who used the 
decision‐aid as specified and in a process of consultation with their 
midwife or doctor would have negated the blinding of their clinicians, 
and perhaps of the women themselves. For the intervention group, this 
may have affected the level and type of information exchanged 
between them and their caregivers.” 
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Bias  Authors’ 
judgment 
Support for judgment 
Blinding of outcome assessment Low Comment: Lack of blinding does not influence outcome measurement. 
Incomplete outcome data Unclear Comment: Insufficient information on attrition. 
Selective reporting bias Low Comment: All expected outcomes reported. 
Other bias High Quote: “Fourth, qualitative evidence gathered during the study 
suggested that data about birth preference may have been compromised 
in some cases, in that women felt compelled by study site factors to 
express preferences that did not reflect their true inclinations.” 
Thomson et al, 2007 
Random sequence generation  Low Quote: “Participants were randomised to either: (a) computerised 
decision aid (intervention) or (b) evidence-based paper guidelines 
(control), using electronically-generated random permuted blocks via a 
web-based randomization service provided by the Centre for Health 
Services Research.” 
Allocation concealment Low Comment: Web-based randomization. 
Blinding of participants and 
personnel 
Unclear Comment: Patients were blinded but not doctors. 
Blinding of outcome assessment Low Comment: Measurement is unlikely to be influenced by lack of 
blinding. 
Incomplete outcome data Low Comment: Missing outcome data is balanced in both groups. 
Selective reporting bias Low Comment: All expected outcomes are reported. 
Other bias Low Comment: Free of other sources of bias. 
Warner et al, 2015 
Random sequence generation  Low Quote: “After enrollment, subjects were randomized to receive either 
the decision aid or usual care. Randomization was stratified according 
to anticipated type of surgery (inpatient vs. outpatient) using blocks of 
size 4, as we had previously shown that type of surgery is an important 
factor determining postoperative smoking behavior. For each stratum, a 
randomization schedule was generated by the Mayo Clinic Division of 
Biostatistics. At the time of enrollment, group assignment was 
determined according to the appropriate stratum using sealed 
envelopes.” 
Allocation concealment Low Quote: “Randomization schedule completed by statisticians.” 
Blinding of participants and 
personnel 
Low Quote: “Separate groups of clinicians delivered the decision aid (n = 
18) and usual care (n = 6) to minimize the potential for contamination.”
Blinding of outcome assessment Unclear Comment: Insufficient information to judge. 
Incomplete outcome data Unclear Comment: Insufficient information provided. 
Selective reporting bias Low Comment: Published report includes all expected outcomes. 
Other bias Unclear Comment: Insufficient information to judge. 
Weymiller et al, 2007 
Random sequence generation  Low Quote: “A computer-generated allocation sequence, unavailable to 
personnel enrolling patients, randomized providers to intervention 
(decision aid) or control groups, stratified by sex and status (fellow or 
faculty), and randomized patients to receive the intervention (decision 
aid or pamphlet) either from their clinician during the visit or from a 
researcher before the visit.” 
Allocation concealment Low Quote: “A computer-generated allocation sequence, unavailable to 
personnel enrolling patients...” 
Blinding of participants and 
personnel 
 
Low Comment: Both were blinded. 
Blinding of outcome assessment Low Quote: “Data analysts and statisticians blinded to allocation used 
generalized estimating equations to estimate the association between 
intervention and outcomes.” 
Incomplete outcome data Low Comment: No missing outcome data. 
Selective reporting bias Low Comment: All pre-specified outcomes are reported. 
Other bias Low Comment: The study appears to be free of other sources of bias 
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Bias  Authors’ 
judgment 
Support for judgment 
Whelan et al, 2003 
Random sequence generation  Unclear Quote: “Consenting patients were randomly assigned to receive the 
medical consultation alone, i.e., presentation and discussion of 
information on treatment alternatives, or the medical consultation plus 
the Decision Board. Patients were stratified by medical 
oncologist/primary care nurse team before randomization, which was 
performed at a central location.” 
Allocation concealment Low Comment: Performed at a central location so the enrollment of 
participants was concealed from clinicians. 
Blinding of participants and 
personnel 
Unclear Comment: Unclear if personnel were blinded. 
Blinding of outcome assessment Low Comment: Research assistant collected the data. 
Incomplete outcome data Unclear Comment: Insufficient information provided to make judgment. 
Selective reporting bias Unclear Comment: Insufficient information provided to make judgment. 
Other bias Low Comment: Study appears to be free of other sources of bias. 
Whelan et al, 2004 
Random sequence generation  Unclear Quote: “Surgeons were pair-matched according to sex and age as 
surrogates for style of information giving. They were then randomly 
assigned in a concealed fashion either to use the decision board in their 
surgical consultation or to retain their routine consultation style.” 
Allocation concealment Unclear Comment: Not enough information to judge. 
Blinding of participants and 
personnel 
Unclear Comment: Not enough information to judge. 
Blinding of outcome assessment Low Comment: The research assistant collected all outcome data. 
Incomplete outcome data Unclear Comment: Not enough information provided to judge. 
Selective reporting bias Unclear Comment: Insufficient information to permit judgment. 
Other bias Low Comment: Appears to be free of other sources of bias. 
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Appendix 8a. Funnel plot comparing encounter patient decision aid use to usual care (control) for 
publication bias detection for the knowledge continuous outcome measure. 
 
 
 
Appendix 8b. Funnel plot comparing encounter patient decision aid use to usual care (control) for 
publication bias detection for the decisional conflict continuous outcome measure. 
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Appendix 9. Effect Size for each individual subscale of the Decisional Conflict Scale. 
 
Outcome Subgroup No. of Studies Statistical Method Effect Size 
   Total Decisional Conflict Score 15 Mean Difference (IV, Random, 95% CI) -0.33 [-0.56, -0.09] 
   Uninformed Subscale 12 Mean Difference (IV, Random, 95% CI) -0.17 [-0.47, 0.12] 
   Unclear Values Subscale 8 Mean Difference (IV, Random, 95% CI) -0.19 [-0.63, 0.24] 
   Uncertainty Subscale 9 Mean Difference (IV, Random, 95% CI) -0.19 [-0.51, 0.13] 
   Unsupported Subscale 10 Mean Difference (IV, Random, 95% CI) -0.06 [-0.30, 0.17] 
   Ineffective Subscale 10 Mean Difference (IV, Random, 95% CI) 0.03 [-0.18, 0.24] 
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Appendix 10a. Forest plot of the odds of patient satisfaction among those who used an encounter patient 
decision aid versus controls. 
 
Satisfaction is significantly higher among the encounter patient decision aid group compared to the control (OR= 1.78; 
95% CI 1.19, 2.66), and the level of heterogeneity was low and non-significant (chi2= 5.72; df= 4; p<0.22; I2= 30%).  
 
 
 
Appendix 10b. Forest plot comparing patient satisfaction for patients who used an encounter patient decision 
aid versus controls. 
 
There is no statistical difference in satisfaction levels between the intervention group and the control group (SMD= 
0.65; 95% CI -0.06, 1.36), and significantly high heterogeneity (chi2= 224.24; df= 7; p<0.00001; I2= 97%).  
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Appendix 11. Forest plot comparing trust in their provider for patients who used an encounter patient 
decision aid versus controls. 
 
There was no statistically significant difference in terms of trust (SMD= 0.13; 95% CI -0.07, 0.33; p=0.19) in their 
clinician with or without the presence of an encounter patient decision aid.  
 
 
 
Appendix 12. Forest plot comparing anxiety (using the Spielberger State Anxiety Inventory) for patients who 
used an encounter patient decision aid versus controls. 
 
There was no statistically significant difference in terms of level of anxiety (SMD= -0.03; 95% CI -0.27, 0.22; p=0.83) 
with or without the presence of an encounter patient decision aid.  
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Abstract 
 
Background: Randomized trials have shown that patient decision aids can modify users' 
preferred healthcare options, but research has yet to identify the attributes embedded in 
these tools that cause preferences to shift. 
 
Objective: The aim of this study was to investigate people’s preferences as they used 
decision aids for 5 health decisions and, for each of the following: 1) determine if using the 
interactive Option Grid led to a pre-post shift in preferences; 2) determine which frequently 
asked questions (FAQs) led to preference shifts; 3) determine the FAQs that were rated as 
the most important as users compared options. 
 
Methods: Interactive Option Grid decision aids enable users to view attributes of available 
treatment or screening options, rate their importance, and specify their preferred options 
before and after decision aid use. The McNemar-Bowker paired test was used to compare 
stated pre-post preferences. Multinomial logistic regressions were conducted to investigate 
possible associations between covariates and preference shifts. 
 
Results: Overall, 626 users completed the 5 most-used tools: 1) Amniocentesis test: yes or 
no? (n = 73); 2) Angina: treatment options (n = 88); 3) Breast cancer: surgical options (n = 
265); 4) Prostate Specific Antigen (PSA) test: yes or no? (n = 82); 5) Statins for heart 
disease risk: yes or no? (n = 118). The breast cancer, PSA, and statins Option Grid decision 
aids generated significant preference shifts. Generally, users shifted their preference when 
presented with the description of the available treatment options, and the risk associated 
with each option. 
 
Conclusion: The use of decision aids for some, but not all health decisions, was 
accompanied by a shift in user preferences. Users typically valued information associated 
with risks, and chose more risk averse options after completing the interactive tool. 
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Introduction 
Patient decision aids that help inform patients about reasonable healthcare options have 
been shown to increase patient knowledge and to modify their preferences [1,2]. However, 
it is unclear how these tools lead to preference shifts. What are the attributes that are 
considered important by patients that lead to changes in patient opinions? One way to 
investigate this question is to analyze online patient decision aids such as the interactive 
versions of Option Grid patient decision aids, and determine the degree to which they lead 
to preference shift. The interactive, web-based version of the Option Grid tools allow us to 
examine which information elements are considered important, their impact on 
preferences, and whether preferences shift.  
 
Debate exists within the decision sciences community on the nomenclature surrounding the 
process of decision making. Some researchers suggest that value clarification is key for 
decision making, assuming some pre-existing opinions. Others suggest that individuals 
construct preferences as they gain greater understanding of the options available. For the 
purpose of this study, we will use the term “preference construction” when other 
researchers might use the term “value clarification”. 
 
Preference construction, according to Witteman et al. is a process for understanding what 
matters most to the person making the healthcare decision, as a prelude to determining a 
preference [3]. Decision aids can potentially help people formulate a preference for a 
particular treatment option [1]. The 2014 Cochrane review details the outcomes of decision 
aid use. Decision aids increase patient knowledge, reduce decisional conflict, improve risk 
perceptions, and aim to help patients make decisions that align with their preferences [1]. 
The primary studies included in the review, however, do not report the attributes embedded 
in decision aids that shift user preferences [1]. We searched for studies that explored which 
factors might contribute to preference shift, and those that compared preferences before 
and after using a decision aid [2]. We did not find any research that indicated the type of 
information embedded in decision aids that was associated with users shifting their 
preference. One RCT demonstrated that a decision aid for early-stage prostate cancer 
changed final treatment preference by getting patients to focus on attributes they 
considered important; however, the researchers did not analyze the information elements 
that induced the change [4]. Researchers have yet to determine the potential effect that 
information provision has on preference [2]. 
 
For a chosen topic, the interactive Option Grid presents users with 2 or more options and 
provides brief evidence-based information, anticipating that users will compare the 
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alternatives and reflect on which option aligns best with their preference. The tool provides 
users with the opportunity to assess which questions are most important to them as they 
compare options. The interactive Option Grid decision aid also asks users to declare their 
preference leanings, and therefore can identify information elements that may be linked to 
preference shifts. 
 
The aim of this study was to 1) determine if using the interactive Option Grid led to a pre–
post shift in preferences; 2) determine which FAQs led to preference shifts; and 3) 
determine the FAQs that were rated as the most important as users compared options. 
 
Methods 
Design 
We conducted a cross-sectional analysis of data derived from the use of interactive Option 
Grid tools to determine whether users shifted their preferences. Data were collected as 
users completed an interactive process. The Option Grid website at the time of the study 
hosted a total of 40 interactive patient decision aids. Ethical approval for the study was 
received from the Dartmouth College Committee for the Protection of Human Subjects 
(STUDY00029501). 
 
Participants 
Data from users of the interactive Option Grid decision aids between June 1, 2015 and 
December 30, 2016 were eligible for inclusion. User-data was excluded if the user closed 
the application before completing an entire interactive decision-aid process. We can infer 
from data collection that many users who created an account on the Option Grid website 
used a joint email account with their spouse or partner, and for this reason, we decided not 
to exclude male users who used the interactive breast cancer or amniocentesis tools. 
Likewise, we did not exclude female users who used the PSA interactive Option Grid. 
 
Intervention 
Option Grid decision aids are organized in a tabular format, and “describe the attributes of 
alternative treatment options [5].” The rows of the Option Grid are made up of questions 
that patients frequently ask (FAQs) [5]. The selection of FAQs is based on both literature 
reviews and consultations with patients and clinicians [6]. This ensures that the questions 
included focus on the issues that patients deem important when considering a preference-
sensitive decision [7,8]. The columns are defined by what is considered to be reasonable 
options for the topic. The content of the tool consists of the relevant answers to the FAQs 
[8]. Answers to the FAQs are based on a synthesis of the relevant research evidence [8]. 
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The interactive tool is intended for independent use, and information embedded in the tool 
could potentially be used to facilitate a collaborative discussion between a healthcare 
professional and their patient during a clinical encounter [6,7]. 
 
The Option Grid tools are available on a website and users search for and use the tools 
independent of any invitation. Study authors did not promote the tool to potential users, so 
we cannot account for how or why users arrived at the website and chose to use the tools. 
 
At the time of this study, users were asked to create an account on the Option Grid website 
before they could access the tool relevant to their interest. Users were offered a choice 
between a pdf version of the tool or an interactive version of the Option Grid. If users 
selected the interactive version, they had the option of providing their age, gender, and 
ethnicity from a drop-down menu. Users were then asked: “Do you already have a 
preferred option in mind?” and had to click the option they were “leaning toward” before 
proceeding to the next step. The user was then shown a series of FAQs (see Figure 1 as an 
example). FAQs are always presented to the user in the same order. Answers to each FAQ 
provided information and outcome probabilities, if available, about each option. The total 
number of FAQs presented varied for each Option Grid (from 5 to 9). Before proceeding to 
the next question, users were required to indicate which option they currently preferred, 
based on the information presented. They were also asked to score how important they felt 
the question was on a scale of 0 (not important at all) to 5 (extremely important). 
Therefore, after each question, data was obtained about the user’s preference and their 
judgment about the importance of each question. 
 
Once all FAQs had been viewed and responses given, the user completed a “self-check” 
step, where they were asked 5 knowledge questions to determine their level of 
understanding of the content presented (see Appendix 1 for an example of the “self-check” 
step). At that point, users were presented with a summary of the choices they had made for 
each question. 
 
Data collection and analysis 
Responses to questions were stored in a database and exported for analysis. We selected 
the top 5 most-used Option Grid decision aids. The dataset variables included: age, gender, 
ethnicity (users could select 3 options: Hispanic, not Hispanic, not identified), the option 
the user preferred before and after using the tool, the importance rating for each question, 
and the knowledge scores. 
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Figure 1. An example of an Option Grid FAQ and importance rating. 
 
 
 
The McNemar–Bowker paired test was used to identify a preference shift before and after 
the use of the tool. This paired test was used because the “Preference Shift” variable had 3 
or more categories (option 1, option 2 [some Option Grids present a third option], and the 
“not sure” category). 
 
To identify the FAQs associated with preference shift, we conducted 5 multinomial 
regression analyses (1 for each of the 5 interactive Option Grid decision aids). For each 
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regression model, we created a new dependent variable with 4 categories: 0, uncertain to 
stated preference; 1, stated preference to uncertain, 2, stated preference retained; 3, 
uncertain retained; 4, preference shift. The reference category was the “Preference 
Retained” category. The FAQs represented nominal, independent variables and were 
inserted as factors in the model. Because multiple treatment options were compared for 
each FAQ, we decided that FAQs with a P value of 0.01 or less would be considered 
statistically significant in terms of shifting user preference. 
 
Results 
From a possible set of 40 Option Grid decision aids, the 5 most-used tools included for 
analysis were: 1) Amniocentesis test: yes or no? (n = 73); 2) Angina: treatment options (n 
= 88); 3) Breast cancer: surgical options (n = 265); 4) PSA test: yes or no? (n = 82); 5) 
Statins for heart disease risk: yes or no? (n = 118). 
 
Participant sample 
Overall, 929 participants accessed these 5 Option Grid decision aids. However, only 67.4% 
(n = 626) successfully completed the tool (attrition rate: 32.6%). Over half of the users 
self-identified as female (58.5%). Nearly half of the sample (46.6%) chose not to reveal 
their ethnicity and 5.9% (n = 37) self-identified as Hispanic. Users were aged between 21 
and 78 y; however, 19.5% of users in this study chose not to identify their age. Table 1 
summarizes the user characteristics. 
 
Table 1. Interactive Option Grid users with completed surveys. 
 
Characteristic Amniocentesis test: 
yes or no? 
n (%) 
Angina: 
treatment options
n (%) 
Breast cancer: 
surgical options
n (%) 
Prostate 
Specific Antigen 
(PSA) test: yes 
or no? n (%) 
Statins for 
heart disease 
risk: yes or no?
n (%)
Gender      
   Male 20 (27) 32 (36) 20 (8) 53 (65) 53 (65) 
   Female 40 (55) 41 (47) 219 (84) 16 (20) 16 (20) 
   Not Identified 13 (18) 15 (17) 23 (9) 13 (16) 13 (16) 
Ethnicity      
   Hispanic 7 (10) 10 (11) 8 (3) 4 (5) 4 (5) 
   Not Hispanic 36 (49) 40 (46) 115 (44) 43 (52) 43 (52) 
   Not Identified 30 (41) 38 (43) 139 (53) 35 (43) 35 (43) 
Age      
   20-30 15 (21) 10 (11) 4 (2) 5 (6) 5 (6) 
   31-40 26 (36) 14 (16) 7 (3) 7 (9) 7 (9) 
   41-50 7 (10) 16 (18) 36 (14) 9 (11) 9 (11) 
   51-60 4 (6) 15 (17) 69 (26) 16 (20) 16 (20) 
   60 and over 2 (3) 9 (10) 107 (41) 25 (31) 25 (31) 
   Not Identified 19 (26) 24 (27) 39 (15) 20 (24) 20 (24) 
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Preference shift 
A significant shift in preference after using the tool occurred in 3 of the 5 Option Grid 
decision aids, namely for “Breast cancer: surgical options” (p < 0.001), “PSA test” (p = 
0.011) and “Statins for heart disease risk” (p < 0.001). There was no significant preference 
shift in the “Angina: treatment options” decision aid (P = 0.200) or the “Amniocentesis 
test: yes or no?” decision aid (p = 0.350). Figure 2 shows the preference shift before and 
after using each interactive Option Grid decision aid. 
 
Figure 2. Initial versus final preference shifts for users of the interactive, online Option Grid. 
 
Decision aids with statistically significant preference shift 
 
A  B 
 
 
 
Decision aids with non-statistically significant preference shift 
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Decision aid with statistically significant preference shift 
 
  E 
 
 
Users of the breast cancer interactive Option Grid generally shifted their preference toward 
the mastectomy treatment option (see Figure 3). Preference shift was significant (P < 
0.001) for participants (n = 265) using this tool. Thirty-nine users began using the 
interactive decision aid feeling uncertain of their preference and shifted to the mastectomy 
option, whereas 31 users retained their uncertainty about which available treatment option 
best aligns with their values. Eighteen users shifted their preference from lumpectomy to 
“not sure,” and 13 users shifted their preference from lumpectomy with radiotherapy to 
mastectomy. Not a single user of the breast cancer interactive Option Grid shifted their 
preference from mastectomy to lumpectomy with radiotherapy. Fifty-three users retained 
their mastectomy preference. 
 
Figure 3. Initial and final Option preference showing shifts over time. 
 
Breast Cancer: Surgical Options Option Grid  
Significant shift – McNemar-Bowker p ≤-.001  
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Middle row = Initial preference 
Bottom row = Final preference 
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Significant shift – McNemar-Bowker p =-.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angina Treatment Option Options Option Grid  
Significant shift – McNemar-Bowker p =-.200 
 
 
n=82
26
Not having a PSA test
27
Not sure
29
Having a PSA test
1 18 7
Not sure
3 12 12
Not having 
a PSA test
Not sureHaving 
a PSA test
10 5 14
Not sure Having 
a PSA test
Having 
a PSA test
Not having 
a PSA test
Not having 
a PSA test
n=88
27
Stenting (angioplasty)
38
Not sure
23
Medical Management
6 10 11
Medical 
Management
Stenting 
(angioplasty)
Not sure
16 11 11
Stenting 
(angioplasty)
Not sureMedical 
Management
12 5 6
Stenting   
(angioplasty)
Medical 
Management
Not sure
Online, Interactive Option Grid Patient Decision Aids and their effect | 87 
Middle row = Initial preference 
Bottom row = Final preference 
 
Amniocentesis Test: Yes or No? Option Grid  
Non-Significant shift – McNemar-Bowker p =-.350 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statins for heart disease risk: Yes or No? Option Grid  
Significant shift – McNemar-Bowker p ≤ 0.001 
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Users of the PSA interactive Option Grid tended to shift their preference to a more 
conservative stance, away from having the PSA test. A significant preference shift (p = 
0.011) was detected for users (n = 82) of this tool, even though 18 users did not shift their 
pre- and post-preference of not undergoing the PSA test. Fourteen users initially preferred 
a PSA test but changed their preference to “not sure” after completing the interactive 
Option Grid (see Figure 3). Twelve users began the interactive decision aid feeling 
uncertain about the best treatment option for them, but shifted their preference to “not 
having a PSA test” after using the tool. Twelve users remained unsure after completing the 
PSA Option Grid decision aid. 
 
Users of the statin Option Grid (n = 118) tended to shift their preference toward increasing 
levels of physical activity to lower cholesterol (see Figure 3). Preference shift was 
significant (P < 0.001). Overall, 23 users who initially preferred the Mediterranean diet 
shifted their preference to “be physically active several times a week.” Further, 18 users 
were initially uncertain of their cholesterol treatment preference but shifted their preference 
to “be physically active several times a week.” Six users were uncertain of their preference 
pre-and-post Option Grid use. 
 
There was no significant preference shift (p = 0.200) for participants using the angina 
interactive Option Grid (n = 88), despite a slight shift toward medical management. 
Sixteen users went from being unsure of their treatment preference to preferring medical 
management after using the Option Grid. Twelve users retained their “medical 
management” preference, and 11 users retained the “not sure” option. Of those who 
initially preferred stenting (angioplasty), 10 users retained that preference, whereas 11 
shifted to being unsure of their preferred treatment option. See Figure 3. 
 
For the amniocentesis Option Grid (n = 73), the preference shift was not significant (p = 
0.350). Users tended to retain their preference for not having amniocentesis (n = 16). 
Twelve users went from feeling unsure at the start of the tool to preferring not to undergo 
amniocentesis, and 12 users retained their “not sure” preference after using the 
amniocentesis Option Grid. Only one user shifted their preference from not having 
amniocentesis to having the test. For further details, see Figure 3. 
 
Attributes associated with preference shift 
In the 3 interactive Option Grid decision aids where we saw significant preference shift, a 
regression analysis revealed the key FAQs embedded in each tool that were associated with 
these preference shifts. 
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For users of the interactive breast cancer Option Grid, 4 FAQs were associated with 
preference shift: FAQ 1 “What is removed?” (p < 0.01); FAQ 6 “Will I need 
radiotherapy?” (p < 0.01); FAQ 7 “Will I need to have my lymph glands removed?” (p < 
0.01); and FAQ 8 “Will I need chemotherapy?” (p < 0.01). Most users (57.3%) preferred 
the lumpectomy with radiotherapy treatment option for the first FAQ (only the cancer lump 
and some surrounding tissue is removed). FAQ 6 proved to be an important juncture for 
users, which led to a significant preference shift toward mastectomy treatment. Answers to 
this question informed users that opting for the lumpectomy treatment option would 
require radiotherapy for up to 6 weeks after surgery, whereas radiotherapy is not usually 
given after mastectomy. Preference shift toward mastectomy was pronounced after FAQ 7, 
which revealed that some or all of the lymph glands in the armpit are usually removed 
regardless of which treatment option is chosen. FAQ 8 solidified the preference shift to 
mastectomy, with over 70% of users preferring the information that they may or may not 
be offered chemotherapy. See Table 2 for details. 
 
Table 2.  Preference shift analysis using multinomial regression (odds ratio and confidence intervals) for 
Option Grid decision aids that were significantly associated with preference shift. 
 
 Breast cancer: surgical options 
 Preference retaineda 
Variable 
Preference shift 
OR (95% CI) 
Shift from 
uncertain to a 
preference 
OR (95% CI) 
No shift-uncertainty 
retained OR (95% 
CI) 
Shift from a preference 
to uncertain 
OR (95% CI) pb 
FAQ 1 
What is removed? 
   
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
0.22 (0.02;2.66) 
0.17 (0.01;2.36) 
1.00 
0.13 (0.03;0.65) 
0.15 (0.03;0.77) 
1.00 
0.24 (0.03;1.85) 
0.24 (0.03;1.89) 
1.00 
0.05 (0.01;0.26) 
0.03 (0.01;0.17) 
<0.01
FAQ 2 
Which surgery is best for long-term survival? 
   
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
19.63(2.43;15.86) 
59.30 (59.30; 59.30) 
1.00 
0.56 (0.22;1.46) 
0.76 (0.26;2.28) 
1.00 
0.79 (0.23;2.70) 
0.23 (0.04;1.45) 
1.00 
0.53 (0.18;1.57) 
0.08 (0.01;0.71) 
0.10 
FAQ 3 
What are the chances of cancer coming back in the breast? 
   
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
1.52 (0.17;13.90) 
2.43 (0.28;21.20) 
1.00 
1.46 (0.48;4.40) 
2.43 (0.82;7.20) 
1.00 
0.67 (0.20;2.19) 
1.04 (0.33;3.30) 
1.00 
0.43 (0.14;1.31) 
0.74 (0.26;2.13) 
0.05 
FAQ 4 
Will I need more than one operation on the breast? 
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
0.48 (0.05;5.16) 
1.42 (0.16;12.60) 
1.00 
1.00 (0.28;3.57) 
1.38 (0.40;4.83) 
1.00 
0.44 (0.12;1.69) 
0.63 (0.17;2.32) 
1.00 
1.45 (0.16;12.83) 
3.47 (0.42;29.05) 
0.18 
FAQ 5 
How long will it take to recover? 
  
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
0.16 (0.01;1.93) 
0.82 (0.08;8.21) 
1.00 
1.73 (0.19;16.09) 
2.82 (0.30;26.45) 
1.00 
0.19 (0.04;0.85) 
0.30 (0.07;1.35) 
1.00 
0.26 (0.06;1.12) 
0.21 (0.04;0.97) 
0.16 
90 | Chapter 3 
 Preference retaineda 
Variable 
Preference shift 
OR (95% CI) 
Shift from 
uncertain to a 
preference 
OR (95% CI) 
No shift-uncertainty 
retained OR (95% 
CI) 
Shift from a preference 
to uncertain 
OR (95% CI) pb 
FAQ 6 
Will I need radiotherapy 
  
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
3.98 (1.04;1.52) 
1.69 (1.49;1.69) 
1.00 
1.06 (0.20;5.64) 
2.29 (0.44;11.99) 
1.00 
0.26 (0.07;0.97) 
0.28 (0.07;1.08) 
1.00 
0.17 (0.04;0.66) 
0.42 (0.12;1.56) 
<0.01
FAQ 7 
Will I need to have my lymph glands removed? 
  
Not Sure 
Lumpectomy 
Mastectomy 
1.00 
1.46 (0.17;12.57) 
2.40 (0.25;23.53) 
1.00 
0.80 (0.31;2.06) 
1.58 (0.56;4.44) 
1.00 
0.63 (0.23;1.72) 
0.04 (0.04; 0.04) 
1.00 
0.20 (0.08;0.49) 
0.13 (0.03;0.52) 
<0.01
*Reference category: preference retained. 
**Estimated p-value for the association between FAQs and preference shift. 
Small cell sample size  
 
The answers to 3 FAQs embedded in the interactive PSA Option Grid were associated with 
preference shift: FAQ 1 “What does the test involve?” (p = 0.01); FAQ 3 “If my PSA level 
is high, what are the chances that I have prostate cancer?” (p = 0.01); and FAQ 8 “What 
risks are associated with prostate biopsy?” (p = 0.01). Most users (63.4%) preferred the 
“having a PSA test” option for the first FAQ. The preference shift toward the more 
conservative option began at FAQ 2, when users were presented with identical risk 
information for both available options (15% of men will develop prostate cancer in their 
lifetime). Answers to FAQ 3 overwhelmingly shifted preference toward “not having a PSA 
test” after users were given information that only 30% of men who have elevated levels of 
PSA have prostate cancer, with a caveat that inflammation and infection may also cause 
high PSA levels. FAQ 6 represented an inflection point, as some users reverted to either 
preferring a PSA test or being uncertain. This question informed users that 33% of prostate 
cancers are aggressive, so having a PSA test can enable physicians to detect the presence 
of cancer cells early, improving the likelihood of successful treatment. Information 
affiliated with not having a PSA test for FAQ 6 indicates that one would avoid the risks 
that go along with biopsies and treatment. We can infer that users prefer “playing it safe” 
when presented with such risk information. Lastly, preferences shifted back to not having a 
PSA test at FAQ 8. Users were informed that by not having a PSA test, you avoid the risks 
(17% of men who have a prostate biopsy will experience a problem, such as infection) 
associated with prostate biopsy. See Table 2 for details. 
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Table 2. Continued. 
 
 PSA test: yes or no? 
 Preference retaineda 
Variable 
Preference shift 
OR (95% CI) 
Shift from 
uncertain to a 
preference 
OR (95% CI) 
No shift-uncertainty 
retained OR (95% 
CI) 
Shift from a 
preference to 
uncertain 
OR (95% CI) pb 
FAQ 1 
What does the test involve? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
0.03 (0.03;0.03)c 
0.01 (0.00;2.94) 
1.00 
0.08 (0.07;0.08) 
0.03 (0.02;0.04) 
1.00 
0.01 (0.05;1.96) 
0.04 (0.02;0.09) 
1.00 
0.07 (0.03;1.33) 
0.08 (0.02;2.83) 
0.01 
FAQ 2 
What are my chances of having prostate cancer in my lifetime? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
0.02 (0.02;0.02)c 
0.04 (0.04;0.04)c 
1.00 
0.01 (0.05;3.46) 
0.02 (0.07;0.42) 
1.00 
0.07 (1.96;2.22) 
0.03 (0.09;0.09)c 
1.00 
0.01 (0.04;0.25) 
0.04 (0.02;0.10) 
0.02 
FAQ 3 
If my PSA level is high, what are the chances that I have prostate cancer? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
0.03 (0.04;1.83) 
0.01 (0.01;0.01)c 
1.00 
0.02 (0.08;0.36) 
0.01 (0.01;0.04) 
1.00 
0.05 (0.03;0.90) 
0.02 (0.13;3.93) 
1.00 
0.02 (0.01;0.04) 
0.01 (0.07;0.26) 
0.01 
FAQ 4 
If m y PSA level is normal, can I be sure that I don’t have prostate cancer? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
1.56 (0.16;15.09) 
0.36 (0.36;0.36)c 
1.00 
0.03 (0.00;6.08) 
0.08 (0.00;2.01) 
1.00 
0.03 (0.00;7.18) 
0.02 (0.00;1.68) 
1.00 
0.01 (0.00;1.04) 
0.05 (0.00;3.75) 
0.08 
FAQ 5 
Will getting the PSA test lower my chance of dying from prostate cancer? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
0.93 (0.15;6.03) 
1.04 (1.04;1.04) 
1.00 
0.01 (0.00;2.38) 
0.02 (0.00;4.42) 
1.00 
0.09 (0.00;3.52) 
0.04 (0.00;5.91) 
1.00 
0.02 (0.00;6.56) 
0.02 (0.00;8.78) 
0.33 
FAQ 6 
What are the advantages? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
0.03 (0.04;0.20) 
0.03 (0.03;0.03)c 
1.00 
0.03 (0.02;0.05) 
0.05 (0.05;0.06) 
1.00 
0.09 (0.66;1.17) 
0.05 (0.04;0.07) 
1.00 
0.02 (0.01;0.03) 
0.02 (0.01;0.03) 
0.03 
FAQ 7 
What are the risks? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
1.04 (0.16;6.75) 
0.98 (0.98;0.98)c 
1.00 
0.06 (0.00;7.79) 
0.07 (0.00;2.72) 
1.00 
0.04 (0.00;2.55) 
0.04 (0.00;4.49) 
1.00 
0.05 (0.00;7.88) 
0.05 (0.00;9.25) 
0.34 
FAQ 8 
What risks are associated with a prostate biopsy? 
  
Not Sure 
PSA test 
No PSA test 
1.00 
0.02 (0.00;6.24) 
1.56 (1.56;1.56)c 
1.00 
0.01 (0.00;1.41) 
0.10 (0.00;1.47) 
1.00 
0.03 (0.91;1.07) 
0.04 (0.49;1.18) 
1.00 
0.08 (0.00;17.95) 
0.06 (0.00;15.12) 
<0.01 
 
For users of the interactive Statins for Heart Disease Risk Option Grid, 2 FAQs were 
associated with preference shift: FAQ 3 “How much will this option reduce my chance of 
getting other health problems?” (p < 0.01); and FAQ 5 “How long will I have to keep this 
up?” (p < 0.01). For answers to the first FAQ, users were not swayed when presented with 
information regarding what the treatment involves. The pattern remained consistent for the 
second FAQ, which detailed the fact that all treatment options decreased the risk of stroke 
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and heart attack: taking a statin would likely reduce the risk by 25% to 30%, being 
physically active several times a week can reduce the risk by up to 30%, and following a 
Mediterranean diet reduced risk anywhere from 5% to 20%. Answers to FAQ 3 proved to 
be decisive, as they informed users that opting for “being physically active several times a 
week” does not mean a high-intensity exercise regimen, and can help keep weight down, 
improve mood, and prevent diabetes and Alzheimer’s disease. This information shifted 
preference toward being physically active and away from the “starting a statin” option 
which indicated that statins reduce the risk of health issues caused by blocked arteries in 
the heart, brain, and legs. Answers to FAQ 5 (the last FAQ in the statins interactive Option 
Grid) also significantly shifted user preference toward “being physically active several 
times a week” and away from the other 2 options. The information associated with the 
“start a statin” option was not appealing to users (28% of users preferred this option) 
because it indicated that the patient may have to take medication for the rest of their life. 
Also, the same information was associated with the diet and exercise options, which 
indicated that better results would be gained from a longer duration on the Mediterranean 
diet or being physically active several times a week. Despite presenting the same 
information for both options, users selected the “physically active” option. See Table 2 for 
details. 
 
Table 2. Continued. 
 
 Statins for heart disease risk: yes or no? 
 Preference retaineda 
Variable 
Preference shift 
OR (95% CI) 
Shift from 
uncertain to a 
preference 
OR (95% CI) 
No shift-uncertainty 
retained OR (95% CI)
Shift from a 
preference to 
uncertain 
OR (95% CI) Pb 
FAQ 1 
What does this treatment involve? 
  
Not Sure 
Follow diet 
Phys. activity 
Start statin 
1.00 
1.00 (0.15;6.64) 
0.27 (0.04;1.70) 
0.10 (0.01;0.67) 
1.00 
0.56 (0.08;4.14) 
0.66 (0.11;3.97) 
0.17 (0.03;1.14) 
1.00 
1.20 (0.07;19.63) 
0.36 (0.02;6.18) 
0.86 (0.07;11.36) 
1.00 
12.14 (8.94;16.48) 
2.76 (1.55;4.93) 
2.17 (2.17;2.17)c 
0.21 
FAQ 2 
How much will this option reduce my risk of having a stroke or heart attack? 
  
Not Sure 
Follow diet 
Phys. activity 
Start statin 
1.00 
1.40 (0.10;19.01) 
0.55 (0.04;6.89) 
0.20 (0.02;2.64) 
1.00 
2.20 (0.11;42.74) 
1.64 (0.09;28.90) 
0.40 (0.02;7.48) 
1.00 
0.40 (0.02;10.02) 
0.27 (0.01;5.77) 
0.40 (0.02;7.48) 
1.00 
1.33 (0.00;8.06) 
4.44 (4.05;4.86) 
1.08 (1.08;1.08)c 
0.75 
FAQ 3 
How much will this option reduce my chance of getting other health problems? 
  
Not Sure 
Follow diet 
Phys. activity 
Start statin 
1.00 
0.78 (0.07;9.08) 
0.36 (0.03;4.04) 
0.12 (0.01;1.43) 
1.00 
3.36 (8.97;12.58) 
3.89 (1.30;11.64) 
1.98 (1.98;1.98)c 
1.00 
0.11 (0.01;1.78) 
0.12 (0.01;1.53) 
0.07 (0.01;0.95) 
1.00 
3.68 (0.00;7.42) 
3.02 (0.00;7.21) 
0.02 (0.00;0.50) 
 
 
<0.01 
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 Preference retaineda 
Variable 
Preference shift 
OR (95% CI) 
Shift from 
uncertain to a 
preference 
OR (95% CI) 
No shift-uncertainty 
retained OR (95% CI)
Shift from a 
preference to 
uncertain 
OR (95% CI) Pb 
FAQ 4 
Are there any harmful effects? 
  
Not Sure 
Follow diet 
Phys. activity 
Start statin 
1.00 
2.74 (6.36;11.82) 
1.92 (4.20;8.74) 
2.60 (5.75;11.73) 
1.00 
1.62 (1.37;1.91) 
1.05 (8.90;12.36) 
0.55 (4.67;6.48) 
1.00 
0.00 (1.57;6.50) 
0.00 (1.97;8.08) 
0.00 (1.27;5.19) 
1.00 
2.35 (5.12;10.81) 
1.92 (4.20;8.74) 
2.60 (5.75;11.73) 
0.47 
FAQ 5 
How long will I have to keep this up? 
  
Not Sure 
Follow diet 
Phys. activity 
Start statin 
1.00 
3.11 (0.25;39.54) 
8.50 (0.61;118.64) 
0.24 (0.01;3.92) 
1.00 
1.10 (3.57;34.07) 
8.69 (2.00;3.78) 
2.63 (2.63;2.63) 
1.00 
0.07 (0.01;0.68) 
1.36 (2.11;8.75) 
0.08 (0.01;0.54) 
1.00 
8.26 (9.74;70.05) 
9.06 (0.00;2.19) 
0.04 (0.00;0.58) 
<0.01 
a Reference category: preference retained. 
b Estimated p-value for the association between FAQs and preference shift. 
c Small cell sample size  
 
Importance ratings 
Most users (71%) of the interactive breast cancer tool valued the answers to FAQ 2 
“Which surgery is best for long-term survival?” as extremely important. For the interactive 
PSA Option Grid, most users (62.2%) valued the answers contained in FAQ 3 “If my PSA 
level is high, what are the chances that I have prostate cancer?” with a 4 of 5 rating (this 
FAQ was also significantly associated with preference shift). About half of the users 
(55.1%) of the interactive statins Option Grid most valued FAQ 2 “How much will this 
option reduce my risk of having a heart attack or stroke?” Interactive amniocentesis Option 
Grid users most valued the answers to FAQ 4 “If a problem is found, what does it mean for 
us? – with 54.8% rating it as extremely important.” Users of the interactive angina Option 
Grid most valued FAQ 2 “What are the risks of the treatment?”; this was valued as 
extremely important by 37.5% of users. Based on these results, users identified risk 
information as being extremely important in their decision making process. The risk of 
prostate cancer with a high PSA level, the risk of angina treatment, and the risk associated 
with statin use, are all examples that indicate the desire for patients to better understand the 
risks associated with each treatment or screening option. 
 
User knowledge scores 
Most users (92.5%; n = 579) who completed an interactive Option Grid achieved a perfect 
knowledge score. Only 31 users (4.95%) made an error and received a 4 out of 5 score; 
13 users (2.1%) achieved 2 out of 5, and 3 users (0.5%) answered all knowledge questions 
incorrectly. Based on these results, we can infer that users understood the content within 
the Option Grid decision aids. 
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Discussion 
The use of interactive Option Grid decision aids for some, but not all health decisions, was 
accompanied by a shift in user preferences. Users typically became more uncertain or more 
risk averse after reviewing answers to some FAQs, and completing the interactive tool. 
Several elements within the interactive breast cancer Option Grid were associated with a 
preference shift: 1) information about the area of tissue that will be removed with 
lumpectomy and mastectomy treatment options, 2) the possibility of radiotherapy, 3) the 
requirement for lymph gland removal, and 4) the need for chemotherapy. For the PSA 
Option Grid, information regarding what the test involves, the significance of an elevated 
PSA level, and the risks associated with biopsy were associated with a preference shift. 
Users of the interactive statins Option Grid significantly shifted their preferences after 
viewing information regarding the degree to which the treatment option would reduce the 
risk of getting other health problems, and the length of time they would have to abide by 
the treatment regimen. Generally, users valued information associated with risks of the 
various treatment options or screening tests. Most users (>90%) achieved a perfect score 
on the knowledge test at the end of the interactive decision aid. 
 
A strength of this study is that we could identify the FAQs that are most valued by users, 
and the answers to FAQs associated with preference shifts using the interactive Option 
Grid. From this, we could detect the type of information that leads to users shifting their 
preference for treatment options. The step-by-step design of the interactive Option Grid 
helps us better understand the nature of the information that influences a change in 
treatment preferences. This study has several important limitations. First, we recognize that 
a larger sample size would have strengthened the findings of our study. Second, we are 
unable to identify whether users of the interactive Option Grid were actual patients and the 
data provided by users is self-reported. Third, all users who proceed through an interactive 
decision aid encounter the same FAQs in the same order. Randomizing the FAQs for every 
user would enable us to be more confident in the significant associations between the 
questions and the preference shift. Finally, the dataset included many missing values 
because users often chose not to provide demographic information. This may be an 
important limitation when we consider, for example, the evidence of previous studies that 
have suggested that African-American men are more likely to want to undergo PSA testing 
[9,10]. Therefore, we are unable to propose a more detailed profile of indicators that might 
lead to shifts in preferences. 
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Interactive decision aids might help us understand the “mechanism by which preference 
construction is achieved” to help us identify the attributes in the tools that lead to 
preference shift [11]. Despite the existence of many preference construction techniques, 
few have been evaluated experimentally [2,3,12]. Our study begins to address this gap by 
investigating the information in interactive Option Grid decision aids that seem to be 
associated with preference shifts. 
 
Preference construction is underpinned by various theories that aim to align the patient’s 
values and treatment decisions [11]. Image theory, differentiation and consolidation theory, 
fuzzy-trace theory, and parallel constraint satisfaction theory all concur that preferences are 
constructed in stages [11]. Users initially have a mental representation that filters the 
information presented, and this can influence judgment, particularly if the user does not 
understand the content [11]. According to the differentiation and consolidation theory and 
the parallel constraint satisfaction theory, most users typically approach a tool with a 
predetermined preference [11]. The interactive Option Grid asks for this initial, 
predetermined preference and enables users to gradually integrate new information along 
the decision aid into their representation. For example, preference shift was induced when 
users of the PSA Option Grid viewed the FAQ related to the validity of the screening test, 
suggesting that users want to better understand the implications of a false-negative test 
result. Also, the PSA screening test is perhaps less appealing for older men who would 
prefer “active surveillance” instead of having a blood test that can set off a chain of events 
leading to unnecessary treatment that will lower quality of life in the final years. Unlike 
users of the PSA Option Grid, users of the Breast Cancer Option Grid did not shift their 
preference to the more conservative option. Women using the breast cancer tool preferred 
mastectomy, perhaps because it decreases the likelihood of cancer recurrence while 
avoiding radiation. Margenthaler and Ollia report that women with breast cancer opt for 
mastectomy predominantly for “peace of mind,” no longer having to deal with the potential 
for future false-positive mammograms and the psychosocial burden associated with 
screening [13]. Ultimately, it is not just the information presented, but the user’s risk 
profile and psychosocial situation that could have led them to shift their preference. 
 
We can hypothesize that the interactive Option Grid provides a framework for a decision-
making process by allowing users to compare each option. According to Svenson and 
Jakobsson, all competing options are always compared with the initial preference of the 
user [14]. Therefore, if a shift does occur, we can detect where the shift occurred in the 
decision aid, and the answers to the FAQs that induced the shift. Asking for users’ initial 
preferences, however, may have negative ramifications [12]. Initial preference can be 
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related to “irrelevant attributes”, predominantly because the user is not yet knowledgeable 
about the health issue [11]. A user identifying an initial preference may also alter ensuing 
interpretations of information to reinforce that early preference [11]. 
 
Determining the attributes in the interactive Option Grid that lead to preference shift may 
have various implications on decision aid content and design. Theoretical work, to date, 
has focused on the cognitive process of decision making and how individuals approach 
decisions [15]. Assessing the contribution of each FAQ allows us to identify the prominent 
questions or concerns for each health topic, which may lead to a change in how we frame 
the content of future decision aids. This implication is consistent with the systematic 
review by Syrowatka et al. that recommends allowing users to control the content they 
view by selecting the order, level of detail, and type of information presented [12]. 
 
Although this study shows that some interactive Option Grid decision aids shift user 
preferences, we do not have data on enacted decisions, and therefore we cannot assume 
that users’ final preference after using the tool matched the actual treatment decision, given 
that preferences, like attitudes, are unstable. Future studies should investigate the potential 
link between the decision aid users’ preference shifts and the final decisions made. 
 
The “Breast cancer: surgical options”, “PSA test” and “Statins for heart disease risk” 
interactive Option Grid decision aids shifted user preference. Interactive Option Grid 
decision aids enabled us to detect a preference shift at the time when users are presented 
with different pieces of information. Attributes associated with preference shift differ 
across different topics but, generally, users shifted their preference when presented with 
the description of the available treatment options, and the risk associated with each option. 
Users most valued the risk information embedded in the answers of the FAQs. These tools 
provide insight into the nature of the questions and the type of information that seem to 
influence treatment preference. 
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Appendix 1. The ‘self-check’ step in the PSA Option Grid to determine the level of user understanding. 
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Abstract 
 
Background: Randomized trials of web-based decision aids for prostate specific antigen 
(PSA) testing indicate that these interventions improve knowledge and reduce decisional 
conflict. However, we do not know about these tools’ impact on people who spontaneously 
use a PSA testing patient decision aid on the internet.  
 
Objective: The objectives of this study were to (1) determine the impact of the Web-based 
PSA Option Grid patient decision aid on preference shift, knowledge, and decisional 
conflict; (2) identify which frequently asked questions (FAQs) are associated with 
preference shift; 3) explore the possible relationships between these outcomes.  
 
Methods: Data were collected between January 1, 2016 and December 30, 2017. Users 
who accessed the web-based, interactive PSA Option Grid were provided with three 
options: have a PSA test, no PSA test, unsure. Users first declared their initial preference 
and then completed 5 knowledge questions and a 4-item (yes or no) validated decisional 
conflict scale (Sure of myself, Understand information, Risk-benefit ratio, Encouragement; 
SURE). Next, users were presented with 10 FAQs and asked to identify their preference 
for each question based on the information provided. At the end, users declared their final 
preference and completed the same knowledge and decisional conflict questions. Paired 
sample t-tests were employed to compare before-and-after knowledge and decisional 
conflict scores. A multinomial regression analysis was performed to determine which 
FAQs were associated with a shift in screening preference.  
 
Results: Of all the people who accessed the PSA Option Grid, 39.8% (186/467) completed 
the interactive journey and associated surveys. After excluding 22 female users, we 
analyzed 164 responses. At completion, users shifted their preference to ‘not having the 
PSA test’ (43/164, 26.2%, vs 117/164, 71.3%; p <.001), had higher levels of knowledge 
(112/164, 68.3%, vs 146/164, 89.0%; p<.001), and lower decisional conflict (94/164, 
57.3%, vs 18/164, 11.0%; p<.001). There were 3 FAQs associated with preference shift: 
‘What does the test involve?’ ‘If my PSA level is high, what are the chances that I have 
prostate cancer?’ ‘What are the risks?’ We did not find any relationships between 
knowledge, decisional conflict, and preference shift. 
 
Conclusion: Unprompted use of the interactive PSA Option Grid leads to preference shift, 
increased knowledge, and reduced decisional conflict, which confirms the ability of these 
tools to influence decision-making, even when used outside clinical encounters. 
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Introduction 
Randomized trials of Web-based decision aids for the prostate-specific antigen (PSA) 
screening test have indicated that these tools increase user knowledge, reduce decisional 
conflict, and reduce interest in having the test in controlled contexts, where users are 
recruited to use the intervention [1,2]. However, what can we say about users who choose 
to use Web-based decision aids independent of any study recruitment? Does spontaneous 
use of a PSA tool have an effect on users’ knowledge and decisional conflict and shift their 
screening preferences? 
 
A recent systematic review of 13 randomized trials assessed the effectiveness of decision 
aids for decision making in prostate cancer testing [3]. Regardless of the mode of delivery 
(ie, paper-based, Web-based, or video) the majority of decision aids improved patient 
knowledge of the PSA screening test and mitigated decisional conflict [3]. An example of a 
Web-based intervention that induced these positive outcomes is Prosdex, which also 
lowered the intention to undergo testing by 18% in comparison with participants in the 
control group who did not receive any decision support intervention [1]. Furthermore, a 
randomized trial found an almost 10% reduction in PSA screening and a 30% increase in 
preference for “watchful waiting” for those who used a Web-based decision aid compared 
to those who viewed public websites [4]. Web-based PSA tools that are tailored to 
individual participants increased knowledge levels among African American men, 
improved decision quality, and decreased levels of decision regret at follow-up [5-7]. 
 
A Web-based PSA decision aid  “PSA test: yes or no?” Option Grid  is a platform for 
men seeking information on the Web. It is designed for independent use. Individuals 
(presumably men) find this tool, independent of any invitation or promotion. This tool 
provides evidence-based information on the risks and pros and cons of the PSA screening 
test to help users make a decision that aligns with their preference [8]. The tool assesses 
user knowledge, level of decisional conflict, and preference before and after viewing the 
information. A prior study among 82 participants shows that users of the PSA Option Grid 
tend to become more risk averse, shifting their preference to “not having the test” after 
viewing risk information associated with the screening test and prostate biopsies [9]. This 
indicates a real-world impact on screening preference for users who spontaneously use this 
tool [9]. 
 
In a recent study, researchers used Google Analytics to track usage data for users of a 
Web-based decision aid for early-stage prostate cancer to determine if the tool was helpful 
and if users would recommend it to others. Although this study analyzed data from an 
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unsolicited sample to determine “real-world” impact, they did not assess outcomes pre- and 
post decision aid use [10]. As far as can be determined, there has been no assessment of the 
direct impact of using a Web-based PSA screening decision aid on specific outcomes like 
preference shift, knowledge, or decisional conflict without actively recruiting or providing 
incentives to users in a research context. 
 
The aims of this study are to: (1) determine the impact of the Web-based PSA Option Grid 
patient decision aids on preference shift, knowledge, and decisional conflict; (2) identify 
which frequently asked questions (FAQs) are associated with preference shift; iii) explore 
the possible relationships between these outcomes. 
 
Methods 
 
Design 
We conducted an analysis of data from a longitudinal sample derived from the Option Grid 
website of users who searched for and used the Web-based “PSA test: yes or no?” Option 
Grid, independent of any invitation. We assessed user preferences regarding PSA 
screening. We also measured levels of knowledge and decisional conflict before and after 
using the intervention. Ethical approval for this study was received from the Dartmouth 
College Committee for the Protection of Human Subjects (STUDY00030776). 
 
Participants 
Data from users of the “PSA test: yes or no?” Option Grid collected between January 1, 
2016, and December 30, 2017, were eligible for inclusion. Data were excluded if the user 
exited the Option Grid website prior to completing the entire interactive process or if the 
user self-identified as female.  
 
Intervention 
Based on the 2017 Cochrane systematic review definition of a patient decision aid 
“decision aids are intended to provide information and to promote self-help in the 
treatment decision-making process, which enables the patient to more actively participate 
in this process, if this is his or her preference”  we identify Option Grid as a patient 
decision aid [11]. Option Grid is available in static (PDF) and interactive (Option Grid 
interactive journey) formats. Both the paper-based and interactive versions of the “PSA 
test: yes or no?” Option Grid were freely available on the optiongrid.org website until 
March 2018. Users searched for and used the tools independent of any invitation. The tool 
was not promoted at any time during the study period. The interactive version of Option 
Assessing preference shift and effects on patient knowledge and decisional conflict | 103 
Grid was intended for independent use, but the information provided could have been used 
to facilitate a more collaborative discussion with a physician. 
 
On the Option Grid website, users could have searched for the PSA interactive Option Grid 
using the keyword function or found it on a list of topics they could have browsed through. 
Once on the PSA Option Grid webpage, users had the option of viewing the PDF version 
of the PSA Option Grid or starting the “interactive journey.” The same information is 
presented in both versions except the interactive journey presents the information in a 
sequential interactive method. If the journey was selected, users provided their 
demographic information such as their age group, gender, ethnicity, and geographic 
location. Before proceeding, users identified the strength of their preference, their level of 
decisional conflict, and their level of knowledge. Next, 10 FAQs, always presented in the 
same order, provided users with evidence-based information on the PSA test (i.e., 
described the test and indicated the chances of having prostate cancer in their lifetime, the 
significance of having a normal or high PSA level, survival risk, and the advantages and 
risks associated with the PSA test), and the risks and side effects associated with prostate 
biopsies and prostate cancer treatments. Appendix 1 illustrates the interface that the user 
encountered for the first FAQ of the tool. To complete the interactive journey, users 
identified their final preference and the strength of that preference and completed the same 
SURE survey and knowledge questionnaire post-PSA Option Grid use. 
 
Outcome measures 
The “self-check” knowledge measure contained 5 items that require a true or false response 
(Appendix 2). The questions were developed in relation to some of the information 
embedded in the interactive PSA Option Grid. Those questions helped us determine if the 
user understood the content and learned new information during the interactive journey. 
Users filled out their responses before and after completing the journey. 
 
Légaré et al developed a short 4-item decisional conflict measure known as SURE (Sure of 
myself; Understand information; Risk-benefit ratio; Encouragement), in which the user 
responded yes or no to each of the 4 questions (Appendix 3) [12]. The 4 items are based on 
the 16-item decisional conflict scale and the Ottawa Decision Support Framework. The 
reliability and validity of SURE was first assessed with French-speaking pregnant women 
considering prenatal screening for Down syndrome and with over 1000 English-speaking 
patients in rural New England who were referred to watch condition-specific video 
decision aids [12]. SURE was found to be a reliable and valid measure to “detect clinically 
significant decisional conflict” in both groups [12,13]. Results of a secondary analysis of a 
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clustered randomized trial supported the conclusions using a primary care sample: SURE 
showed “adequate psychometric properties” [13]. 
 
We also collected user preference data before and after reading the information associated 
with each FAQ in the interactive Option Grid (Appendix 4).  
 
Data collection and analysis 
A database stored all responses provided by the user throughout the entire interactive 
journey; we only analyzed data from users of the interactive version. This included their 
responses to the knowledge questions, SURE survey, and their preferences pre-and post-
Option Grid use.  
 
The 3 preference options were represented in the dataset as 0=having the PSA test, 1=not 
having the PSA test, and 2=I am not sure. The McNemar test was used to determine if 
users significantly shifted their preference after completing the interactive journey in 
comparison with their initial preference prior to viewing the information. Chi-square tests 
were performed to explore possible relationships between knowledge, decisional conflict, 
and preference shift. 
 
We conducted a multinomial regression analysis to determine which FAQs were associated 
with preference shift. We created a dependent variable with 4 categories: 0=“having a PSA 
test” shifted to “not having a PSA test,” 1=“not having a PSA test” shifted to “having a 
PSA test,” 2=“not having a PSA test” preference retained, and 3=“having a PSA test” 
preference retained (reference category). The FAQs represented nominal independent 
variables and were inserted as factors in the model. Due to the fact that multiple treatment 
options are being compared for each FAQ, we decided that FAQs with a P value of ≤.02 
would be considered statistically significant in terms of shifting user preference [9]. 
 
Users received a score from 0 to 5 (a perfect score) on the “self-check” knowledge 
questionnaires. This score was recorded as a continuous variable in the database. The pre- 
and post knowledge scores were used in a paired sample t test to determine whether 
knowledge significantly increased after Option Grid use. The dataset also contained the 
user’s responses (0=no, 1=yes) to each SURE survey item before and after completing the 
interactive Option Grid. A perfect score indicated that the user was not experiencing 
clinically significant decisional conflict. A score of ≤3 meant that the user was 
experiencing clinically significant decisional conflict [13]. A paired sample t test was 
employed to compare the total pre-and post decisional conflict scores.  
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Results 
 
Participant sample 
A total of 467 users accessed the Option Grid website and began using the Web-based, 
interactive PSA decision aid. However, only 186 users completed the entire interactive 
journey. Of the 186 completed “journeys” (attrition rate of 60.2%, 281/467), 22 users self-
identified as female, leaving a sample of 164 users. The majority of 281 users who dropped 
out either did so after viewing the first FAQ (118/281, 42.0%) or at the midway point of 
the journey (66/281, 23.5%). Over half (88/164, 53.7%) of users indicated that they were 
between the ages of 45-64 years, and over 70.1% (115/164) of the sample self-identified as 
white or not Hispanic or Latino. The majority (87/164, 53.0%) of the sample resided in 
North America. See Table 1 for details. 
 
Table 1. User characteristics of the web-based, interactive ‘PSA test: yes or no?’ Option Grid. 
 
Characteristic n (%) 
Age  
   18-24 5 (3.0) 
   25-44 29 (17.7) 
   45-64 88 (53.7) 
   Over 65 42 (25.6) 
Ethnicity  
   Hispanic or Latino 15 (9.1) 
   Not Hispanic or Latino 115 (70.1) 
   Not Identified 34 (20.7) 
Race  
   White 130 (79.3) 
   Black or African-American 11 (6.7) 
   Asian 12 (7.3) 
   Native Hawaiian or other Pacific Islander 1 (0.6) 
   American Indian or Alaska Native 5 (3.0) 
   Other or Not Identified 5 (3.0) 
Geographic Region  
   North America 87 (53.0) 
   South America 8 (4.9) 
   Europe 59 (36.0) 
   Africa 1 (0.6) 
   Asia 5 (3.0) 
   Australia 4 (2.4) 
 
Preference shift 
Prior to being presented with the FAQs, 73.8% (121/164) users selected “having the PSA 
test” as their initial preference. After completing the interactive journey, 28.7% (47/164) 
users indicated that they preferred having the PSA test  a decrease of 45.1% (74/164). The 
number of users who preferred “not having the PSA test” increased from 43 users pre-FAQ 
to 117 users post-FAQ. Overall, a significant preference shift (p<.001) to “not having the 
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PSA test” occurred after viewing the information embedded in the interactive tool. 
Figure 1 illustrates the decrease in the number of users who selected “having a PSA test” 
for each FAQ. 
 
Figure 1. The percentage of users who declared their preference (having a PSA test, not having a PSA test, 
not sure) for each FAQ. 
 
 
 
There were 3 FAQs associated with a preference shift from “having the PSA test” to “not 
having the PSA test,” namely, FAQ1, “What does the test involve?” (p=.002); FAQ 3, “If 
my PSA level is high, what are the chances that I have prostate cancer?” (p=.01); and FAQ 
7, “What are the risks?” (p=.01; Table 2). The majority of users in the sample selected 
“having a PSA test” for FAQ 1, which informed them that the PSA is a blood test that 
measures the antigen level in the blood from the prostate gland; no information was 
provided for the “not having a PSA test” option. A slight increase in PSA preference 
occurred for FAQ 2, where users were presented with the same risk information for both 
options: 15% of men will develop prostate cancer in their lifetime. Numbers significantly 
declined for preference of the PSA test at FAQs 3 and 4. When users were presented with 
the fact that 30% of men with a high PSA level have prostate cancer (FAQ 3), albeit 
inflammation and infection also increase levels, they shifted their preference to “not having 
the PSA test.” Preference for this option continued with FAQ 4, which stated that 15% of 
men with a normal PSA have prostate cancer. More users opted for “not having the test” at 
FAQ 5, which stated that only 0.6% of men who do not have a PSA test die from prostate 
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cancer. FAQ 6 represented an inflection point because this was the only question that 
reversed the trend (albeit not significantly) of preferences shifting to “having the test.” 
FAQ 6 indicated that 33% of prostate cancers are aggressive, and a small number will 
benefit from early treatment. FAQ 7 significantly shifted preference. It informed users that 
the PSA test cannot identify an aggressive form of prostate cancer and that more tests 
(biopsies) would be needed. The number of users who preferred having the screening test 
continued to decline after this question until it hit the lowest point at the last question when 
only 31.7% (52/164) of the sample preferred having the PSA test. 
 
Table 2.  FAQs associated with preference shift for the interactive PSA Option Grid decision aid based on the 
multinomial regression analysis (odds ratios and confidence intervals presented). 
 
PSA test: yes or no? 
Reference category: ‘having a PSA test’ preference retained 
 
 
Variable 
‘Having a PSA’ to 
‘Not Having a PSA’ 
OR (95% CI) 
n=76 
‘Not Having a PSA’ 
to ‘Having a PSA’ 
OR (95% CI) 
n=2 
‘Not Having a PSA’ 
preference retained 
OR (95% CI) 
n=41 
 
p* 
FAQ 1 
What does the test involve? 
   Not Sure 1.00 1.00 1.00  
<0.01    Have a PSA Test 0.48 (0.07;3.09) 205 (0.00; 0.00) 9.7x106 (0.00;0.00) 
   Not Have PSA Test 5.9x105 (0.00;0.00) 0.00 (0.00;0.00) 7.0 x1013 (0.00;0.00) 
FAQ 2 
What are my chances of having prostate cancer in my lifetime? 
   Not Sure 1.00 1.00 1.00  
0.94    Have a PSA Test 0.40 (0.04;3.73) 0.00(0.00; 0.00) 0.27 (0.02;4.09) 
   Not Have PSA Test 0.12 (0.00;0.00) 3.89 (0.00;0.00) 0.03 (0.00;0.00) 
FAQ 3 
If my PSA level is high, what are the chances that I have prostate cancer? 
   Not Sure 1.00 1.00 1.00  
0.01    Have a PSA Test 1.02 (0.08;13.63) 236 (0.00;0.00) 0.07 (0.00;1.81) 
   Not Have PSA Test 0.71 (0.04;13.73) 0.00 (0.00;0.00) 0.26 (0.01;8.23) 
FAQ 4 
If my PSA level is normal, can I be sure that I don’t have prostate cancer? 
   Not Sure 1.00 1.00 1.00  
0.26    Have a PSA Test 0.11 (0.01;1.33) 2.81x1010 
(0.00;0.00) 
0.57 (0.02;14.53) 
   Not Have PSA Test 0.33 (0.02;4.71)  94.79(0.00; 0.00) 1.13 (0.04;30.95) 
FAQ 5 
Will getting the PSA test lower my chance of dying from prostate  cancer? 
   Not Sure 1.00 1.00 1.00  
0.07    Have a PSA Test 13.43 (0.73;246) 2.06 x1011 
(0.00;0.00) 
114.96 (0.78;169.02) 
   Not Have PSA Test 17.69 (0.88;353) 0.00 (0.00;0.00) 223.42 (1.51;330.33) 
FAQ 6 
What are the advantages? 
   Not Sure 1.00 1.00 1.00  
0.09    Have a PSA Test 1.60 (0.09;30.35) 0.00 (0.00; 0.00) 1.66 (0.05;51.22) 
   Not Have PSA Test 
 
16.23 (0.70;377) 0.25 (0.00;0.00) 10.72 (0.31;373.95) 
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PSA test: yes or no? 
Reference category: ‘having a PSA test’ preference retained 
FAQ 7 
What are the risks? 
   Not Sure 1.00 1.00 1.00  
0.01    Have a PSA Test 0.26 (0.01;11.67) 0.00 (0.00;0.00) 0.05 (0.00;2.95) 
   Not Have PSA Test 0.76 (0.02;39.09) 0.00 (0.00;0.00) 0.26 (0.00;17.42) 
FAQ 8 
What risks are associated with a prostate biopsy? 
   Not Sure 1.00 1.00 1.00  
0.99    Have a PSA Test 2.75 (0.05;154) 0.00 (0.00;0.00) 0.98 (0.01;167.57) 
   Not Have PSA Test 4.33 (0.07;255) 7.64 (7.64;7.64) 1.37 (0.01;237.35) 
FAQ 9 
What other side effects can I  expect from a prostate biopsy? 
   Not Sure 1.00 1.00 1.00  
0.89    Have a PSA Test 0.25 (0.01;4.33) 0.00 (0.00;0.00) 0.43 (0.01;15.63) 
   Not Have PSA Test 0.24 (0.01;4.27) 0.00 (0.00;0.00) 0.53 (0.02;18.50) 
FAQ 10 
What are the risks associated with prostate cancer treatment? 
   Not Sure 1.00 1.00 1.00  
0.61    Have a PSA Test 0.23 (0.03;1.88) 0.00 (0.00; 0.00) 0.50 (0.03;7.45) 
   Not Have PSA Test 0.42 (0.05;3.53) 0.00 (0.00;0.00) 0.39 (0.03;5.95) 
* Estimated p-value for the association between FAQs and preference shift. 
 The cell sample size is too small, so we cannot compute an OR or CI.  
 
Knowledge 
Before viewing the FAQs, 68.3% (112/164) users achieved a perfect score compared with 
the 89.0% (146/164) users who achieved a perfect knowledge score after viewing the 
FAQs. The mean post-FAQ knowledge score was 4.88 (SD 0.36) compared with the pre-
FAQ knowledge score of 4.64 (SD 0.56). Overall, there was a statistically significant 
knowledge increase after viewing the Web-based, interactive PSA Option Grid FAQs 
(t163=−6.70, p<.001). 
 
Decisional conflict 
Before reviewing the FAQs, 89.0% (146/164) users answered “no” to at least 1 of the 4 
SURE survey items, indicating decisional conflict. After completing the Option Grid 
interactive journey, decisional conflict decreased to 42.7% (70/164) users. Overall, the 
decisional conflict score pre-FAQs was 1.49 (SD 1.38) and post-FAQs was 3.24 (SD 1.03). 
A statistically significant decisional conflict reduction occurred after viewing the Web-
based, interactive PSA Option Grid (t163=−15.234, P<.001). The percentages of users who 
selected yes for each SURE item are listed in Table 3. 
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Table 3. The percentage of users who responded ‘yes’ to each item on the SURE decisional conflict survey 
before and after viewing the information embedded in the interactive PSA Option Grid. 
 
 % Yes 
SURE Item Pre Post 
Do you feel sure about the best choice for you? 55 (33.5) 110 (67.1) 
Do you know the benefits and risks of each option? 52 (31.7) 156 (95.1) 
Are you clear about which benefits, and risks matter most to you? 63 (38.4) 136 (82.9) 
Do you have enough support and advice to make a choice? 74 (45.1) 129 (78.7) 
 
Relationship between knowledge, decisional conflict and preference 
Analyses indicated no association or relationship between preference shift and increased 
knowledge levels (p=.45) or between reduced decisional conflict and preference shift 
(p=.29). Furthermore, no relationship was established between increased knowledge and 
reduced decisional conflict (p=.85). 
 
Discussion 
The Web-based interactive PSA Option Grid decision aid shifted preference toward not 
having the screening test, increased user knowledge, and reduced decisional conflict. In 
particular, there were 3 elements of information that induced a shift. First, the description 
of the PSA test  a blood test that measures the antigen level in the blood from the prostate 
 was associated with the preference of having the PSA test. Second, FAQ 3 (stating that 
30% of men with a high PSA level have prostate cancer, but that inflammation and 
infection can also increase PSA levels) shifted user preferences to declining the screening 
test. Lastly, the risks of having the PSA test were presented at FAQ 7, which represents a 
significant juncture in the “journey” in terms of shifting user preference to not having the 
PSA test. FAQ 7 stated that it is not possible to know whether a cancer is aggressive with 
the PSA test alone; a high PSA level means that one would need more tests like biopsies, 
and biopsies carry risks. No relationships were established between knowledge, decisional 
conflict, and preference shift. 
 
The main strength of our study is that we obtained information from a self-selected sample 
of participants who freely accessed the Web-based intervention to better understand 
whether the effect of using a Web-based tool is replicated in a naturalistic setting (i.e., 
outside of a controlled, incentivized research context). However, we know that a self-
selected sample of individuals who access Web-based health information is likely to have a 
higher computer literacy and educational attainment, which means that we may not have 
had a representative sample of the greater population. Increasing the sample size and 
randomizing the FAQs would strengthen the study findings. We recognize that having a 
more diverse sample may have influenced our findings. Only 6.7% (11/164) participants of 
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our sample identified as African American people, and we know that this patient 
population is considered to be at high risk for prostate cancer [14]. Further, we were unable 
to determine whether users were health care professionals or actual patients. Lastly, it is 
important to note that following data analysis, the interactive PSA Option Grid decision aid 
(in the Web-based format used for this study) was removed from the Web in March 2018 
and is no longer available for public use. 
 
A paucity of data exists on the outcomes associated with the use of Web-based PSA 
decision aids for individuals spontaneously searching the internet for information. Our 
study shows that even for a self-selected sample, a Web-based tool increased knowledge 
and reduced decisional conflict. Our previous work indicated that FAQs 1, 3, and 8 shifted 
user preferences to not having the PSA screening test. In this study, FAQs 1, 3, and 7 
shifted preference in the same direction, confirming that risk information (FAQs 7 and 8 
both discuss risk) may be the active ingredient in the PSA Option Grid responsible for the 
shift [9]. FAQs 7 and 8 discuss the risk of the PSA test and the risk of the prostate biopsy, 
respectively. Thus, we can infer that men value risk information in their decision making. 
Our data are also consistent with previous studies suggesting that men who used Web-
based decision aids reported higher knowledge and lower decisional conflict and were less 
likely to want prostate cancer screening [1,2,15,16]. The preference not to undergo 
screening aligns with the Agency for Healthcare Research and Quality’s recommendation, 
which indicates that the “benefits of PSA-based screening for prostate cancer do not 
outweigh the harms” [17]. 
 
Our study showed no relationship between knowledge, decisional conflict, and preference. 
This differs from Evans et al’s randomized trial that showed a link between increased 
knowledge and a less favorable attitude toward testing [1]. Although we did not test 
attitude, we still did not see an association between increased knowledge and preference 
shift. Rubel et al used a Solomon 4-group design to demonstrate that increased knowledge 
was related to reduced decisional conflict for those using a prostate cancer screening 
decision aid [18]. Based on our data, we can infer that men who spontaneously used the 
Option Grid already had high levels of knowledge to begin with, despite being conflicted 
about their screening preference. Further investigation is required to better understand the 
potential associations between these outcomes. We did not collect data on the final 
screening decision of the user; thus, more research is needed to understand the actual effect 
of using interactive decision aids on the quality of the real-world decision-making process. 
 
In light of the high attrition rate observed in this study, future work should focus on 
creating or modifying Web-based patient decision aids to reduce the burden on the user. 
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Many men search the internet for credible health information, but the high attrition rate in 
our study indicates that interest or engagement is impacted by the time it takes to complete 
the Option Grid interactive journey. For example, an observational Web-log analysis 
showed that the mean total time spent on a Web-based decision aid is 20 minutes [19]. 
Evidently, these tools, which rarely undergo extensive usability testing, can be made easier 
to use [20]. Furthermore, research should focus on minimizing the “digital divide” [21]. 
Men who use these tools tend to be white people, highly educated, and reasonably 
computer literate, with internet access [21,22]. Men exhibiting these characteristics have a 
significant advantage in terms of access to health information. We need to better 
understand how to reach men across socioeconomic strata and how to create Web-based 
tools that are suitable to all demographics, health literacy levels, and computer literacy 
levels. 
 
Conclusion 
The Web-based PSA Option Grid decision aid enabled users to increase their level of 
knowledge while reducing decisional conflict. The risk information embedded in the tool 
shifted preference away from having the screening test. Efforts should be made to increase 
access to evidence-based information for men in all socioeconomic categories. This would 
lead men to be more informed when communicating with their clinician and would help 
them make a decision that aligns with their preference. 
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Appendices 
 
Appendix 1. The interface the user encountered for the first FAQ of the web-based PSA Option Grid patient 
decision aid . 
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Appendix 2. The ‘self-check’ knowledge questionnaire that users encountered before, and after completing the 
interactive journey. 
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Appendix 3. The SURE survey presented to users before and after completing the interactive journey to 
measure decisional conflict. 
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Appendix 4. Users identify their preference pre-and-post interactive journey. 
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Abstract 
 
Objective: To user-test the ‘PSA test: yes or no?’ web-based, interactive Option GridTM 
decision aid to determine its usability, acceptability, and feasibility with men of high and 
low health literacy.  
 
Design: A semi-structured interview study. 
 
Setting: Interviews were conducted at a senior center, academic hospital, or college library 
in the Upper Valley of New Hampshire and Vermont. 
 
Participants: Individuals over 45 years of age with no history of prostate cancer who 
voluntarily contacted study authors via phone or email were eligible for inclusion. Twenty 
interviews were conducted: ten participants had not completed a college degree, of which 
eight had low health literacy, and ten participants completed at least one college degree and 
had high health literacy. 
 
Intervention: The ‘PSA test: yes or no?’ interactive, web-based Option Grid patient 
decision aid. 
 
Results: Users with lower health literacy levels were able to understand the content 
embedded in the tool, but, due to their unfamiliarity with computers, were not able to 
navigate the Option Grid independent of assistance. The tool was usable for men with high 
health literacy. In terms of acceptability, the flow of questions and answers embedded in 
the tool did not seem intuitive to users who preferred seeing more risk information related 
to age and family history. Users envisioned feasible implementation of the tool prior to a 
clinical encounter. 
 
Conclusion: Men with limited health literacy may not be able to access web-based, 
interactive decision aids like Option Grid if they are unfamiliar with how to use or navigate 
a computer. This indicates that Option Grid may not be usable or accessible by all 
audiences. The information provided in the tool is acceptable, but users preferred to view 
personalized risk information. Some participants can see themselves using this tool prior to 
a consultation so they can bring the results to their physician to facilitate a better dialogue. 
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Introduction 
A growing number of developers are creating web-based, interactive decision aids and this 
includes tools for men considering the PSA test [1]. Patient decision aids are designed to 
provide users with evidence-based information on a particular health condition or 
screening test, and many men are using these tools when needing to make a preference 
sensitive decision – such as whether they should have a PSA test. Part of the development 
process is to user-test these web-based PSA decision aids to ensure they are easy to use and 
meet the needs and desires of men [2-4].  
 
The IPDAS indicate that users should be involved in the development process of these 
interventions [2]. Elwyn et al proposed a four-step process map for developing web-based 
tools which recommends usability testing and field testing [3]. Once a prototype is deemed 
ready by developers, it should be user-tested by stakeholders, including patients, to provide 
their perspective on elements of the tool that need to be improved (i.e. navigation and 
design). This is a key step in the process prior to introducing the web-based decision aid in 
clinical settings for further evaluation [3]. A review conducted by Coulter et al outlined 
similar processes to evaluate patient decision aids all of which recommend user-testing or 
determining the needs of patients who will eventually use these tools [4]. The Ottawa 
Decision Support Framework, for example, described an iterative process to decision aid 
development which includes ‘assessment of determinants of decisions’ through the lens of 
the patient and provider [4,5]. Patient input enables developers to create robust tools that 
are acceptable to potential users while addressing their needs and concerns [6]. However, 
involving patients is time-consuming and costly [4]. Many developers bypass the user-
testing step and post tools that may not be suitable for the target audience.  
 
According to a recent explanatory study by Dugas et al, of the patient decision aid 
development projects that have been conducted, less than twenty percent include 
vulnerable populations [7]. A clear theme regarding web-based tools that have been user-
tested by low health literacy populations is that they are helpful (improve knowledge and 
reduce decisional conflict), but improvements are needed to resolve navigation issues and 
make them easier to use [8-13]. These tools often provide a heavy dose of information 
which increases the cognitive load, particularly for individuals unfamiliar with medical 
jargon [9,10]. Evidence also exists that elderly individuals may need assistance when using 
web-based applications [14]. Fine-tuning the information elements and layout of these 
web-based tools to provide simplicity are frequently suggested alterations by low health 
literacy users regardless of health topic.  
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In the case of web-based PSA screening tools, it is clear that the majority available to the 
public have not been user-tested or tested with men of low health literacy. We searched for, 
and found, only one web-based PSA screening tool that has been user-tested. The tool was 
designed for men with a family history of prostate cancer and it was deemed acceptable to 
use by that demographic who provided positive feedback related to navigation, the amount 
of information, and time required to complete the decision aid [15]. However, this tool was 
customized for a certain segment of the male population and did not take into account the 
experience of men with lower levels of health literacy. Our study fills this gap by user-
testing a web-based interactive tool known as Option Grid patient decision aids, with men 
of various education, and health literacy backgrounds.  
 
The aim of our study is to user-test the ‘PSA test: yes or no?’ web-based, interactive 
Option Grid patient decision aid to determine its usability, acceptability, and feasibility 
with men of higher and lower health literacy.  
 
Methods 
 
Design 
A semi-structured interview study was designed and reported according to the COREQ 
checklist using purposive sampling, with embedded think-aloud methods to evaluate the 
user experience with the ‘PSA test: yes or no?’ interactive Option Grid decision aid. The 
think-aloud technique (see data collection section) was employed to examine the activities 
and comments of the user and get feedback on the usability and feasibility of the tool. 
Semi-structured interviews were conducted following users’ completion of the web-based 
Option Grid to get a better understanding of how to improve the interactive version. The 
study received ethical approval from the Dartmouth College Committee for the Protection 
of Human Subjects (STUDY00030116). 
 
Recruitment 
We posted advertisements at bus stops throughout the Upper Valley region describing the 
study in order to invite men to use the PSA Option Grid and provide feedback. Also, 
coordinators at community centers and senior centers in the Upper Valley granted us 
permission to post advertisements at their centers. The advertisements encouraged men 
who were interested in participating to contact PS to agree on an interview time. The 
advertisement included information that participants would receive a $20 gas card for their 
participation. 
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Settings 
Interviews were conducted at three locations in the Upper Valley of New Hampshire and 
Vermont: (i) the Dartmouth Hitchcock Medical Center (DHMC); (ii) Dartmouth College 
library; (iii) the Upper Valley Senior Center in Lebanon, New Hampshire. 
 
Participants 
Individuals over 45 years of age living in the Upper Valley of New Hampshire and 
Vermont with no history of prostate cancer, who voluntarily contacted study authors via 
phone or email, and indicated their willingness to participate, were eligible for inclusion. 
Participants were excluded if they had a self-reported limited ability to engage with written 
material in the English language. Participants were not excluded if they underwent a PSA 
test at any point prior to their participation in the study. Study aims and procedures were 
explained to participants using an information sheet prior to their consent to take part in 
user-testing the tool.  
 
Development of the PSA Option Grid Decision Aid 
Option Grid patient decision aids are available in both a paper-based and web-based, 
interactive version and provide brief, evidence-based information on the available 
treatment options for various health conditions or screening tests, including the PSA [16]. 
An editorial team comprised of researchers and physicians, and led by GE, developed the 
web-based, interactive PSA Option Grid based on the IPDAS. The team, in consultation 
with patients, determined the FAQs. Evidence-based answers to those FAQs were provided 
by conducting a literature review. The search focused on systematic review papers to 
determine the risk information embedded in the tool. A document listing the references 
used to formulate the answers for each FAQ accompanies the interactive PSA Option Grid. 
Users have the option of printing a paper-based version of the tool or using the interactive, 
web-based version of the PSA Option Grid. Printed Option Grid decision aids use a tabular 
format to identify the available treatment options for a chosen healthcare topic (columns) 
and the questions that patients most frequently ask (rows) [16]. The content embedded in 
the tool consists of the evidence-based answers to the FAQs [17].  
 
If users selected the interactive version, they were asked to provide demographic 
information such as their role (patient/patient caregiver or healthcare professional), race, 
age group, gender, ethnicity and geographic region. Users are asked: ‘Do you already have 
a preferred option in mind?’ Users can select one of three options: having a PSA test, not 
having a PSA test, or not sure. They are then asked how strong their preference is – weak, 
moderate, or strong. Next, users fill out a four-item SURE survey which helps determine 
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their level of decisional conflict, followed by a series of five questions to check their 
knowledge of the PSA test. A series of ten FAQs are then presented, always in the same 
order. Users select their preference leaning based on the answer given for each treatment 
option. They then identify, on a scale of 0 (not important at all) to 5 (extremely important), 
the importance of the information presented. Once all ten steps are completed, the user 
indicates their final preference, identifies their preference strength based on the scale, and 
completes the SURE survey and knowledge questions. Finally, the user is presented with a 
summary of the choices they make for each FAQ. 
 
Data collection 
All interview sessions were conducted face-to-face with the participant and occurred in a 
private room at one of the three study settings. The Chew et al health literacy measure was 
completed by all participants [18]. It is a validated three-item measure that uses a Likert 
scale (always, often, sometimes, occasionally, never) to determine the confidence with 
which individuals fill out forms and medical forms independent of any help, and how often 
they require help reading hospital materials [19]. The study author queried each participant 
on their highest level of education attained. For the purposes of this study, participants who 
did not graduate with a college degree were considered to be of lower educational 
attainment.   
 
Participants were provided with a laptop. The interactive PSA Option Grid webpage was 
open, so participants can begin the interactive journey when ready. As participants were 
using the interactive tool they were asked to verbalize their thoughts - a technique known 
as think-aloud. Think-aloud was used because it enabled us to have a better understanding 
of the usability, feasibility, and the impact on user ‘cognition and emotion’ [20,21]. It 
provided participants with the opportunity to voice their satisfaction or dissatisfaction with 
various elements of the interactive Option Grid, recommend changes, and identify any 
difficulties related to navigation or understanding.  
 
Following the completion of the interactive PSA tool, we conducted semi-structured 
interviews (interview guide can be viewed in Appendix 1). Questions (derived from 
Morville’s framework – see analysis section) were focused on five elements: (1) usability 
(including design and navigation); (2) usefulness (including questions on content); (3) 
desirability (positive or negative features); (4) value; (5) credibility. Interviews were audio-
recorded, and duration of the interviews was noted. Data was collected until saturation was 
achieved – sampling more data would not have led to new information regarding usability 
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of the tool as users kept repeating the same concerns or ideas. Transcripts were not 
returned to participants for comment or correction. 
 
Analysis 
We searched for, but could not find, a validated framework to user-test a web-based patient 
decision aid. This is a relatively new field, and although there does not seem to be a well-
used or recognized framework, we opted to use Morville’s ‘honeycomb’ framework to 
provide structure to our data (see Figure 1) [22]. It has been used in the past to test oral 
health education applications, mobile device applications, business process management 
tools, and social software [23-26]. This framework has also been employed once before to 
user-test a decision aid known as the ‘decision-box’, and by the Cochrane Collaboration to 
test user’s experience with their systematic review library. [27,28]. We applied this 
framework to analyze our data since it contains all the features that we wanted to evaluate 
in our interviews. It was developed to assess seven different elements associated with the 
user’s experience with an intervention: usability, usefulness, credibility, desirability, value, 
findability, and accessibility [22]. Usability refers to the ease of use, and the degree of 
satisfaction attained from using the PSA interactive Option Grid. Usefulness relates to the 
value of the tool to the user’s knowledge-base or potential decision-making regarding the 
PSA test. Credibility explores the user’s level of trust for the evidence-based information 
embedded in the tool. We used the desirability element of the framework to examine the 
type of changes the user recommends making to improve the user experience. Value 
explores whether the interactive PSA Option Grid ‘advances the mission’, which in this 
case, means improving knowledge of the PSA test so a user can make a more informed 
decision, or can have a more efficient conversation with their provider in future encounters. 
For the purpose of this study, findability and accessibility were not assessed because study 
authors introduced the interactive PSA Option Grid to the user. We did not test the ease 
with which one could find the interactive tool online, or the barriers to access. We applied 
five of the seven (usability, usefulness, credibility, desirability, value) “honeycombs” to 
evaluate any issues the user may encounter with the PSA interactive Option Grid which 
may be the basis for re-design. 
 
Qualitative data analysis 
We employed Wallace et al’s recommendation to use the ‘sometimes’ response on Chew’s 
Likert scale as the cut-off to determine the number of participants with ‘limited or marginal 
health literacy skills’ [29].  
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Figure 1. Morville’s user-experience “Honeycomb” framework. 
 
 
 
User-testing sessions were recorded and transcribed by PS. The framework analysis 
method was used to analyze and code the data [30]. We conducted a deductive thematic 
analysis using Morville’s framework, and the data was coded independently by two 
researchers (PS and JS). We used this type of qualitative analysis because the coding and 
theme development were directed by the framework which enabled us to best achieve our 
study objectives. The ATLAS.ti software was used to assign codes, generated based on the 
five facets of the framework, to sections of participant statements, and additional codes 
were created to group codes together. All codes were reviewed to determine the themes 
associated with usability and feasibility of the PSA interactive Option Grid. We also 
highlighted specific changes or alterations suggested by the participant to improve the tool.  
 
Results 
Twenty interviews were conducted with men in the Upper Valley region. Ten participants 
interviewed had not completed a college degree (low educational attainment), and ten 
participants completed at least one college degree (high educational attainment). Of the ten 
participants in the low educational attainment group, eight had low health literacy skills. 
All participants who achieved a college degree had high health literacy. All participants 
were White, and their ages ranged from 49 to 81. See Table 1 for details.  
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Table 1. Participant characteristics. 
 
User Age Ethnicity Education Level Health Literacy Level 
1 65-70 White Low Low 
2 70 White Low Low 
3 70-75 White Low Low 
4 79 White Low Low 
5 76 White Low Low 
6 70-75 White Low Low 
7 50-55 White Low Low 
8 50-55 White High High 
9 49 White High High 
10 66 White High High 
11 45-64 White Low High 
12 69 White High High 
13 75 White High High 
14 81 White High High 
15 70 White High High 
16 50-55 White Low High 
17 50-55 White Low Low 
18 65-70 White High High 
19 65 White High High 
20 62 White High High 
 
Thematic Analysis 
We identified four key themes: (1) Perceived usability was contingent on familiarity with 
digital interfaces (and on health literacy); (2) Desire for revisions to improve user 
experience; (3) The value of communicating risks and tailoring content to individual 
attributes like age and family history; (4) Credible source of information, useful for pre-
visit use. See Table 2 for themes and sub-themes. 
 
Theme 1:  Perceived usability was contingent on familiarity with digital interfaces (and on 
health literacy). 
 
According to Morville’s framework, usability encompasses the ease of use, and the degree 
of satisfaction attained from using the intervention. Throughout their journey, participants 
with lower levels of health literacy (according to the Chew health literacy measure) 
described their difficulty with using and navigating the tool which affected their level of 
satisfaction with the intervention. Participants with higher health literacy levels used the 
tool with ease but envisioned potential challenges for men with lower levels of education. 
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Table 2. Themes and sub-themes derived from user-testing data. 
 
Themes Sub-themes 
Perceived usability was 
contingent on familiarity with 
digital interfaces (and on health 
literacy). 
 
 
-Participants with low health literacy have difficulty using computers. 
 
-A solution to alleviate computer intimidation is to provide low health 
literacy users with a paper-based decision aid. 
 
-Participants with high health literacy skills recognized that navigating the 
PSA Option Grid could be challenging for participants with low health 
literacy, so they suggested having a coach accompany them through the tool. 
 
-Increase the size of the words throughout the interactive Option Grid. 
 
Desire for revisions to improve 
user experience. 
-The layout of the FAQ pages need to be changed. Preferably stating a fact 
about the PSA test, and then asking: are you more or less inclined to have 
the PSA test? Based on that fact.  
 
-Embed the data viewer icon array on the FAQ page, so the user does not 
have to click on an option to view the pictorial. 
 
-Remove the importance ratings at the bottom of each FAQ page. 
 
The value of communicating risks 
and tailoring content to individual 
attributes like age and family 
history. 
-Men desire a comprehensive source of information, and appreciate the risk 
information embedded in the tool. 
 
-Participants believed that the PSA Option Grid is an ideal foundation for a 
more collaborative discussion with their physician. 
 
-Users would prefer to see age—specific information, and information 
related to family history and its impact on prostate cancer risk.  
 
Credible source of information, 
useful for pre-visit use. 
-Completing the interactive PSA Option Grid is not burdensome. 
 
-It is best to complete the tool prior to the clinical encounter and bring the 
results to the physician to have a discussion.  
 
- The PSA Option Grid represents a credible source of knowledge that can 
be used by men to be more involved in their healthcare decision making. 
 
Six of the eight users who had lower levels of health literacy and education levels were 
unable to use or navigate the PSA interactive Option Grid due to their stated unfamiliarity 
with the computer interface. The interviewer (PS) had to read and select the various 
options for the participant. Using an electronic device proved to be an intimidating factor 
in their user-testing experience and decreased satisfaction: 
 
‘I’m not computer literate. That’s obvious…I’m intimidated by computers to be honest’ 
(Participant 2 – age 70, low educational attainment and health literacy). 
 
‘I don’t like this. You go ahead and use it’ (Participant 3 - age 70-75, low educational 
attainment and health literacy). 
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According to multiple users, the majority of the population at the senior center would not 
be computer literate. We were advised to simplify the tool for a lower health literacy 
population: 
 
‘I’d say about 40% of the people that come here are computer literate. But, for older 
people that aren’t, and I’m thinking about people that come here…you need a more 
simplified version’ (Participant 5 – age 76, low educational attainment and health literacy). 
 
The men with higher health literacy, who were also part of the high-education bracket, had 
no issues with using or navigating the tool, but did express their concern for men who lack 
a higher level of education. They could envision how this interactive tool may not be 
usable for those men and hypothesized that a coach would be needed to guide them 
through the tool.  
 
‘I think it takes a certain level of sophistication and education to be able to understand and 
respond to those questions’ (Participant 16 - age 50-55, low educational attainment and 
high health literacy). 
 
Lastly, twelve users recommended we increase the size of the words to make the content 
easier to read for all users. Regardless of health literacy levels, elderly men being the target 
population of the PSA Option Grid have specific needs in terms of usability: 
 
‘The font needs to be bigger. Particularly for people like me who may have vision 
problems… everything needs to be bigger’ (Participant 3 - age 70-75, low educational 
attainment and health literacy). 
 
The discrepancy between men with higher and lower health literacy levels regarding 
usability was evident and is a factor in the ability to use and navigate the PSA interactive 
Option Grid.  
 
Theme 2: Desire for revisions to improve user experience. 
 
The desirability component of the framework highlights the desire to change various 
attributes of the tool to improve the user experience. What type of changes do users want to 
see? We describe these changes in detail. 
 
Participants had some difficulty understanding the actions they needed to take when faced 
with the FAQ portion of the interactive tool. For instance, the first FAQ poses the question: 
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what does the test involve? The having a PSA test option states that the PSA is a blood test 
that measures the antigen level in the blood from the prostate gland, and the not having a 
PSA test option simply states ‘does not apply.’ For the second FAQ, the same information 
was associated with each option – “15% of American men will develop prostate cancer in 
their lifetime”. Eight participants felt like the information associated with each option were 
unclear, leading to confusion on which screening option they should choose.  
 
‘So, I’m confused as to why I have to check this box as opposed to this box because they 
both have the same information. What are you trying to tease out here in this question with 
the two choices?’ (Participant 12 - age 69, high educational attainment and health literacy). 
 
To alleviate confusion, users suggested we alter the organization of the material for each 
FAQ. Participants indicated we should state a fact related to the PSA test, and then ask: 
does this information make you more or less inclined to have, or not have, a PSA test? 
Then, the participant can check the box based on their preference. This adjustment would 
also decrease the amount of material embedded in each FAQ page.  
 
‘Start out with this bit of information up here, and then that’s when you get the two 
options. Put the statement you just made, and then add…does this information make you 
more or less inclined to have the test or not?’ (Participant 10 - age 66, high educational 
attainment and health literacy). 
 
‘I’m suggesting that you have the piece of information, and then you’re given two boxes, 
yes/no, click one’ (Participant 12 - age 69, high educational attainment and health literacy). 
 
‘I would be more…it would seem a little more logical to me is to have a number of those 
facts laid out, and then say: do these make you feel more or less likely to want to have a 
PSA?’ (Participant 18 - age 65-70, high educational attainment and health literacy). 
 
For some FAQs, the having a PSA test option provided risk information. Below that risk 
information was a ‘data viewer’ option that, if clicked, provided users with an icon array to 
help them better understand the frequencies or percentages presented (see figure 5.2). Only 
two participants in the sample recognized the data viewer due its small presence on the 
page. Once we directed their attention to the icon array, users indicated that it should be 
embedded with the rest of the information: 
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‘Yeah, pictorials are good. I didn’t have problems with the 15%, but I would incorporate this [the 
icon array] in here [on the FAQ page]’ (Participant 15 - age 70, high educational attainment and 
health literacy). 
 
Figure 2. Icon array embedded in the ‘data viewer’ option in the PSA interactive Option Grid. 
 
 
 
The third recommended adjustment was the removal of the importance ratings at the 
bottom of each FAQ. The majority of users did not understand the purpose or usefulness of 
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that exercise, considering their attention was focused mainly on the information. The 
information was generally considered to always be of high importance to the user: 
 
‘So, to me the importance ratings of each question were less important than the stuff 
above. I thought the top part was informative, and then the zero to five scale was 
informative to you, the researcher, but not to me’ (Participant 8 - age 50-55, high 
educational attainment and health literacy). 
 
Ultimately, users suggested to re-organize the material for each FAQ by stating a piece of 
information, and then asking whether or not that information made the user more or less 
inclined to have the PSA test, thus clarifying the action required. Moving the icon array 
embedded in the data viewer to accompany the information for each FAQ would also help 
users visualize and understand the percentages and frequencies presented.  
 
Theme 3:  The value of communicating risks and tailoring content to individual attributes 
like age and family history.  
 
Value, according to the framework, refers to the attributes that participants deem most 
valuable. Viewing the tool through this lens, we identified that the risk information was 
most valued. In particular, users wanted to see prostate cancer risk information related to 
the age and family history.  
 
Participants felt that the greatest asset of the PSA interactive Option Grid was the level of 
high-quality, evidence-based information. It was also easy to understand, and much of the 
numerical information was new to users: 
 
‘There were a couple of things that I wasn’t aware of regarding the PSA test, which came 
up in here. About the 30% of men with a high PSA have prostate cancer. I didn’t know 
that’ (Participant 2 – age 70, low educational attainment and health literacy). 
 
Even for participants who already possessed knowledge of the risks and benefits associated 
with the PSA test, they felt that the tool provided the foundation for a discussion with a 
physician:  
 
‘I think this is a good introduction because you have people out here who haven’t 
considered or worried about it, and need to be educated. They need to be brought up to 
speed… as an introduction this will work. You may have had some people today that didn’t 
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know what the heck they were doing or haven’t really paid attention…’ (Participant 3 - age 
70-75, low educational attainment and health literacy). 
 
In particular, participants highlighted the value of the various probabilities associated with 
the PSA test, including: likelihood of developing prostate cancer in one’s lifetime, the 
chances of getting prostate cancer if the PSA test is high, or normal, the percentage of 
prostate cancers that are aggressive, and the risks associated with prostate biopsies and 
cancer treatments.  
 
‘The immediate risk of the various procedures, or if you had a high PSA, the risk 
associated with having a biopsy. That was the most helpful piece of information for 
me’ (Participant 9 - age 49, high educational attainment and health literacy). 
 
Despite the participants’ satisfaction with the true content in the tool, they indicated that 
there were two key information elements missing. The first is age-specific risk information 
related to prostate cancer. Stratifying the risk information according to age would help men 
better understand when the ideal time is to consider the PSA test. Second, how does family 
history influence one’s risk of prostate cancer, and how important a factor is that in 
determining whether or not one should have a PSA test? These are questions that 
participants felt should be addressed in order to create a more comprehensive tool for 
users. 
 
‘I think it would be interesting to know something about age because I’ve been told, I 
heard, that if you are over a certain age, the speed at which the average prostate cancer 
moves is very slow that you’ll probably die of something else first’ (Participant 13 – age 
75, high educational attainment and health literacy). 
 
Theme 4:  Credible source of information, useful for pre-visit use. 
 
According to the framework, credibility refers to the trust given to the tool’s contents. It is 
because of the trust in the evidence-based nature of the PSA Option Grid that participants 
found the tool useful. The intervention was useful in expanding the user’s knowledge-base 
and helped him make a decision regarding the PSA test. The two mechanisms of the 
framework are linked in the sense that the tool represented a credible source of information 
for users, and it could be used in a clinical setting prior to their discussion with the 
physician. 
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Participants felt that the ideal time to complete the tool would be prior to the clinical 
encounter due to the time pressures physicians experience. The patient can then bring the 
summary of their results to the physician to facilitate a better discussion about whether or 
not the PSA test is worthwhile.  
 
‘Yes. I think people could fill this thing out before the visit, so that they don’t have to sit 
with the doctor and hash through it’ (Participant 8 - age 50-55, high educational attainment 
and health literacy). 
 
Participants recognized that physicians have limited time with their patients, but the need 
to have a more constructive discussion about the PSA test still exists. They believed that 
the interactive PSA Option Grid represented the basis for an improved interaction with the 
provider because it was a credible source of information. There is a plethora of resources 
available in print or online regarding the PSA test, but men indicated their difficulty 
deciphering which information is credible and which information is not. All participants 
felt that being provided with one source that can provide accurate facts can be helpful to 
men in their decision-making, alleviating concerns of getting misinformation.  
 
‘Everyone Google’s…all the time, and so, more and more people, are going to their 
physician with questions they found online…I feel like a tool like this if presented within 
the context of a healthy conversation with your physician is valuable’ (Participant 9 - age 
49, high educational attainment and health literacy). 
 
Discussion 
Overall, men indicated that the interactive PSA Option Grid was useful despite the 
challenges those with limited health literacy skills faced engaging with the tool, the 
information acceptable with an emphasis to add more risk information associated with age 
and family history, and potentially feasible to implement this tool prior to a clinical 
consultation. Comfort with navigating digital interfaces influenced the user’s perception – 
Option Grid, and other web-based patient decision aids, may not be accessible to the male 
demographic that has lower health literacy levels. These users expressed their feelings of 
intimidation with having to use a laptop to access the interactive decision aid and would 
have preferred to use a paper-based decision aid instead. Regardless of health literacy 
levels, users stated their desire for changes (i.e. moving the icon array) related to the layout 
and organization of the information for each FAQ of the interactive tool. The risk 
information provided by the Option Grid was found to be highly valuable with most 
hoping to see content tailored to their specific attributes like age and family history in a 
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future version of the tool. The PSA Option Grid also represented a credible source of 
information, and users envisioned using this tool prior to the clinical encounter to facilitate 
an improved discussion with their physician. 
 
The strength of this study was the use of the think-aloud technique in conjunction with in-
depth interviews to examine the usability, acceptability, and feasibility of the tool with a 
diverse sample of individuals. This includes participants with lower levels of health 
literacy and education who are not computer-savvy. Due to two study authors’ (GE and 
MAD) involvement in developing the PSA interactive Option Grid, PS conducted the 
interviews and analysis of the data to mitigate the risk of bias. A weakness of our study is 
the fact that we did not use a validated framework to user-test patient decision aids. We 
also recognize that including a more diverse sample of men (i.e. ethnicity and geographic 
location) could have provided us with a different user-testing perspective. 
 
Our research highlights the importance of user-testing interactive decision aids prior to 
making it available to the online world. Developing a decision aid that is usable by men 
with lower health literacy involves an iterative interview process as described by Barton et 
al in their development of an encounter-based decision support intervention for rheumatoid 
arthritis medications [31]. Patients were interviewed on two separate occasions in order to 
refine the tool prior to pilot testing [31]. The developers of the PSA Option Grid did not 
user-test prior to its publication and based on this study we know men with lower health 
literacy struggled to navigate the application. Using a laptop proved to be a challenging 
exercise that provoked feelings of intimidation - an unprecedented finding that adds a layer 
of complexity for developers of interactive tools. The design changes recommended by 
users also suggests a desire for simplicity by embedding one fact about the PSA per FAQ 
to assess preference.   
 
Our study indicates that men value risk information regarding the PSA test, and seek 
information tailored to their own characteristics, particularly age and family history. 
Survey and qualitative research echoes these findings [32,33]. Despite information needs 
being highly variable and dependent on demographics, the desire for risk information 
remained stable for men making a decision on whether to have the PSA test or not [32]. 
Davison et al concluded that ‘men who had sons, a positive family history, and lower 
levels of education ranked hereditary risk’ as a key component in their prostate screening 
decision-making process [34]. Family history was repeatedly mentioned by participants in 
our sample as a factor that weighs heavily on the decision-making process. Although 
sexual function was not an issue raised by participants in our study, research shows that the 
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potential effects of prostate screening on sexual function is significant to younger men 
considering the PSA test [35,36]. In particular, participants with higher education consider 
sexual function to be of value when reflecting on the test [36].  
 
The source of the various facets of information regarding the PSA test is also a major 
theme in the literature. The internet has become the prime resource for men seeking 
credible information on the PSA test [37]. The preferred sites are those that are recognized 
or ‘institutions with established reputations’ [38]. Also, men often resort to online patient 
discussion forums for information support– a platform that was not mentioned by 
participants in our sample [39,40]. 
 
Participants felt that it would be feasible to use the tool prior to the consultation with the 
physician. According to the Ottawa Inventory of patient decision aids, there are eight PSA 
tools available for men – three of which are designed for use in the encounter. The 
feasibility or routine implementation of these decision aids has yet to be studied. Future 
work should examine how and when to best integrate these online decision support tools 
that have shown to increase patient knowledge and satisfaction related to the prostate 
cancer screening decision [41]. 
 
Conclusion 
The PSA interactive Option Grid decision aid was useful, but not usable for the section of 
the sample that was not computer literate. Research is needed to determine how best to 
increase access to patient decision aids (and the information embedded in these tools) so 
individuals in all demographics can benefit. The value of the evidence-based risk 
information embedded in the tool rendered it credible and acceptable by users who wish to 
see information associated with family history and age in a future version of the PSA 
Option Grid. Users envisioned the tool being feasibly implemented prior to their visit with 
the physician. Overall, this highlights the importance of user-testing web-based decision 
aids prior to their release in order to get a comprehensive understanding of user needs and 
priorities. More research is needed to better understand how interactive, web-based 
decision aids can be better designed to be usable by individuals across the health literacy 
spectrum.  
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Appendix 1. Interview guide formulated based on the “consolidated criteria for reporting qualitative studies 
(COREQ): 32-item checklist”. 
 
Introduction  
Which author/s conducted the interview or focus group? Peter Scalia 
What were the researcher’s credentials? PhD candidate 
What was their occupation at the time of the study? Research Assistant 
What experience or training did the researcher have? Research in shared decision making in healthcare - 
how online decision aids influence patients’ decisions and how they can be implemented in routine care. 
Was a relationship established prior to study commencement? No 
What did the participants know about the researcher? Participant will only know information stated above. 
What characteristics were reported about the interviewer/facilitator? Colleagues at The Dartmouth Institute 
create and develop Option Grid decision aids.  
 
Interview Questions 
 
(1) Usability (including design and navigation) 
 
-What do you think of the overall design of the Option Grid?  
Probe: What do you think of the font and colors used throughout the journey? What about the size of the 
words? 
 
-Was it easy or difficult to navigate? Please discuss how ‘usable’ it was for you. 
 
-Were you comfortable using the tool? 
Probe: How can we improve the tool graphics to improve user experience? 
 
-What do you think about the amount of time it takes to complete the journey? 
 
(2)  Usefulness  
 
-What do you think of the information presented?  
Probe: Was it easy to understand? Was there too much information or detail in your opinion?  
 
-Was their information that you thought was missing/was there information you would’ve liked, but 
couldn’t find?  
Probe: Any other types of information you would like to see in the Option Grid? 
 
-What type of information would you find useful in an interactive decision aid like Option Grid? 
 
(3)  Desirability (positive/negative elements of the tool) 
 
-What did you like or not like about the tool?  
 
-Do you think this tool can be potentially useful for patients weighing the different options? 
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-How can this help patients? Do you see yourself using this? Would you bring this decision aid to your 
doctor? 
 
-What features (importance ratings, information elements) did you like or not like?  
Probe: Do you think there was anything missing? 
 
-Did you notice the “data viewer” below some of the options? If so, what is your opinion? Is it easy to 
understand?  
 
(4)  Value and credibility  
 
-How feasible is the application?  
 
-Should physicians present this application to patients? If so, when?  
 
(5)  Closing comments 
 
-Do you have any other comments about the Option Grid 
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Abstract 
 
Background: Research on the implementation of patient decision aids to facilitate SDM in 
clinical settings has steadily increased across Western countries. A study which 
implements decision aids and measures their impact on SDM has yet to be conducted in the 
Eastern part of Europe.  
 
Objective: To study the use of Option Grid patient decision aids in a sample of Grupa 
LUX MED clinics in Warsaw, Poland, and measure their impact on SDM.  
 
Method: We conducted a pre-post interventional study. Following a three-month period of 
usual care, clinicians from three Grupa LUX MED clinics received a one-hour training 
session on how to use three Option Grid decision aids and were provided with copies for 
use for four months. Throughout the study, all eligible patients were asked to complete the 
three-item CollaboRATE patient-reported measure of SDM after their clinical encounter. 
CollaboRATE enables patients to assess the efforts clinicians make to: (i) inform them 
about their health issues; (ii) listen to ‘what matters most’; (iii) integrate their treatment 
preference in future plans. A hierarchical logistic regression model was performed to 
understand which variables had an effect on CollaboRATE.  
 
Results: 2,048 patients participated in the baseline phase; 1,889 patients participated in the 
intervention phase. Five of the thirteen study clinicians had a statistically significant 
increase in their CollaboRATE scores (p < .05) when comparing baseline phase to 
intervention phase. All five clinicians were located at the same clinic, the only clinic where 
an overall increase (non-significant) in the mean CollaboRATE top score percentage 
occurred from baseline phase (M = 60 %, SD = 0.49; 95 % CI [57-63%]) to intervention 
phase (M = 62%, SD = 0.49; 95% CI [59-65%]). Only three of those five clinicians who 
had a statistically significant increase had a clinically significant difference.  
 
Conclusion: The implementation of Option Grid helped some clinicians practice SDM as 
reflected in CollaboRATE scores, but most clinicians did not have a significant increase in 
their scores. Our study indicates that the effect of these interventions may be dependent on 
clinic contexts and clinician engagement. 
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Introduction 
SDM, a process that involves patients in medical decisions, has been shown to improve 
patient-clinician communication, decision outcomes, and patient satisfaction [1,2]. As a 
result, it has become increasingly embedded in healthcare policy across Western countries 
[1,3]. A recent editorial describes the accomplishments in areas of policy, research, and 
implementation of SDM in twenty-two countries [3]. However, there is little evidence of 
SDM activity in Eastern Europe, or in countries formerly under communist influence [3]. 
A RCT in Romania showed that using decision aids is an effective way of portraying risk 
over time with, and without, the use of oral anticoagulants for treatment of atrial 
fibrillation [4]. We were unable to find other studies conducted in the former communist 
states of Eastern and Central Europe [4]. This might be because of the ‘cultural imprint’ in 
this part of Europe. A study conducted in East Germany suggested a lower preference for 
SDM in comparison to patients living in West Germany, which could be due to the 
influence of the former authoritarian political structure [5]. 
 
Patient decision aids provide information on the pros and cons of comparable treatment 
options for preference-sensitive healthcare topics [6,7]. A Cochrane systematic review of 
patient decision aids indicates that these tools increase patient knowledge, risk perception, 
patient satisfaction, and participation in decision-making [2]. These tools are available in 
various lengths, formats, and modes of delivery [8]. Some are longer and are formatted to 
be used prior to the consultation, while other shorter tools are created for use in the 
encounter – also known as encounter patient decision aids [8].  
 
Option Grid encounter decision aids are brief, evidence-based tools that describe the 
available healthcare options associated with a particular health condition by using a set of 
FAQs [9]. Studies show that these shorter encounter decision aids are practical and easier 
to use compared to the pre-encounter tools [7,8,10,11]. However, there is limited evidence 
about the impact of pre-encounter tools on healthcare communication (using observer 
measures). 
 
Encounter-based decision aids hold promise at improving communication in healthcare and 
impacting interactions between patients and their healthcare professionals [10].  
 
A recent stepped wedge trial with 72 patients demonstrated that six physiotherapists who 
used an Option Grid for osteoarthritis of the knee showed higher levels of SDM (using 
Observer OPTION-12). Patients also demonstrated increased knowledge and readiness to 
decide on the most appropriate treatment option [12]. Wood et al.’s qualitative study 
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examined how the Option Grid tools influenced SDM when used with an interpreter. 
Results indicated that patients asked more questions when the tool was present in the 
encounter [13]. 
 
Randomized trials have also shown that Option Grid is feasible to use by clinicians [12]. 
These tools help clinicians provide information, structure the conversation, and confer 
agency to the patient [11,14]. These positive outcomes have led a few healthcare 
organizations to try and adopt Option Grid as a means to practice SDM with varying 
degrees of success [15]. There is some evidence to suggest that having a ‘champion’ 
clinician in the organization improves the likelihood of routine adoption, as opposed to 
using financial incentives to entice clinicians into using these tools [15]. Yet, it is clear that 
challenges to the implementation of encounter tools in clinic workflow patterns persist 
[16].  
 
Barriers to implementing patient decision aids exist at multiple levels in the healthcare 
system [16]. A systematic review by Elwyn et al. [17] indicates that some clinicians are 
reluctant to use decision aids because they do not agree with the content embedded in the 
tools, or do not want to impose the ‘decisional responsibility’ on their patients. Time 
pressure and competing priorities make it difficult for clinicians to incorporate decision 
aids in their routines [17]. These barriers were also apparent in the MAking Good 
Decisions In Collaboration (MAGIC) program, which was commissioned in the United 
Kingdom in an effort to implement SDM in routine care [18]. Clinicians in the program 
believed that providing the tool in the encounter was equivalent to practicing SDM [18]. 
This reflects the need to dedicate resources to educating clinicians about SDM as well as 
how to use patient decision aids.  
 
We know that implementing SDM in the clinical setting is difficult [7]. Despite a growing 
body of research on implementation barriers and strategies, we do not yet know the impact 
that individual doctors or clinics have on implementing patient decision aids in the medical 
encounter. Is it the cultural context, the organizational factors, or the attitudes of individual 
clinicians? We set out to routinely implement Option Grid encounter patient decision aids 
in clinical settings to examine their influence on SDM [19]. We believe this is the first time 
this approach has been taken in Poland, and therefore gave us an opportunity to examine 
implementation challenges in a context where SDM has not been promoted at the policy 
level. The aim of this study was to examine the use of Option Grid patient decision aids in 
a sample of Grupa LUX MED clinics in Warsaw, Poland, and measure their impact on 
SDM. 
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Methods 
A mixed-method approach was used. First, a pre-post interventional study was conducted 
at three Grupa LUX MED clinics in Warsaw, Poland. Second, to better understand the 
context and quantitative results from the pre-post interventional study, we asked 
participating clinicians to fill out a brief survey and conducted a debrief interview with the 
study project manager at Grupa LUX MED in Warsaw. See Figure 1 for an overview of the 
study design. 
 
Figure 1.  Summary of study design. 
 
 
 
Settings and participants 
Grupa LUX MED is the largest private healthcare provider in Poland serving over 1.5 
million patients across the country with over 170 facilities and almost 4,600 clinicians. 
Clinicians employed at three Grupa LUX MED clinics in Warsaw, Poland (Postepu St 
Clinic, Marriott Hotel Clinic, and Szernera St Clinic) were invited to take part in the study 
by their Medical Director. These clinics were selected by the Medical Director due to their 
high patient volume. All patients over 18 years old visiting one of the participating 
clinicians were invited by research assistants in the waiting room to take part in the study, 
irrespective of the reason for their clinic visit. The healthcare privacy laws in Poland 
protecting clinicians’ and patients’ identity influenced the data collection procedures and 
design of the study. Unique patient identifiers were used in both the baseline phase of data 
collection (usual care) and intervention phase (Option Grid; see data collection section), to 
identify a sub-sample of patients who had one of three Grid- specific conditions (i.e., 
patients who had heartburn, osteoarthritis of the knee, or were considering statins). 
Specifically, each clinician was provided with three-letter codes – each code corresponding 
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to patients who had one of the three Grid-specific conditions and one code for all 
remaining patients. Baseline data collection was conducted from February 2, 2016, to May 
17, 2016. After the baseline phase a one-hour workshop was delivered to participating 
clinicians in Warsaw on May 11, 2016. 
 
Intervention 
Both the workshop and the Option Grid patient decision aids represented the interventions 
in our study. GE presented a one-hour power point presentation to participating clinicians 
in a workshop that provided a definition of SDM, described its principles, explained how it 
could be implemented, and provided a blueprint (three-talk model) [20] on how to practice 
it. The presentation had three objectives: (i) deepen understanding of SDM; (ii) get familiar 
with the study, CollaboRATE and Option Grid; (iii) feel confident using Option Grid with 
patients. Clinicians were expected to use the three Option Grid decision aids whenever 
relevant to their patients, after the workshop.  
 
For this study, the selection of Option Grid patient decision aids was based on high patient 
volume at the participating Grupa LUX MED clinics. The three patient decision aids were 
translated into Polish using an established translation protocol to ensure fidelity to the 
original version and cultural adaptation for local clinical acceptability [20]. The protocol is 
an adaptation of the translation procedure of the AHRQ, successfully used in previous 
studies [21–23]. A bilingual reviewer compared and reconciled the translations to the 
original version until consensus was achieved. The last step relied on data from interviews 
with both patients and clinicians fluent in the target language to ensure cultural 
appropriateness. Translations were tested using two rounds of cognitive debriefing 
interviews.  
 
We interviewed two doctors and two patients per round, per Option Grid. In total, we 
completed 24 cognitive debriefing interviews. 
 
Consent process 
Patients of the 13 participating clinicians were recruited at the three participating Grupa 
LUX MED clinics. Patients recruited in the baseline phase were not required to sign a 
consent form. In the intervention phase, research assistants informed patients, assessed 
their eligibility and gauged their interest in participating prior to obtaining consent. 
Consent forms were prepared in collaboration with Grupa LUX MED to ensure 
comprehensibility and embedded in the online survey completed post-consultation (see 
data collection). Patients reviewed the consent form prior to the six-item questionnaire on 
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the tablet computer provided to them post-consultation (see data collection for more 
details). 
 
Outcome measures 
CollaboRATE is a three-item, patient-reported experience measure of SDM [24]. 
CollaboRATE evaluates the core tenets of SDM, namely: (i) information provision and 
explanation of health issues, (ii) elicitation of patient preferences, (iii) integration of patient 
preferences into decisions [23]. It asks patients to respond to the following questions on a 
scale of 0 (no effort was made) to 9 (every effort was made):  
 
1. How much effort was made to help you understand your health issues?  
2. How much effort was made to listen to the things that matter most to you about your 
health issues?  
3. How much effort was made to include what matters most to you in choosing what to do 
next? 
 
The CollaboRATE score represents a percentage of patients who give a ‘top score.’ A ‘top 
score’ is achieved when a patient gives the highest possible score (9) for each item of 
CollaboRATE. 
 
The top-score approach has been validated as a strategy for reducing the impact of ceiling 
effects for patient-reported measures [24]. We are aware of other patient-reported SDM 
measures such as the Perceptions of Involvement in Care Scale (PICS), the SDM-Q-9, and 
the Consumer Assessment of Health Care Providers and Systems Clinician and Group 
(CG- CAHPS®), but we opted to use CollaboRATE because it is a fast and frugal measure 
that can be easily implemented in clinic workflow patterns [25–28]. Translation of 
CollaboRATE into Polish followed the same process as Option Grid patient decision aids. 
 
Data collection 
To comply with privacy laws, participating clinicians provided all eligible patients with a 
three-letter code in the exam room before completing the visit. This ensured that the 
patient’s information collected, including health condition and characteristics (age and 
gender), were de-identified. In both baseline and intervention phases, the patient completed 
a six-item questionnaire on a tablet computer provided by a research assistant, immediately 
following the visit with their clinician. The questionnaire included an information and 
consent page, the three-item CollaboRATE measure as well as gender, age range, and the 
three-letter code they received from their provider. In the intervention phase, eligible 
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patients who provided consent used the Option Grid decision aid with their clinician prior 
to completing the six-item questionnaire. The manner in which we collected the data (de-
identification), and the sheer volume of the dataset enabled us to report the patient’s age (in 
categories) and gender in the baseline and intervention phase while respecting Polish 
privacy laws. To protect privacy, we did not collect any clinician demographic 
information. 
 
After the intervention phase, clinicians received a five-item survey via email to assess their 
attitude toward the CollaboRATE measure and the acceptability, feasibility, and impact of 
Option Grid decision aids in routine clinical practice. Clinicians had the opportunity to rate 
items on a Likert scale – strongly disagree, disagree, unsure, agree, strongly agree – for 
each of the first four survey statements. For the last statement, clinicians had to indicate if 
they had a positive or negative attitude to the use of Option Grid. To reinforce our 
understanding of clinician attitude toward Option Grid and CollaboRATE, we conducted a 
debrief interview with the study project manager at Grupa LUX MED. 
 
Data analysis 
First, to investigate the effect of using Option Grid on SDM in the intervention phase, we 
conducted a one-way ANOVA comparing the CollaboRATE scores from encounters where 
clinicians used Option Grid for Grid-specific conditions to scores from encounters where 
patients had one of the Grid-specific conditions but did not consent to use Option Grid.  
 
Second, to evaluate the unique contribution of clinicians and clinics to SDM, a 
Hierarchical Logistic Regression model was created using four blocks: patient 
characteristics (to control for age and gender), Grid-specific conditions and other 
conditions, the specific clinic, and clinicians. The dependent variable was the dichotomous 
“CollaboRATE top score” variable (0 = received a top score; 1 = did not receive a top 
score). We used the Hierarchical Logistic Regression model to account for the variability 
at each level in the hierarchy and to analyze the cluster effects at different levels within the 
model. We wanted to identify a statistically significant change in CollaboRATE scores, but 
we also wanted to detect any clinically significant difference. To do this, we used the 
‘distribution-based method’ to determine the minimal important difference (MID) in 
CollaboRATE scores at the clinician level [29]. This signifies that clinicians ‘improving 
more than one-half of the outcome score’s standard deviation have achieved a minimal 
clinically important difference [30].’ Essentially, the minimal clinically important 
difference is the ‘smallest change in an outcome that a patient would identify as important. 
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It is a threshold above which the outcome experienced could be considered relevant by the 
patient [31].’  
 
Finally, we examined the clinicians’ responses to the survey statements to help us 
understand the clinicians’ attitudes towards CollaboRATE and Option Grid, and their 
views on the acceptability, feasibility, and impact of Option Grid decision aids in routine 
clinical practice. We also summarized the project manager’s responses to the debrief 
interview (see Appendix 1 for interview guide). 
 
Results 
 
Demographics 
Thirteen clinicians participated in the study. Five gastroenterologists, two orthopedic 
surgeons, one family doctor, and one cardiologist were located at the Szernera St Clinic. 
Two family doctors and one cardiologist were located at the Marriott Hotel Clinic. One 
orthopedic surgeon was located at the Postepu St Clinic. In the baseline phase, we 
collected data from 2048 patients over a three-month period. In the intervention phase, we 
collected data from 1889 patients. The majority of patients who participated in each phase 
were female (56%). See Table 1 for details. 
 
Table 1. Patient demographics for baseline and intervention phases*. 
 
Variable Baseline, n (%) Intervention, n (%) 
Gender 
  Male 
  Female 
  Missing 
  
887 (43) 
1121 (55) 
40 (2) 
  
768 (41) 
1065 (56) 
56 (3) 
Age 
  18-29 
  30-39 
  40-49 
  50-59 
  60-69 
  70+ 
  Missing 
  
258 (12) 
509 (25) 
403 (20) 
362 (18) 
363 (18) 
128 (6) 
25 (1) 
  
214 (11) 
430 (23) 
376 (20) 
353 (19) 
320 (17) 
150 (8) 
46 (2) 
Total 2048 (100) 1889 (100) 
* Due to privacy laws in Poland, we were not able to include clinician demographic data. 
 
The effect of Option Grid decision aids on CollaboRATE 
In the intervention phase, there was a small decrease in the mean CollaboRATE top score 
percentage when we compared patients who had consented to use Option Grid (M = 66%, 
SD = 0.47; 95% CI [61%-72%]), and those who had the Grid-specific condition, but did 
not consent to use Option Grid (M = 68%, SD = 0.47; 95% CI [63%-73%]). The one-way 
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ANOVA result confirmed that the difference between those two groups was not significant 
(F(1,652) = 0.12, p = .73). 
 
Clinics and clinician role in CollaboRATE scores 
Results indicate that the patient’s age – being in the younger age categories – was 
associated with higher CollaboRATE top score (see Table 2 for details). There were five 
clinicians [clinician 1 (77% to 82%, p < .01), clinician 2 (65% to 75%, p < .01), clinician 9 
(56% to 71%, p < .01), clinician 10 (55% to 80%, p < .01), and clinician 11 (57% to 62%, 
p < .01)] who had a statistically significant increase in their mean CollaboRATE top score 
percentage from baseline phase to intervention phase (see Table 2 for details).  
 
Table 2.  Hierarchical Logistic Regression analysis to identify the variables associated with CollaboRATE top 
scorea,b 
 
Variables  Standard Error p-value Odds Ratio 
Patient’s Age 
   18-29 
 
0.139 
 
0.037 
 
0.000 
 
1.149 
   30-39 -0.763 0.258 0.003 0.466 
   40-49 -0.769 0.235 0.001 0.463 
   50-59 -0.849 0.234 0.000 0.428 
   60-69 -0.536 0.235 0.023 0.585 
   70+ -0.358 0.237 0.130 0.699 
Patient Gender -0.170 0.104 0.101 0.844 
Grid-specific condition -     
Statin -0.274 0.305 0.947 1.021 
Knee Osteoarthritis 0.328 0.377 0.384 1.388 
Heartburn -0.565 0.406 1.939 0.164 
Other 0.329 0.404 0.082 1.015 
Szernera St Clinic -0.274 0.368 0.456 0.760 
Marriott Hotel Clinic 0.102 0.950 0.914 1.108 
Postepu St Clinic 0.114 0.972 0.691 0.868 
Clinician 1 1.170 0.380 0.002c 3.220 
Clinician 2 1.104 0.424 0.009 3.017 
Clinician 3 1.147 0.956 0.230 3.148 
Clinician 4 -0.268 0.943 0.776 0.765 
Clinician 5 1.325 0.960 0.167 3.762 
Clinician 6 1.160 0.401 0.003 3.172 
Clinician 7 -0.250 0.395 0.528 0.779 
Clinician 8 0.410 0.392 0.296 1.506 
Clinician 9 1.172 0.407 0.004c 3.229 
Clinician 10 1.312 0.460 0.004c 3.714 
Clinician 11 1.155 0.389 0.003 3.172 
Clinician 13 -0.404 .348 0.245 0.667 
aDependent variable: CollaboRATE top score 
bAdjusted R2=0.136 
cMinimal important difference detected 
 
All five clinicians were located at the same clinic, the Szernera St. Clinic. Clinician 6 had a 
statistically significant decrease in the mean CollaboRATE top score percentage (73% to 
51%, p < .01). Clinician 12 dropped out of the study in the intervention phase of the study. 
Exploring the use of Option Grid patient decision aids | 151 
Figure 2 shows mean CollaboRATE top score at baseline and intervention for each 
clinician.  
 
In terms of clinical significance, only three of the five clinicians (clinician 1, clinician 9, 
and clinician 10) who experienced a significant increase in their mean CollaboRATE top 
score percentage from baseline phase to intervention phase had a minimal important 
difference – which ranged from 0.05 to 0.83. Minimal important difference was not 
detected in any other study clinician.  
 
Figure 2. Mean CollaboRATE top score percentage at baseline phase and intervention phase for each clinician. 
 
 
 
The Szernera St. Clinic was the only clinic where an overall increase (non-significant) in 
mean CollaboRATE top score percentage occurred when comparing baseline phase (M = 
60%, SD = 0.49; 95% CI [57%-63%]) to intervention phase scores (M = 62%, SD = 0.49; 
95% CI [59%- 65%]). The Marriott Hotel Clinic experienced an overall decrease in mean 
CollaboRATE top score percentage when comparing baseline phase (M = 78%, SD = 0.42; 
95% CI [74%-81%]) to intervention phase scores (M = 73%, SD = 0.45; 95% CI [69%-
77%]). The Postepu St Clinic also experienced a decrease in CollaboRATE scores between 
the baseline (M = 61%, SD = 0.49; 95% CI [55%-67%]) and intervention phases (M = 
47%, SD = 0.50; 95% CI [42%-53%]). 
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Survey and debrief interview results 
Of the thirteen participating clinicians, twelve answered the attitudinal survey. Nine 
clinicians (75%) agreed that Option Grid made it easier to promote SDM. Seven clinicians 
(58%) indicated that they had a positive attitude toward Option Grid. Six respondents 
(50%) answered unsure when presented with the statement: “it is easy to use CollaboRATE 
as a measure of SDM from a patient viewpoint”. Five clinicians (42%) reported a negative 
attitude (see Appendix 2). The interview with the study project manager revealed that some 
clinicians were prepared to use the intervention to improve their practice, while others 
were hesitant to use the tool due to time constraints. According to the project manager, 
younger clinicians appeared more receptive to using the tool. The younger clinicians 
seemed to make a concerted effort to improve interactions with patients and generally had 
a favorable impression of the Option Grid, appreciating the layout of the tool. The tool 
helped them better organize the conversation. Clinicians with more clinical experience had 
cited time constraints and disagreement with the clinical content of the tool. A few 
clinicians had suggested that some of the tools were biased toward one particular option 
 
Discussion 
Overall, the use of the Option Grid for patients in Grid-specific conditions did not lead to 
significant differences in CollaboRATE scores. The Hierarchical Logistic Regression 
model did however indicate a significant increase in CollaboRATE top score percentage 
for five of the thirteen clinicians – all five were located at the same clinic. Only three of 
those five clinicians had a clinically meaningful difference in their CollaboRATE top score 
percentage in the intervention phase compared to the baseline phase. One clinician 
experienced a significant decrease in their mean CollaboRATE percentage. The results of 
the survey and debrief interview provide context for our statistical results. The survey 
indicates that the clinicians included in this study had mixed attitudes toward the 
implementation of Option Grid. The project manager informed us that many clinicians 
(primarily the older clinicians) were concerned about time constraints and content bias and 
did not understand how to use these tools. 
 
A strength of this study is the implementation of the CollaboRATE measure on a large 
scale (n = 3937) to test the effect of Option Grid on SDM with thirteen clinicians across 
three different sites in Poland. Another strength is the thorough translation process of the 
Option Grid and CollaboRATE measure. One of the limitations of our study is that the 
dataset contained only patient’s age and gender demographics and no clinician 
demographics because of privacy laws in Poland that protect patients and clinicians’ 
identity. Other demographic variables like the patient’s level of education, socio-economic 
Exploring the use of Option Grid patient decision aids | 153 
status, and date of diagnosis may have had an impact on CollaboRATE scores, although no 
prior evidence exists that this may be the case. Interviewing the study clinicians would 
have strengthened the findings our study. However, given language barriers and time 
constraints, this was not possible. 
 
Barr et al. demonstrated the discriminative validity of the CollaboRATE measure [32]. It is 
now being used in ten different countries and available in Polish. Recently, Barr et al. 
assessed the CollaboRATE response rate across different modes of administration in a 
primary care clinic in New Hampshire and found that 68.0% of patients gave their 
clinicians a top score [23]. Results from our study indicate that patients gave their 
clinicians a top score 63% of the time. This might reflect the fact that SDM has never been 
promoted in Poland at the policy level and, as far as we can determine, is not taught in 
medical schools. In contrast, SDM has been promoted in the health policy of the United 
Kingdom and US [1]. 
 
Our results indicate that Option Grid decision aids slightly improve CollaboRATE scores 
for some clinicians. This was an expected result considering prior research that shows that 
Option Grid improves patient knowledge, increases patient involvement and readiness to 
make decisions that align with preferences, and influences clinicians to be more 
collaborative in their interactions with patients [23,33]. A previous randomized trial that 
showed the benefit of using a statin decision aid to help clinicians adopt SDM as opposed 
to the patient education pamphlet used at the Mayo Clinic, but we did not see this type of 
effect with the statin Option Grid used in our study [34]. Despite the positive outcomes 
associated with Option Grid in the literature, making use of encounter tools like Option 
Grid is challenging for clinicians [33]. 
 
The findings from the debrief interview indicate that time constraints and clinicians’ 
disagreement with the content are significant barriers to implementation. This information 
mirrors some of the ‘structural and conceptual’ barriers found in previous studies that 
assessed the practicability and feasibility of Option Grid decision aids for facilitating SDM 
[23,33]. In our study, we can infer, based on the information provided by the project 
manager, that the attitudes of older clinicians were much different from the attitudes of 
younger clinicians, and the likely impact of clinicians’ characteristics (i.e. age and their 
medical area of practice) on CollaboRATE scores was reflected in the statistical model. 
 
All study clinicians whose CollaboRATE scores increased with the use of Option Grid 
were located at the same clinic. Based on this evidence, we can infer that, to a certain 
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degree, a coherent strategy to implement tools like Option Grid and CollaboRATE in clinic 
workflow was established at that particular location. A commitment by clinicians to adhere 
to a SDM ethos is an important factor in successful implementation of a patient decision 
aid [14] and, in turn, can improve patients’ perception of how well their preference was 
discussed and integrated into the decision-making process. Commitment also needs to be 
demonstrated at higher levels of the healthcare organization, preferably through training 
and development for the healthcare professionals who will be using the tools. Perhaps the 
brief, one-hour training session was not sufficient in helping clinicians understand why and 
how these instruments were being used. Further, it is worth noting that the training session 
was also not delivered by a native Polish speaker, which may have influenced clinicians’ 
reluctance to use the tool. This may re-enforce the notion that a clinical champion would 
be an effective mode of communication for SDM training. Peer-to-peer training benefits 
would enable clinicians to ask peers questions that they would feel less confident asking an 
external host, and the clinical champion would represent a resource for ongoing support 
throughout the implementation of the tools. 
 
Furthermore, a clinical champion hosting a session would have existing knowledge of the 
clinical team, so he or she would be able to speak to the potential challenges clinicians 
would face with implementation of decision aids. Providing structured SDM training 
would confirm the commitment to shifting the clinic culture to a more patient-centered 
approach and would provide clinicians with the opportunity to learn how to practice it [35].  
 
Future studies need to investigate the implementation of encounter-based decision aids in 
more settings to determine the factors associated with low CollaboRATE scores at the 
clinician and clinic level. This would provide more insight into the cultural context and 
clinician characteristics that underpin the success or failure of routine adoption of patient 
decision aids. Ultimately, it could help researchers develop implementation strategies 
tailored to specific cultures and contexts to aid the implementation of SDM in regions like 
Eastern Europe. 
 
Conclusion 
The Option Grid intervention helped some clinicians practice SDM, but for most, it did not 
have an effect. The extent to which Option Grid patient decision aids can improve SDM is 
contingent on a variety of factors – mainly the clinician’s attitude toward using a decision 
aid, the clinicians’ characteristics (e.g., age), the setting in which the intervention is 
implemented, their understanding of the SDM approach, and their understanding of how 
decision aids can help facilitate a more efficient discussion with patients. 
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Appendix 1. The number of clinicians who circled each option on the Likert scale of the study survey. 
 
Statement Strongly 
Disagree 
Disagree Unsure Agree Strongly 
Agree 
CollaboRATE is a good 
measure of shared 
decision making from a 
patient viewpoint 
 
0 
 
0 
 
5 
 
5 
 
2 
It is easy to use 
CollaboRATE as a 
measure of shared 
decision making from a 
patient viewpoint 
 
0 
 
0 
 
6 
 
4 
 
2 
In my opinion, Option 
Grid patient decision aids 
are easy to use with 
patients in the clinical 
encounter 
 
0 
 
2 
 
3 
 
 
6 
 
1 
 
In my opinion, Option 
Grid makes it easier to do 
shared decision making 
 
0 
 
2 
 
1 
 
7 
 
2 
 Positive Negative 
My attitude to the use of 
Option Grid is: 
7 5 
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Appendix 2. Interview guide. 
 
1) First, could you tell us about the doctors’ reactions to being invited to take part in the study?  
 
a. Did they all agree to take part?  
 
b. Did they need convincing? 
 
c. If they did not agree to take part, which reasons did they provide?  
 
d. Are you able to identify the main barriers to doctors’ involvement in the study? 
 
e. For those who agreed to take part, why did they accept to participate?  
 
2) In addition to what was collected in the survey, what is, in your opinion, the doctor’s initial reaction to 
Option Grid decision aids?  
 
a. What did they think about Option Grid?  
 
b. Do you know whether it has changed the interactions they have with patients?  
 
3) What is, in your opinion, the doctor’s reaction to CollaboRATE?  
 
a. What did they think about having their patients complete CollaboRATE scores?  
 
b. What did they think about receiving CollaboRATE feedback? 
 
4) In your opinion, what did doctors think about the training session they attended in May? 
 
5) Do you think they would change anything about CollaboRATE? 
 
6) Do you think they would change anything about Option Grid?  
 
7) Do you think they would change anything about the study and data collection process? 
 
8) We know that research assistants were allocated to physicians to help them administer the Option Grid. 
Do you think this represents a barrier to routine implementation of Option Grid? 
 
9) Do you think that doctors would like to continue using Option Grid? Why or why not? 
 
10) Do you think that doctors would like to continue using CollaboRATE? Why or why not? 
 
11) Do you think that LUXMED would like to continue using CollaboRATE and/or Option Grid? Why or 
why not? 
 
 
7 
 
 
 
 
Chapter Seven 
 
 
“Provoking conversations”: case studies of organizations 
where Option Grid decision aids have become ‘normalized’ 
 
 
 
 
Peter Scalia MSc 
Glyn Elwyn MD, PhD 
Marie-Anne Durand PhD 
 
 
 
 
 
 
 
 
 
 
 
BMC Medical Informatics and Decision Making. 2017; 17(1):124. 
160 | Chapter 7 
Abstract  
 
Background: Implementing patient decision aids in clinic workflow has proven to be a 
challenge for healthcare organizations and physicians. Our aim was to determine the 
organizational strategies, motivations, and facilitating factors to the routine implementation 
of Option Grid™ encounter decision aids at two independent settings.  
 
Method: Case studies conducted by semi-structured interview, using the Normalization 
Process Theory (NPT) as a framework for thematic analysis. Twenty three interviews with 
physicians, nurses, hospital staff and stakeholders were conducted at: 1) CapitalCare 
Medical Group in Albany, New York; 2) HealthPartners Clinics in Minneapolis, 
Minnesota.  
 
Results: ‘Coherent’ motivations were guided by financial incentives at CapitalCare, and 
by a ‘champion’ physician at HealthPartners. Nurses worked ‘collectively’ at both settings 
and played an important role at sites where successful implementation occurred. Some 
physicians did not understand the perceived utility of Option Grid™, which led to varying 
degrees of implementation success across sites. The appraisal work (reflexive monitoring) 
identified benefits, particularly in terms of information provision. Physicians at both 
settings, however, were concerned with time pressures and the suitability of the tool for 
patients with low levels of health literacy.  
 
Conclusion: Although both practice settings illustrated the mechanisms of normalization 
postulated by the theory, the extent to which Option Grid™ was routinely embedded in 
clinic workflow varied between sites, and between clinicians. Implementation of new 
interventions will require attention to an identified rationale (coherence), and to the 
collective action, cognitive participation, and assessment of value by organizational 
members of the organization. 
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Introduction 
Why are some innovations easier to adopt than others, and what can we learn by examining 
settings in which innovations are spontaneously adopted? These questions are particularly 
relevant if we consider patient decision aids. Over 100 randomized trials have shown that 
their use increases patient knowledge, enhances their understanding of risk and 
participation in decisions [1]. Nevertheless, it remains difficult to implement these tools in 
routine practice [2,3]. 
 
Attempts to adopt patient decision aids in routine clinical settings have identified many 
barriers, and include the healthcare system context, and the various actors, notably, 
patients, physicians and others in that system [3,4]. The integration of patient decision aids 
is difficult, particularly when the tools have to fit into clinical workflows, without 
increasing time pressures [5, 6]. In addition, the tool’s potential lack of applicability to 
specific clinical problems and a lack of trust in the information they contain have been 
cited as significant barriers [6–8]. 
 
The IPDAS collaboration has developed a quality framework and criteria for the 
assessment of patient decision aids [9]. The IPDAS criteria includes health literacy in the 
development process section, however, very few developers ensure that their tool is usable 
by patients with low health literacy [9,10]. Frosch described design challenges: few tools 
are suitable for minority or disadvantaged groups [11-13]. Acknowledging and addressing 
the limitations of these interventions might provide solutions, but there may also be a need 
to explore what other strategies might exist to support implementation. 
 
Decision aids have a higher likelihood of being adopted if they do not compete with 
existing ‘priorities, targets and incentives’ [5]. Financial incentives to promote distribution 
have been shown to have a short term positive effect, but did not lead to sustained use 
when rewards were withdrawn [14]. Training physicians to use tools and building use into 
performance feedback can lead to a more sustainable implementation of patient decision 
aids [15,16]. Clinical leadership and distributing responsibility across teams are also 
critical success factors as is organizational investment [17,18]. Yet, this level of investment 
is rare [19]. The internal medicine department at the Massachusetts General Hospital in 
Boston and DHMC in New Hampshire are examples of organizations that have made the 
policy and financial commitment to embed decision aids in clinical systems, but these 
examples are not commonplace [18]. 
 
162 | Chapter 7 
Given these implementation challenges, an alternative approach to examine successful 
implementation would be to search for examples where organizations have independently 
identified and used patient decision aids, where the use of such tools have become 
embedded in existing workflows independently of research or evaluation efforts. 
 
We had become aware of settings where the Option Grid decision aids for clinical 
encounters had been adopted or ‘normalized’ as part of routine practice. These tools are 
one-page, evidence-based summaries of treatment or screening options and their attributes 
in a tabular format [5,20]. By using ‘frequently asked questions’, they are designed to 
promote an informed dialogue between patients and clinicians [21,22]. 
 
To explore and explain the degree to which organizations had embedded the tools into their 
normal work, we used the NPT. NPT is a conceptual framework developed to understand 
the mechanisms that predict the implementation of new interventions into practice settings 
[23,24]. NPT has four theoretical tenets: (i) coherence: the ‘sense-making’ that helps 
people working in the organization reach consensus about the intervention and its aim. In 
other words, the ability of the members within both organizations to get on the same page 
through understanding the intervention’s tenets, and the mechanisms underlying its 
delivery in routine care, realizing how it differs from the existing approach, and the 
willingness to routinely practice SDM in their practice [25]; (ii) collective action: the 
operational work that allocates tasks to each member of the organization to build and 
sustain the use of the intervention. The collective action addresses the how – how was 
Option Grid implemented? (iii) cognitive participation: the relational work that influences 
‘implementation and legitimation’ of the intervention. In other words, members of an 
organization working together and organizing themselves to participate in implementing a 
new intervention; (iv) reflexive monitoring: the communal appraisal work that aids the 
assessment and comprehension of the effects of the intervention [25]. This means 
identifying the pros and cons of using Option Grid, and suggesting modifications that 
would help make the intervention more accessible and easier to integrate into practice 
settings. 
 
The aim of our study was to use NPT to explore how and why two separate healthcare 
organizations in the US had spontaneously adopted Option Grid in routine clinical practice, 
and investigate the factors that have facilitated routine use. 
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Methods 
A case study design was selected to understand why organizations had decided to use 
Option Grid routinely, and explore facilitating factors. We chose this design because it 
enables one to ‘investigate cases in depth and employ multiple sources of evidence where 
the focus is on a specific situation or context where generalizability is less important’ [26]. 
The case study design also helped us describe the implementation of the intervention by 
addressing the how and why [26]. This aligns with our aim to investigate how and why 
these two organizations implemented Option Grid [26]. 
 
Settings  
The sites included in this study had been using Option Grid for over a year before we 
approached them for their potential inclusion in this case study. We are not aware of, nor 
did we search for, any other organization who was claiming to have routinely implemented 
Option Grid in their clinical setting. The case study method does not necessarily require us 
to include other settings who may have tried, and failed, to implement Option Grid. Case 
studies focus on the particular in order to provide in-depth assessments. We became aware 
of the CapitalCare Medical Group in Albany, because they had inquired about an update to 
one of the Option Grid decision aids that they had been using. The HealthPartners Practice 
had informed us of their intention to use Option Grid, which they had identified by their 
independent search for suitable tools, and because one of the clinicians in this organization 
had contributed to the development of some of those tools. 
 
CapitalCare Medical Group in Albany, New York, provides primary care services across a 
range of practices [27]. The HealthPartners Practice is located at the Riverside Clinic in 
Minneapolis, Minnesota and at a Specialty Center in neighboring Saint Paul, Minnesota, 
which provides orthopedic care [28]. Both sites offer a range of medical and dental 
services, including family practice, internal medicine, pediatrics, Obstetrics, Gynecology, 
and Nurse Midwifery [27,28]. We considered our unit of analysis to be the macrosystem 
(the organization) and the microsystem (the health professionals) who were using the 
Option Grid decision aids. We interviewed health care providers and staff in each 
organization who had been familiar with the use of the encounter decision aids. All 
interviews were conducted by GE and MAD in person at the CapitalCare and 
HealthPartners sites. Three group interviews were conducted at CapitalCare. All interviews 
were conducted individually with participants at HealthPartners. 
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Data collection  
We conducted semi-structured interviews using a schedule informed by NPT mechanisms 
(see Appendix 1). Health professionals were asked to: (1) describe their experience with 
the Option Grid, (2) describe the impact on patients and on their clinical encounters, (3) 
discuss the impact on the clinic workflow, and to (4) explain whether the tools were 
helpful in achieving a SDM process or not. Interviews and verbal consents were audio-
recorded. The study received ethical approval from the Dartmouth College Committee for 
the Protection of Human Subjects (STUDY00028711). 
 
Analysis 
NORMALIZATION PROCESS THEORY (NPT) 
This theory was developed to investigate the processes by which interventions become part 
of normal work [23,24]. The NPT proposes that ‘complex interventions become routinely 
embedded (implemented and integrated) in their organizational and professional contexts 
as the result of people working, individually and collectively, to implement them’ [25]. We 
considered NPT to provide an ideal approach to analyze the study data, and have 
successfully used this approach before to analyze qualitative data [23–25]. The two 
organizations did not have rigorous quantitative data, but did list which Option Grid 
decision aids were used, the number of sites that were using the tools, the total number of 
times the decision aid was given to patients, and the year of implementation (see Table 1). 
We were not provided with any other quantitative information regarding the extent to 
which Option Grid decision aids were used. Therefore, we were not able to investigate how 
often Option Grid was used, by how many physicians or practitioners, with what percent of 
eligible patients, etc. 
 
We applied the four mechanisms coherence, collective action, cognitive participation and 
reflexive monitoring to examine why Option Grid decision aids had been adopted, who 
used them, how they were implemented in the workflow, and how they were understood to 
be helpful contributions to the work of the clinic. According to NPT, these four 
mechanisms require collective and continuous sense-making, commitment, effort and 
appraisal for the intervention to become ‘normalized’ [24]. 
 
QUALITATIVE DATA ANALYSIS 
Initial descriptive codes were generated based on the four NPT mechanisms by PS. Short-
phrase labels were assigned to data sections (in-vivo coding) and additional categorical 
codes were developed to group codes together. Groups were based on codes that supported 
or refuted the analytical NPT framework. Once the groups of codes were classified among 
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the four NPT mechanisms, we reviewed them to identify four themes that accurately 
represented the how and why these tools were being implemented and the facilitators to 
routine implementation of decision aid tools. Following the analysis of data, triangulation 
was performed by asking two colleagues who were not involved in the study (PB and MM) 
to review the codes and themes, to critically appraise the findings, and to offer alternative 
explanations for the reported outcomes. 
 
Results 
We conducted semi-structured interviews (see Appendix 1) with health professionals who 
had used the Option Grid or facilitated its use, and were available to take part in an 
interview. The manager at CapitalCare selected health professionals who had experience 
using Option Grid, who would be interviewed by GE and MAD. At HealthPartners, we 
asked to interview all people who were engaged in using, or coordinating the use of Option 
Grid decision aids. We then relied on each site to schedule interviews with those health 
professionals based on their availability and willingness to participate. Nine interviews 
were conducted jointly by GE and MAD at the CapitalCare Medical Group, and comprised 
of three interviews with physicians, and six other interviews, with a nurse, a staff member, 
a manager, a medical assistant, an administrator and a clinical quality analyst. Fourteen 
interviews were independently conducted at HealthPartners Practice, in Minneapolis, 
Minnesota (by MAD, SA, SG), and comprised of three interviews with physicians, six with 
licensed practice nurses, three with physician assistants, one manager and one with a hand 
surgery fellow. 
 
Case study: The CapitalCare medical group, Albany  
This primary care organization is physician-owned and offers services in family practice, 
internal medicine and pediatrics from 65 physicians across ten sites [27]. CapitalCare 
practices chose to utilize a total of 5 Option Grid decision aids. CapitalCare was able to 
provide quantitative data about Option Grid decision aid use through the electronic health 
record from 2013 until July 2015 (time of data collection in Albany). Table 1 ranks the 
tools from most to least commonly used by the practices, and indicates the number of 
practices using each Option Grid, the number of tools that have been given out by each 
practice, and the year of implementation.   
 
Case study: The HealthPartners practice, Minneapolis  
This organization has over 600 physicians [28]. The lead hand surgeon at the 
HealthPartners Specialty Center had been an editor for the Dupuytren’s disease, Carpal 
Tunnel syndrome and Trigger Finger Option Grid decision aids. The organization had been 
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using the encounter decision aids for 1 year before we contacted them for inclusion in the 
study. HealthPartners did not use a metric to track the use of Option Grid decision aids, 
however, the lead hand surgeon provided the data presented in Table 1 during the 
interview. 
 
Table 1. CapitalCare and HealthPartners Option Grid metric tracking. 
 
Setting Option Grid 
decision aid 
Number of sites 
using Option Grid 
decision aids 
Total number of times 
the decision aid was 
given to patients 
Year of 
implementation 
 
 
 
 
CapitalCare 
High cholesterol 6 887 2013 
Antibiotics for pharyngitis 2 163 2014 
Sciatica 3 80 2013 
Knee pain 1 41 2013 
Prostate-specific antigen (PSA) 1 32 2014 
 
 
HealthPartners 
Dupuytren’s contracture 2 100* 2014 
Carpal tunnel syndrome 2 200* 2014 
Trigger finger 2 200* 2014 
*This is an estimated number based on information provided during the interview with the ‘champion’ physician at 
HealthPartners.  
 
Thematic analysis 
Our analysis led to the identification of four themes - see Table 2. We describe the four 
themes identified and assess how we used the NPT mechanisms to interpret the results. 
 
Table 2.  Themes underpinning organizational implementation of Option Grid decision aids. 
 
Themes 
1) Coherence – organizational motivation 
2) Collective action – the interventions viewed as workable solutions 
3) Cognitive participation – slow adaptation to new interventions 
4) Reflexive monitoring – assessment of benefits and drawbacks 
 
Theme 1: Organizational motivation  
 
Each organization reported that their overall motivation to practice SDM had led to the 
search for, and adoption of encounter decision aids. 
 
The CapitalCare medical group, Albany  
CapitalCare was located in a region that was participating in the Comprehensive Primary 
Care Initiative (CPCI), initiated by the Centers for Medicare and Medicaid Services 
(CMS). The CPCI was a primary care quality improvement program focused on promoting 
patient engagement where practices were required to meet stipulated milestones each year 
in order to obtain financial incentives offered [29]. To meet one of the milestones, 
CapitalCare had introduced ‘SDM’ into their organization. To operationalize ‘SDM’ they 
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had decided to introduce encounter decision aids, and had identified Option Grids as their 
preferred tool. To qualify for the financial incentives, reports detailing the use of decision 
aids with patients were required. The use of the tools had been initiated therefore as a 
means to an end. Due to this sentiment, and the fact that not all physicians were motivated 
to use the tool, four of the ten CapitalCare sites in Albany failed to routinely implement 
Option Grid. One of the organization’s managers recognized the incoherent, top-down 
approach to how Option Grid implementation came about: 
 
‘Our central business office, they kind of pushed us in that direction’ (Site Manager, The 
CapitalCare Medical Group, Albany).  
 
‘Yeah, all we heard from CMS was… go use these tools’ (Site Manager, The CapitalCare 
Medical Group, Albany). 
 
The HealthPartners practice, Minneapolis  
At HealthPartners the use of Option Grid decision aids had been initiated by a hand 
surgeon, reported in the interviews to have been the primary advocate. The hand surgeon 
had also played a significant role in the development of the three Option Grid decision aids 
that were being used in the hand surgery clinic. Data confirmed the importance of this 
‘champion’ role as an example for her colleagues:  
 
‘We just started giving them out in her clinics and then some of the other providers got 
interested in it and we started rolling it out in their clinics’ (Nurse, The HealthPartners 
Practice, Minneapolis).  
 
‘Dr. [champion physician] presented it to the group and encouraged us to try it…she said 
these [Option Grid] were a great tool, and she thought that we should start to use them’ 
(Physician, The HealthPartners Practice, Minneapolis).  
 
Coherence: the ‘sense-making that promotes or inhibits the coherence of the intervention.’  
 
When we consider these two settings using the ‘coherence’ lens of NPT, we realize that the 
motivation at the CapitalCare organization, and to some degree, the consensus for adopting 
the use of Option Grid, had been stimulated by an external initiative. CapitalCare wanted 
to benefit from the financial incentives offered by the CPCI initiative. This ‘sense-making’ 
management plan was the extrinsic motivation that led to the use of the encounter patient 
decision aids. In contrast, at HealthPartners, the motivation was intrinsic, in that a 
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‘champion’ physician had influenced her colleagues by demonstrating the benefit of using 
the encounter decision aids. 
 
Theme 2: The interventions viewed as workable solutions  
 
The brief nature of the Option Grid decision aid was a workable solution to health 
professionals at CapitalCare who were looking to satisfy financial incentives set by the 
organization. The collective action of the nurses at both settings was reported as a key 
factor in promoting adoption of the tools.  
 
The CapitalCare medical group, Albany  
Providers had searched for free, seemingly easy-to-use tools that would satisfy the 
financial incentives set by management, yet not burden the clinical workflow. Using the 
Option Grid encounter decision aid enabled physicians to enter codes in the patient’s 
electronic health record, which fulfilled the CPCI requirements for compensation. Some 
physicians altered the content of the tool yet kept the one-page format: 
 
‘We had taken the tool, and adjusted it to a way that it would be more patient friendly, 
more patient literate by changing some of the words and the layout’ (Physician, The 
CapitalCare Medical Group Albany).  
 
Others did not understand the difference between SDM and patient education, and saw the 
tool as an information leaflet to be given to patients rather than as a tool to support 
deliberation about options and to elicit patient preferences:  
 
‘It’s still a challenge to get them [other clinicians] to understand the difference between 
shared decision making and patient education’ (Staff Member, The CapitalCare Medical 
Group, Albany). 
 
‘I think this is more patient education. So, I see them as an extra educational tool to use.’ 
(Physician, The CapitalCare Medical Group Albany).  
 
CapitalCare, as part of the CPCI program, also asked nurses to identify patients that could 
benefit by receiving an encounter decision aid, and alert physicians to its possible utility in 
their clinical encounters:  
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‘A lot of our offices are engaged in pre-visit planning. So during that process if the person 
... identifies that the patient may be a good candidate for shared decision making, then that 
individual may flag the record or attach it [the Option Grid] to the encounter form ...’ 
(Staff Member, The CapitalCare Medical Group, Albany). 
 
The HealthPartners practice, Minneapolis  
Nurses at HealthPartners helped embed the encounter decision aids without much 
disruption to the existing clinical workflow. Nurses determined patient eligibility for one 
of the three Option Grid decision aids (Dupuytren’s disease, carpal tunnel syndrome and 
trigger finger), based on the referral and reported symptoms. Before the surgeon entered 
the examination room, the nurses reported facilitating a discussion with the patient using 
the Option Grid content. This method ensured patients were already familiar with the 
content and comparisons described in the encounter tools ahead of their discussions with 
the hand surgeons:  
 
‘So, we, the rooming nurses, give the patients the Option Grid. So, when they’re waiting 
for the provider to come in the room they can start reading about trigger finger, carpal 
tunnel .. I think we have a Dupuytren’s one’ (Nurse, HealthPartners Practice, Minneapolis). 
 
Nurses at HealthPartners would also explain to newer staff how best to integrate the tool in 
the clinic workflow:  
 
‘That’s a clinical training thing, you know. The more seasoned nurses would be explaining 
to the newer people who rotate’ (Nurse, HealthPartners Practice, Minneapolis).  
 
All those interviewed emphasized the importance of the nurses as facilitating the adoption 
of Option Grids, a process made easier in this setting because of the limited number of pre-
specified problems:  
 
‘Well, I talk about all their symptoms and I say, well I feel like you may have carpal tunnel. 
I have this Grid; it talks about all your treatment options’ (Nurse, HealthPartners Practice, 
Minneapolis).  
 
Collective Action: the operational work that enables the enactment of the intervention.  
 
The brief nature of the Option Grid represented a workable solution for health 
professionals at CapitalCare to, not only satisfy the financial incentives, but also to modify 
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the content of the tool before providing it to patients. The work performed by nurses at 
both settings was important to routine adoption of Option Grid. Pre-visit planning by 
nurses enabled them to attain the appropriate tool for the patient prior to the consultation, 
thereby alleviating the responsibility to operationalize the tool from the physician. In 
summary, at both settings, we saw evidence of collective action to adopt the tools by a 
range of professionals with different roles in the organizations. 
 
Theme 3: Slow adaptation to new interventions  
 
The clinics reported a lack of support and resources, coupled with an absence of formal 
training as a reason for the challenges initially experienced in adopting the Option Grid 
decision aids. This was particularly true for the primary care setting at CapitalCare, where 
the physicians reported resistance to using the tools.  
 
The CapitalCare medical group, Albany  
Meetings, tutorials and webinars had been offered to clinicians at CapitalCare, but a 
number of physicians interviewed reported a lack of specific training about how to use 
Option Grids:  
 
‘I don’t think there’s been any formal training. I mean no, not really’ (Physician, The 
CapitalCare Medical Group, Albany). 
 
‘A lot of emails, but no formal training’ (Physician, The CapitalCare Medical Group, 
Albany). 
 
This lack of training led to both resistance and skepticism, by both staff and physicians:  
 
‘They [the clinicians] didn’t understand what the benefit was’ (Staff Member, The 
CapitalCare Medical Group, Albany).  
 
At the time of our interviews, six out of the ten CapitalCare clinics had adopted the 
encounter decision aids in their clinics. Four clinics did not wish to use the tools and the 
management reported mixed views about the tools:  
 
‘And there are certain sites that have those physician champions ... and some physicians 
struggle with the concept, and that’s really where we’re at’ (Site Manager, The 
CapitalCare Medical Group, Albany). 
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The HealthPartners practice, Minneapolis  
Interviewees reported initial levels of reluctance to the implementation of the encounter 
decision aids. Before being introduced to these tools, most surgeons had not been aware of 
SDM, had not used encounter decision aids, nor come across the idea of using these tools 
collaboratively with patients.  
 
‘We did active listening in residency and got critiqued on it, but we never actually used a 
tool’ (Physician, HealthPartners Practice, Minneapolis).  
 
A nurse described this reluctance as a reaction to having to change established practice:  
 
‘I don’t know if that’s because they don’t like it [the Option Grid], but it’s a different way 
to practice and they’re used to doing it their way’ (Nurse, HealthPartners Practice, 
Minneapolis). 
 
Interviewees also reported concerns about time pressure and a lack of perceived utility for 
some patients as a significant contribution to their hesitation. Physicians reported being 
selective in their use of the Option Grid, making judgments based on patient 
characteristics:  
 
‘So, it’s patient-dependent, obviously. We don’t bring one in every visit’ (Nurse, 
HealthPartners Practice, Minneapolis).  
 
‘Well, when we use it, it’s highly variable based on the patient’ (Physician, HealthPartners 
Practice, Minneapolis). 
 
Cognitive Participation: the relational work that influences ‘enrolment and legitimation’ of 
the intervention.  
 
As these data illustrate, the health care professionals at CaptalCare and HealthPartners 
assessed the utility of the tools as members of a work setting, and did so in relation to each 
other’s reactions and the reactions of patients. Our analysis reveals that over time they 
gradually saw the usefulness of the tool in their work. On the other hand, their lack of 
awareness that these tools had been purposefully designed to facilitate SDM in clinical 
encounters led to mixed views about their utility. This was particularly noticeable at 
CapitalCare where physician resistance was more vocal, and less of a barrier at 
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HealthPartners because of the way in which the nurses had facilitated the integration of the 
tools into the clinical workflow.  
 
Theme 4: Assessment of benefits and drawbacks  
 
Participants in both settings reported perceived benefits of using Option Grid decision aids. 
They also suggested modifications that would help make the interventions more accessible 
and easier to integrate into practice settings.  
 
The CapitalCare medical group, Albany  
Participants reported that the encounter decision aids provided benefits, particularly in 
terms of information provision and as a way for preparing patients:  
 
‘The importance of your tools, though, is that [they have] evidence-based accurate 
information’ (Staff Member, The CapitalCare Medical Group, Albany).  
 
‘It [the Option Grid] provides a structured format for the patient to understand the nature 
of their health disease and provide information that helps make a better informed decision’ 
(Physician, The CapitalCare Medical Group, Albany).  
 
Physicians reported improved interactions when the tools were used, and noticed how 
patients asked more questions and were more satisfied.  
 
‘I think the people with the grid maybe ask a few more questions. Maybe the grid, for them 
brings a few things up that they may not have thought of’ (Physician, The CapitalCare 
Medical Group, Albany).  
 
In addition, a few physicians reported the benefits of using the tools as a means to generate 
and document different kinds of dialogue with patients: 
 
‘It’s a great way, in our medical record, to document the conversations we’ve had with 
patients, the way they’ve changed, the way they’ve thought over the months, and so that’s 
where I like it’ (Physician, The CapitalCare Medical Group, Albany).  
 
Physicians at CapitalCare were concerned about the high literacy levels that would be 
required by patients to make good use of the Option Grid:  
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‘We see people ... who have a low literacy rate, so I just want the communication to go 
both ways’ (Physician, The CapitalCare Medical Group, Albany).  
 
Physicians at CapitalCare recognized that extra time was needed but were able to adopt the 
tools by using them with selected patients:  
 
‘It slowed down the day a little bit, so we had to pick and choose where we were going to 
use it’ (Physician, The CapitalCare Medical Group, Albany). 
 
The HealthPartners practice, Minneapolis  
Physicians at HealthPartners appreciated patients having access to the evidence-based 
information presented in the Option Grid. The concise format served to empower patients 
and improve collaboration:  
 
‘I think that the quality of the conversation is much better’ (Nurse, HealthPartners Practice, 
Minneapolis).  
 
‘I think it is a nice way to just march people through their options and have something on 
paper that they can see and read, which is nice’ (Physician, HealthPartners Practice, 
Minneapolis). 
  
‘Also, it makes them feel a bit empowered in that they know what their options are and can 
pick and choose what they think is best for them’ (Physician, HealthPartners Practice, 
Minneapolis). 
 
Physicians at HealthPartners raised similar concerns about readability for patients with low 
health literacy:  
 
‘The only question of possible concern is some of our patients may be illiterate or have 
poor health literacy’ (Physician, HealthPartners Practice, Minneapolis).  
 
In contrast to CapitalCare, interviewees at HealthPartners indicated that using the Option 
Grid shortened their clinical encounters by ensuring that patients were better informed and 
better prepared to make decisions:  
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‘If anything, slightly shorter [encounters] because the patient has had a chance to read it 
and go through it, and then they focus in on the area that they like’ (Physician, 
HealthPartners Practice, Minneapolis).  
 
Reflexive Monitoring: the appraisal work that aids the assessment of the effects of the 
intervention.  
 
Health professionals and managers at both settings had spent time reflecting about the 
overall contribution of Option Grids to their practice. Some were critical, even skeptical at 
times, but overall, the data indicates that the organizations as a whole felt that the tools 
added value rather than brought extra burden. 
 
Discussion 
This case study suggests that patient decision aids that are specifically designed for use in 
clinical encounters can be embedded in clinical settings, provided there is agreement about 
the need to use them, that the team members are willing to work together to make sure that 
such tools can be integrated in existing work patterns, and understood as making a positive 
overall contribution to the work that has to be performed. These considerations match the 
mechanisms of the NPT, which provides an explanatory framework for understanding the 
sustained use of these tools by the two systems examined. The motivation for the use of the 
Option Grid at CapitalCare was their wish to achieve success in an external quality 
improvement initiative. At HealthPartners, implementation efforts were motivated by a 
‘champion’ physician. The nursing staff also played a pivotal role by systematically 
identifying eligible patients and providing those patients with the relevant encounter tool. 
These organizations, in different ways and to different degrees, exhibited coherence, 
collective action and cognitive participation that supported the sustained use of the tools. 
The organizational appraisal, in other words, their reflexive monitoring, was positive 
overall, despite concerns about readability and time pressures.  
 
A strength of this study was the in-depth interviews with multiple stakeholders (physicians, 
nurses, staff members) at two independent clinical service settings. Another strength of this 
study is the case study method to investigate the two real-world settings who had adopted 
Option Grid decision aids independent of any invitation. This provides insight into how 
real clinical practices address the issue of patient decision aid implementation. We 
recognize that two study authors (GE and MA) are involved in the Option Grid 
Collaborative, a nonprofit making organization that develops and disseminates patient 
decision aids for clinical encounters. To mitigate the risk of bias, the analysis was 
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conducted by PS. The addition of other settings would have given us access to data from 
organizations that tried to implement Option Grid in their practice, but did not succeed, or 
organizations that chose not to adopt Option Grid. We were not privy to any quantitative 
data regarding how often Option Grid decision aids were used, by how many clinicians, 
with what percentage of eligible patients, or any demographic information regarding the 
patients (including patient health literacy levels). This would have strengthened the study 
findings, which we recognize 
 
Implementing patient decision aids into clinical settings is a difficult process [1,4,25,30]. 
In the UK, an implementation program known as MAGIC highlighted the need for an 
organizational coherence, i.e. a widely held and agreed understanding of SDM principles 
in order to facilitate the implementation of patient decision aids [25]. Commitment at 
multiple organizational levels has been recognized as an important precondition for 
implementation [1,4,31]. This lack of commitment was noticeable at the CapitalCare sites 
that did not use patient encounter tools. A systematic review identified that a key 
implementation success factor is the presence of a respected clinical champion [1]. This 
was reinforced by the MAGIC program when it demonstrated the power of clinical leaders 
to recruit colleagues [25]. 
 
Whether the introduction of incentives is a sustainable way to encourage the 
implementation of patient decision aids is a matter of debate [32]. Management decisions 
at CapitalCare were clearly made as a response to financial incentives but this interest did 
not translate into consistent motivation among the front-line clinicians. In contrast, at the 
HealthPartners setting, the willingness to adopt the encounter tools on the basis of their 
perceived inherent value to both clinicians and patients; financial incentives were not 
instrumental. These two contrasting strategies can be used as examples by other 
organizations looking to implement decision aids. This study indicates that financial 
incentives may not be the best approach for implementing decision aids in comparison to 
using a ‘champion’ clinician that can lead by example.  
 
Few studies have examined the implementation of patient decision aids in routine service 
systems, and this case study work needs replication in many other settings. More work is 
needed to understand how social context and the relationships between actors within the 
social system affects ‘real world’ implementation [33]. There is evidence emerging that 
encounter tools are effective: when physiotherapists were trained on how to use an Option 
Grid developed for patients with osteoarthritis of the knee, shared decision levels and 
patient knowledge increased, without an increase in encounter duration [22]. Examination 
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of videotapes showed that using encounter tools led to parents asking more questions and 
getting more involved in the clinical discussion about circumcision [34]. Encounter tools 
seem to be viewed as ‘flexible artifacts’, allowing physicians to adapt how they use the 
tools, making it easier to embed the interventions into clinical work [31,35]. 
 
Future studies should also consider ideas to support the implementation of patient decision 
aids. Organizations may want to consider providing clinicians with SDM workshops to 
facilitate the approach and clarify any questions or concerns they may feel about using a 
decision aid. To ease the time pressures on clinicians, organizations can also enable 
patients to use an interactive tool via their electronic health record before the encounter, so 
they can bring their results to the clinician with any questions they may have. If 
organizations choose to implement a financial incentive to promote SDM, then it may be 
worthwhile to invest in modifying the electronic health record to make it easier for health 
professionals to indicate the use of decision aids to satisfy the financial incentives. This can 
help bypass administrative barriers that may impede the success of implementation. In the 
future, moving decision aids to an online platform can also lead to the creation of 
algorithms to customize decision aids for each individual patient according to their profile 
and health literacy. 
 
Conclusion 
The data in these two case studies illustrate the gap between research and practice. 
Research has shown the effectiveness of patient decision aids, including those that are 
designed for use in clinical encounters. However, providing proof of effectiveness is not 
enough to ensure that practice settings will adopt these interventions. The tools have to 
successfully pass the tests of ‘normalization’ - an agreed rationale for using them, 
agreements to work together to make the implementation successful, and agreement that 
the benefits outweigh the burden of change and new processes. These two case studies 
provide some evidence that Option Grid decision aids are meeting some of these 
requirements, although reservations were also expressed. Implementation of new tools and 
practices will require methods to assess whether they can successfully fulfill the 
requirements of ‘normalization’ and to examine, what, if anything, could facilitate a 
normalization process. 
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Appendix 1.  Interview guide. 
 
1) INTERVIEW GUIDE – OTHER STAFF’s PERSPECTIVES 
Using Option Grid in Routine Clinical Settings 
  
A. Experience with Option Grid decision aids to date 
  
We understand that MDs in your clinic have been using Option Grid decision aids for a little while. 
  
1. ESTABLISHED USE: Could you tell me a little more about how Option Grids are used in this clinic? 
  
Probe: First, could you specify your role in the Clinic? 
Probe: Who uses Option Grids? How often? 
Probe: Which Option Grid(s) are they using? 
Probe: How long have they been using it for? 
Probe: Are MDs using the Grids with all clinically eligible patients? How do they choose which patients to 
use it with? 
Probe: How are Option Grids typically used? How are they introduced to patients? By who? 
Probe: Do some MDs refuse to use them? Why? 
Probe: Probe: How does it compare to a consultation without the Option Grid? 
  
2. EARLY USE: Thinking back about when Option Grids were introduced … 
Probe: Can you describe how the use of the Option Grid was initiated? Who had the idea? What was your 
reaction? 
Probe: How were Option Grids introduced to MDs? 
Probe: What were their reactions? What did the MDs think of the Option Grids? 
Probe: Were they prepared to use it? 
Probe: Was training offered? If not, do you think it was needed? 
Probe: How did Option Grids become part of your clinic’s usual practice? 
Probe: What were, if any, the key challenges to routine use? How were they overcome? 
Probe: Did it become easier over time? Why? 
Probe: Has anything changed since using the Option Grid for the first time xx months ago? Are the Option 
Grids being used or introduced to patients differently since initial use? 
  
3. Why are you still using Option Grids now? 
  
Probes: Are there, for you, any clear benefits to using it? Or are you using it for other reasons? Benefits to 
patients? 
Probe: Could you explain what those benefits are? 
  
4. What have you found most difficult or challenging about using Option Grids? 
                      
Probe: How could this be improved? 
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B. Perceived Fit in Clinic Workflow and Routine Care 
5. Do Option Grids fit into the clinic workflow? 
  
Probe: If so, how? 
Probe: Did you have to make changes to the clinic flow in order to use the Option Grids? 
Probe: What factors in your office made it easy to use? Where any other changes needed? 
Probe: If yes, why? 
Probe: Is there any evaluation? 
Probe: Is it part of 'what is done' (normalized)? 
Probe: Is there any plan for endorsing/embedding Option Grids in the clinic? Or do you consider that this 
has already happened? 
Probe: Is there any plan for embedding Option Grids in exiting systems? Could it be accessible via the 
Electronic Health Record? 
Probe: Do you think these tools need to be marketed directly to patients? 
  
6. Why would other clinicians want to use Option Grid routinely? 
 
Probe: Are tools like Option Grids considered helpful or problematic by MDs? 
Probe: Based on your experience so far, can you anticipate barriers to widespread use? 
Probe: Do you think that using Option Grids requires training? How? 
Probe: Would you recommend it to other clinics and colleagues? 
Probe: Could it be used by other members of the medical team? 
  
C. Implementing Shared Decision Making 
  
10. Forgetting about Option Grids for a moment, how else have you promoted shared decision making in 
the clinic? 
  
Probe: Have you used other decision aids? Why? How do these compare to Option Grids? 
Probe: Have you received training in shared decision making? Is there a need for it? 
Probe: What is the best way of engaging patients and families in decision making about all aspects of care? 
Probe: What are the main barriers? 
  
11. Do you have any other comments about the implementation of shared decision making in your clinic? 
  
12. Do you have any other comments about using Option Grids in your clinic? 
 
We would like to thank you very much for your time. 
  
 
 2) INTERVIEW GUIDE – CHIEF MEDICAL OFFICER’S PERSPECTIVE 
Using Option Grids in Routine Clinical Settings 
  
A. Experience with Option Grids to date 
  
We understand that health care professionals in your clinics have been using Option Grids since 2013. 
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1. Could you tell us a little more about how this happened? 
 
Probe: Why did you decide to promote and implement shared decision making? 
Probe: How did you first come across Option Grids? 
Probe: Why did you decide to use Option Grids? 
Probe: Did you consider other alternatives? 
  
2. What do you think about Option Grids? 
 Probe: How about the content? Format? Layout? 
 Probe: What could we change? Improve? 
 Probe: How do you think they are currently being used? 
  
2. EARLY USE: Thinking back about when Option Grids were introduced … 
Probe: Can you describe how the use of the Option Grid was initiated? Who had the idea? 
Probe: How were Option Grids introduced to staff in your Clinics? 
Probe: What were their reactions? 
Probe: Was training offered? 
Probe: Did Option Grids become part of the clinics’ usual practice? If so, how? 
Probe: What were, if any, the key challenges to routine use? How were they overcome? 
  
3. Why are you still using Option Grids now? 
  
Probes: Benefits to health care professionals? Benefits to patients? Time? Cost? Other? 
Probe: Could you explain what those benefits are? 
  
B. Perceived Fit in Clinic Workflow and Routine Care 
  
4. Do Option Grids fit into the clinics’ workflow? 
  
Probe: If so, how? 
Probe: Did you have to make changes to the clinic flow in order to use the Option Grids? 
Probe: Is there any evaluation? 
Probe: Is it part of 'what is done' (normalized)? 
Probe: Is there any plan for endorsing/embedding Option Grids in the clinic? Or do you consider that this 
has already happened? 
Probe: Is there any plan for embedding Option Grids in exiting systems? Could it be accessible via the 
Electronic Health Record? 
Probe: Do you think these tools need to be marketed directly to patients? 
  
5. Why would other clinicians/other health care systems want to use Option Grid routinely? 
                   
Probe: Are tools like Option Grids considered helpful or problematic? 
Probe: Based on your experience so far, can you anticipate barriers to widespread use? 
Probe: Do you think that using Option Grids requires training? How? 
Probe: Would you recommend it to other clinics and colleagues? 
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C. Implementing Shared Decision Making 
  
6. Forgetting about Option Grids for a moment, how else have you promoted shared decision making in the 
clinic? 
  
Probe: Have you used other decision aids? Why? How do these compare to Option Grids? 
Probe: Have you trained staff in shared decision making? Is there a need for it? 
Probe: What is the best way of engaging patients and families in decision making about all aspects of care? 
Probe: What are the main barriers? 
  
11. Do you have any other comments about the implementation of shared decision making in clinic? 
  
12. Do you have any other comments about using Option Grids or other shared decision making 
interventions? 
  
We would like to thank you very much for your time. 
  
 
 
 3) INTERVIEW GUIDE – HEALTH CARE PROFESSIONALS’ PERSPECTIVES 
(for HCP who are using the Option Grids with patients) 
Using Option Grids in Routine Clinical Settings 
  
A. Experience with Option Grids to date 
  
We understand that you have been using Option Grids in your clinic for some time. 
  
1. ESTABLISHED USE: Could you tell me a little more about your experience of using Option Grids so 
far? 
  
Probe: How long have you been using it for? How often do you use it? with all clinically eligible patients? 
If not, why not? How do you decide whether or not to use it with a patient? 
Probe: Which Option Grid(s) are you using? 
Probe: How do you find those Grids? Difficult/easy to use? 
Probe: How do you use them? How do you normally introduce it to patients? Do you give it to them or do 
they typically bring it to the visit? 
Probe: Can you estimate how long it takes to use it? 
Probe: How does it compare to a consultation without the tool? 
Probe: How are your colleagues finding it? 
Probe: Could you estimate how many of your colleagues are using the tool(s) now? 
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2. EARLY USE: Thinking back about when you first started using Option Grids (e.g. first and second 
use)… 
  
Probe: Can you describe how the use of the Option Grid was initiated? Who had the idea? What did you 
think? 
Probe: Why did you first start using it? 
Probe: Did you feel comfortable using the Option Grid? If not, what about it felt awkward? 
Probe: What were your colleagues’ reactions? 
Probe: Did you receive any training/information as to how best to use it with patients? 
Probe: Did it become easier to use over time? 
Probe: Has anything changed since using the Option Grid for the first time xx months ago? Are you using 
the tool differently now, compared to your first attempt? 
Probe: Are patients responding differently compared to early use? 
  
3. Why are you still using Option Grids now? 
  
Probes: Are there, for you, any clear benefits to using it? Or are you using it for other reasons? Benefits to 
patients? 
Probe: Could you explain what those reasons/benefits are? 
  
4. What have you found most difficult or challenging about using Option Grids? 
                      
Probe: How could this be improved? 
Probe: What do you think about its content? 
Probe: Did you have to adapt it to individual patients? How? 
Probe: Was it easy for patients to understand? 
  
B. Perceived Impact on Consultation and on Patients 
  
5. Has it changed the conversation you are having with patients? 
                      
Probe: How? Can you give an example? 
Probe: What has been the impact, if any, on the consultation? 
Probe: Has it lengthened the consultation? Has it made the consultation more focused and efficient? 
Probe: What is the impact on your patients? Do patients behave differently compared to consultations 
without the Option Grid? How? 
Probe: What are the benefits for patients? What are the drawbacks? 
Probe: Are patients generally willing to give their opinion and participate in the decision making process? 
Probe: Do patients typically take it home? 
Probe: How do families/caregivers respond to it? 
  
6. How does using the Option Grid affect the decision making process? 
  
Probe: Does it facilitate or hinder the decision making process? 
Probe: Does it help patients make an informed decision? How? 
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Probe: Are patients ready to make a treatment decision after using the Option Grid? More prepared than 
without the Option Grid? 
Probe: Is the decision generally made in the consultation? 
Probe: Have you noticed any differences in patients’ decision making process compared to consultations 
where the tool wasn’t used? 
  
C. Perceived Fit in Clinic Workflow and Routine Care 
  
7. Do Option Grids fit in the current workflow? 
  
Probe: If so, how? 
Probe: Did you have to make changes to the clinic flow in order to use the Option Grids? 
Probe: What factors in your office made it easy to use? 
Probe: If yes, why? 
Probe: Is there any plan for endorsing/embedding Option Grids in the clinic? Or do you consider that this 
has already happened? 
Probe: Is there any plan for embedding Option Grids in exiting systems? Could it be accessible via the 
Electronic Health Record? 
Probe: Do you think these tools need to be marketed directly to patients? 
  
8. Why would other clinicians want to use Option Grid routinely? 
                   
Probe: Are tools like Option Grids considered helpful or problematic by clinicians? 
Probe: Based on your experience so far, can you anticipate barriers to widespread use? 
Probe: Do you think that using Option Grids requires training? Why? How? 
Probe: Would you recommend it to your colleagues ? 
Probe: Could it be used by other members of the medical team? 
  
D. Implementing Shared Decision Making 
  
9. Forgetting about Option Grids for a second, how else have you promoted shared decision making with 
your patients? 
  
Probe: Have you used other decision aids? Why? How do these compare to Option Grids? 
Probe: Have you received training in shared decision making? Is there a need for it? 
Probe: What is the best way of engaging patients and families in decision making about all aspects of care? 
Probe: What are the main barriers? 
  
10. Do you have any other comments about the implementation of shared decision making in your clinic? 
  
11. Do you have any other comments about using Option Grids, or anything that particularly struck you 
when using it? 
  
We would like to thank you very much for your time. 
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Discussion 
 
Brief synopsis 
Summarizing the studies included in the thesis, encounter patient decision aids increase 
knowledge, satisfaction, and involvement in the decision-making process, and reduce 
decisional conflict without significantly increasing duration of clinical encounters, 
however implementing these tools in practice is challenging regardless of cultural context. 
Independent use of a web-based, interactive version of an encounter tool has the same 
positive impact on patient outcomes – they increase user knowledge, reduce decisional 
conflict, and the risk information embedded in the tool shifts preference to the more risk 
averse treatment or screening option. Despite these positive findings, the web-based patient 
decision aids were designed in a way that was not usable for individuals who are less 
familiar with digital interfaces or have lower health literacy skills.  
 
This thesis was designed to user-test and study the outcomes associated with the 
independent use of the Option Grid online, interactive encounter patient decision aid, 
implement the paper-based version in clinical practice, and synthesize data on encounter 
patient decision aids through a meta-analysis and narrative synthesis. Box 1 lists the six 
research objectives of the thesis: 
 
Box 1. The research objectives. 
 
Objective 1: Determine the effect associated with the use of encounter patient decision aids by 
conducting a meta-analysis of RCTs, and a narrative synthesis of non-randomized studies to determine 
the feasibility, utility and integration into clinical workflow from different stakeholder perspectives. 
Objective 2: Determine if using the interactive Option Grid patient decision aids led to a pre-post shift 
in preferences; which FAQs led to preference shifts; which FAQs that were rated as the most important 
as users compared options.  
Objective 3: Determine the impact of publicly available web-based PSA Option Grid patient decision 
aids on preference shift, knowledge, and decisional conflict; identify which FAQs are associated with 
preference shift; explore the possible relationships between these outcomes.  
Objective 4: User-test the ‘PSA test: yes or no?’ web-based, interactive Option Grid patient decision 
aid to determine its usability, acceptability, and feasibility with men of higher and lower health literacy. 
Objective 5: Examine the use of Option Grid patient decision aids in a sample of clinics in Warsaw, 
Poland, and measure their impact on SDM.  
Objective 6: Use NPT to explore how and why two separate healthcare organizations in the US had 
spontaneously adopted Option Grid patient decision aids in routine clinical practice and investigate the 
factors that have facilitated routine use.  
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Main findings 
 
Chapter 1: Meta-analysis and narrative synthesis of encounter patient decision aid 
research 
 
In our first chapter, we analyzed the impact of encounter patient decision aids in a meta-
analysis and found that they significantly increased patient knowledge, reduced decisional 
conflict and, based on observational data, increase SDM without increasing duration of the 
consultation. In a narrative synthesis of non-randomized studies using encounter patient 
decision aids, we found that these tools have high utility for structuring and facilitating 
conversations according to patients and clinicians. However, their implementation is 
challenging due to time constraints, lack of education on the purpose of decision aids, and 
training on how to use them; and some clinicians were concerned about the content or 
format which may be incompatible with patient populations with lower health literacy. 
Implementation can be feasible if there is a coherent organizational strategy that provides 
resources to help clinicians become familiarized with encounter patient decision aids and 
their potential role in the SDM process.  
 
Chapter 2: The type of information in web-based Option Grid that shifts user preference 
 
Three of the top five most-used web-based, interactive Option Grid patient decision aids 
shifted preference for an unsolicited sample of users. The breast cancer, PSA, and statins 
for heart disease risk web-based Option Grids shifted preference to the more risk averse or 
conservative treatment or screening option. The tools for angina and amniocentesis were 
not associated with preference shift. Based on the logistic regression model, the FAQs that 
provided risk information were associated with preference shift. For example, information 
about the area of tissue that will be removed with lumpectomy and mastectomy treatment 
options, the possibility of radiotherapy, lymph gland removal, and chemotherapy were 
elements within the interactive breast cancer Option Grid associated with preference shift. 
Information regarding what the test involves, the significance of an elevated PSA level, 
and the risks associated with biopsy were information elements associated with preference 
shift for users of the PSA Option Grid. Users of the interactive statins Option Grid saw 
their preferences significantly shift toward increasing levels of physical activity when they 
viewed information regarding the degree to which the treatment option would reduce the 
risk of getting other health problems, and the length of time they would have to abide by 
the treatment regimen. The data also indicated that the risk information was the most 
valued by users.  
188 | Chapter 8 
Chapter 3: Impact of the PSA web-based Option Grid on knowledge, decisional conflict 
and preference 
 
To validate our results from the previous chapter, and to explore if the patient outcomes 
associated with a web-based tool mirror those found when using other types of patient 
decision aids, we conducted a cross-sectional analysis of data collected from the PSA 
Option Grid. Like the previous chapter, the risk information found in the web-based PSA 
Option Grid shifted user preference to ‘not having the PSA test.’ Preference shifts occurred 
because of exposure to the description of the PSA test, the fact that 30% of men with a 
high PSA level have prostate cancer, but that inflammation and infection can also increase 
PSA levels, and the fact that it is not possible to know if a cancer is aggressive with the 
PSA test alone (a high PSA level means that one would need more tests like biopsies, and 
biopsies carry risks all shifted preference). Furthermore, using the web-based PSA Option 
Grid increased user knowledge and reduced decisional conflict.  
 
Chapter 4: Usability, acceptability, and feasibility of the PSA web-based Option Grid 
 
Men with high and low health literacy skills considered the risk information embedded in 
the PSA web-based Option Grid useful and acceptable but were hoping to see more risk 
information associated with age and family history, tailored to individual patients. Users 
appreciated the evidence-based, credible nature of the information and could envision 
using the online Option Grid prior to a clinical consultation. To improve the Option Grid’s 
usability, however, participants recommended adjustments to the layout and organization 
of the tool’s content. Importantly, participants with limited health literacy skills had 
difficulty navigating the Option Grid and felt intimidated with having to use the computer 
to access the tool. Lack of user-centered design may render web-based patient decision 
aids unusable and inaccessible for men with lower educational attainment or health 
literacy. More research is needed to create online tools that are suitable for all men to use. 
 
Chapter 5: The impact of Option Grid patient decision aids on SDM in a sample of clinics 
in Poland 
 
The implementation of Option Grid patient decision aids in three clinics in Warsaw, 
Poland did not lead to a significant increase in SDM based on our pre-post study. Only five 
of the thirteen clinicians, all located at the same clinic, had a significant increase in SDM 
based on the 3-item, patient-reported measure known as CollaboRATE. One clinician 
experienced a significant decrease in their CollaboRATE score following implementation 
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of the Option Grid tools. A survey determined that clinicians had a mixed attitude toward 
the implementation of Option Grid. Clinicians with more experience were particularly 
concerned about time constraints in workflow, disagreement with the content of the tools, 
and lack of training on how to use them in practice.  
 
Chapter 6: Lessons from the implementation of Option Grid patient decision aids at two 
different healthcare settings 
 
Using the NPT framework, we analyzed transcripts of interviews from health professionals 
from two healthcare organizations (HealthPartners and CapitalCare) that implemented 
Option Grid patient decision aids. We found that these tools can be routinely integrated 
into clinic workflow patterns if there is agreement about the need to use them (coherence). 
Second, that the team members are willing to work together to make sure that such tools 
can be integrated in existing work patterns (collective action). Third, if they are understood 
as making a positive overall contribution to the work that has to be performed (cognitive 
participation). Implementation efforts were motivated by a ‘champion’ clinician at 
HealthPartners who was a part of the editorial team for tools implemented at this site: the 
Dupuytren’s, Carpal Tunnel, and Trigger Finger Option Grid decision aids. By contrast, 
the CapitalCare organization promoted SDM using financial incentives to try and 
implement Option Grid decision aids in practice. These tools represented a means to an end 
for clinicians to receive financial compensation which led to a few sites failing to 
implement these tools in routine practice.  
 
Strengths and limitations 
Generally, the diversity of our methods to achieve our research objectives is a major 
strength. We used quantitative and qualitative research methods to achieve our objectives. 
Qualitative work included framework analyses (Chapter 5 and 7), and a narrative synthesis 
of non-randomized studies (Chapter 1). We used multinomial and hierarchical linear 
regression models as part of our quantitative data analysis which also included t-tests, 
McNemar and ANOVA tests (Chapter 3,4,6). The limitations of this thesis are 
concentrated mainly on the makeup of the sample in each chapter, the setting, the design of 
each study and the context of the research. The following paragraphs identify the 
overarching methodological strengths and limitations of the thesis: 
 
Study participants 
We used a diverse sample to user-test and to determine the outcomes associated with the 
use of web-based Option Grid patient decision aids. In the case of user-testing, we 
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recruited an equal number of men who were considered to have high and low health 
literacy skills to receive feedback on the online tool from different perspectives. 
Furthermore, we collected data from an unsolicited sample of users to analyze the tools’ 
content on preference, knowledge and decisional conflict. The spontaneous use eliminates 
the possibility for selection bias or other potential biases associated with active 
recruitment, thereby increasing the quality of the data. Despite these strengths, the 
characteristics of our sample in some studies may be considered a weakness. 
 
We did not interview patients in the two implementation studies we conducted. Particularly 
in Poland, where decision aids had never been implemented prior to our study, 
interviewing patients would have enriched our CollaboRATE data and helped us better 
understand how patient decision aids can potentially improve healthcare delivery. 
Similarly, we did not interview patients at CapitalCare or HealthPartners. Logistical 
barriers and time constraints made interviews impossible to include in our study designs. 
Therefore, the absence of patient participants in our implementation studies is a limitation. 
Lastly, we studied only one type of encounter patient decision aid. 
 
Setting 
We consider the setting of our two implementation studies to be a strength. Our case study 
was conducted at two different healthcare organizations aiming to promote SDM in the US 
– a country that has incorporated SDM as part of its healthcare legislation. Recognized at 
the policy level, there are examples of healthcare organizations across the country aiming 
to promote SDM by using patient decision aids to facilitate its practice. At the minimum, 
there is more familiarity with the concept of SDM than there is in a country like Poland – 
the site of our second implementation study. There are no policy initiatives to promote 
SDM in Eastern Europe, and we were the first to implement patient decision aids in a 
sample of clinics in Poland. However, we found an organization that was willing and able 
to implement patient decision aids, so the issue of clinician willingness and attitude needs 
further investigation. We were able to collect data in two very different cultural and 
clinical settings, which strengthens our findings regarding the impact these tools have on 
encounters (Chapter 6 and 7), and the barriers and facilitators to their routine adoption. 
Lastly, the fact that users of the online, interactive Option Grids were not in a study setting 
may be a limitation because we do not know if any other variables played a role in their 
preference selections while using the tool. 
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Study Design 
We used a variety of study designs, each with strengths and weaknesses, to achieve our 
research objectives:  
 
First, qualitative research provides nuanced insight into ideas and perceptions of the 
various actors in the clinical setting. We used two different qualitative analysis methods: 
thematic and framework. Thematic analysis enables the identification of themes 
independent of any framework, which provides flexibility in the analysis. By contrast, 
framework analysis helped us organize data and investigate various elements of the 
participant experience. For example, NPT helps investigate and assess the mechanisms by 
which interventions become integrated into normal workflows [1-3]. It proposes that 
“complex interventions become routinely embedded (implemented and integrated) in their 
organizational and professional contexts as the result of people working, individually and 
collectively, to implement them” [1-3]. A recent qualitative systematic review concluded 
that NPT “can effectively assist in the explanation of the success or failure of specific 
implementation projects” [1-5]. This theory has also been used in previous implementation 
studies of patient decision aids [6] making it an ideal theory to analyze our prospective 
data.  
 
Pre-post and case study designs were used in this thesis to explore implementation of 
patient decision aids. As mentioned in chapter 7, case study designs enabled us to study 
healthcare organizations in-depth and put focus on each specific situation [7]. 
Generalizability, however, is impacted by this design. The strength of a pre-post study is 
temporality (we can suggest that the outcome was impacted due to the Option Grid 
intervention) and this design provides insight using a real-world setting [8]. However, 
participants are not randomized and there is an absence of a control group, which could 
lead to potential confounders or selection, performance, or detection biases [8]. 
 
Lastly, the combination of systematic review, meta-analysis, and narrative synthesis of 
non-randomized data is the most comprehensive overview of encounter patient decision 
aids. It summarizes all available information, regardless of study design, in one review - a 
significant strength in the thesis.  
 
Context 
Option Grid patient decision aids are designed for and implemented in the clinical 
encounter. However, preferences and decision-making may be influenced by events or 
information that is received outside of the clinical encounter. This is a limitation, but at the 
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same time, in other studies, we capture information that people value through analysis of 
spontaneous use of the web-based Option Grid – a platform that was likely used outside 
the encounter. Overall, a strength of this thesis is its demonstration of the impact of Option 
Grid patient decision aids in the encounter, and outside the clinical experience. 
 
Results in context  
The results of our meta-analysis of RCTs of encounter patient decision aids (chapter one) 
align with the most recent Cochrane systematic review of pre-encounter tools - they 
increase patient knowledge and reduce decisional conflict [9]. However, we provide unique 
observational evidence that encounter tools increase SDM without significantly increasing 
the duration of encounters. This finding raises two key issues – the type of measure used to 
assess SDM, and the perception that encounter patient decision aids significantly increase 
the duration of encounters. Regarding the first issue, the measure used to assess SDM, 
whether observational or patient-reported, remains a contentious issue. Evidence indicates 
that patient perceptions correlate weakly with observed patient involvement [10]. 
Generally, patients do not know what ‘good’ SDM looks like, so they do not have the 
ability to contrast the conversation they had with their clinician to an ideal clinical 
exchange [10]. Using observational data eliminates the potential bias that comes with self-
report and strengthens the finding that the use of encounter tools increases SDM. A recent 
systematic review by Legare et al, however, indicates that there remains uncertainty as to 
whether interventions targeting patients increases SDM (regardless of the outcome 
measure used) [11]. More research is required in order to consolidate our finding that the 
use of encounter tools increases SDM. As for the issue of time, our findings dispel a myth 
that encounter tools are not feasible to implement in clinics where visits typically last 
approximately 15 minutes [12]. ‘Time constraints’ is identified across non-randomized 
studies in our narrative synthesis as a prominent barrier to routine adoption. We provide 
evidence, that the use of patient decision aids in the encounter does not significantly 
increase encounter time which has important implications for organizations considering 
implementing encounter tools to promote SDM. Nevertheless, if implementation of 
encounter tools provokes trepidation on the part of clinicians, then we provide evidence 
that access to online, interactive decision aids is associated with similar outcomes. 
 
Unsolicited use of the online, interactive Option Grid patient decision aids shifts user 
preferences to the more risk-averse treatment or screening option. Individuals accessed the 
Option Grid website independent of an invitation, so we can ascertain that, based on our 
findings, that the risk information embedded in these tools represent the active ingredients 
responsible for the preference shifts. In the case of the PSA test, users shifted their 
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preference to ‘not having the PSA test,’ and the Option Grid significantly increased user 
knowledge of the test and reduced decisional conflict. The fact that decision aids in the 
online environment increase knowledge and reduce decisional conflict is not new. As 
mentioned in the chapter three introduction, a systematic review of randomized trials of 
decision aids for decision making in prostate cancer testing found that, regardless of mode 
of delivery, these tools increase knowledge and lower decisional conflict [13]. Other 
randomized trials using web-based PSA screening tools as the intervention replicated the 
result found in the systematic review – online PSA tools increase patient knowledge and 
reduce decisional conflict regardless of patient ethnicity [14-22]. Owens et al. recently 
developed a computer-based decision aid called iDecide which significantly improved 
prostate cancer knowledge and ‘enhanced the capacity for informed prostate cancer 
screening decisions’ for African-American men – a patient population that is more likely to 
develop aggressive prostate cancer [23]. Our findings replicate previous conclusions 
regarding patient outcomes such as knowledge and decisional conflict, but the type of 
information that is valued and that precipitates the preference shift is novel.  
 
We concluded in chapters 3 and 4 that the risk information associated with the PSA test, 
and prostate biopsies embedded in the online, interactive PSA Option Grid shifts 
preference to ‘not having the test.’ Patient decision aids for prostate cancer screening 
typically lead to a reduced intention to undergo screening. For example, Evans et al. in an 
online RCT showed that the Prosdex intervention decreased intention to undergo prostate 
cancer screening compared to the control arm that did not receive the decision aid [24]. 
Two of the five studies investigating men’s values and preferences in a systematic review 
by Vernooij et al. suggested that men were willing to “forego screening if it would 
decrease the likelihood of unnecessary treatment or biopsies” [25]. A recent randomized 
survey study compared exposure to prostate cancer screening decision aids from the United 
States Preventive Services Task Force (USPSTF), Centers for Disease Control (CDC), and 
American Academy of Family Physicians (AAFP) and found that their use “decreased the 
participant likelihood of undergoing or recommending prostate cancer screening” [26]. So, 
a large body of evidence demonstrates that patient decision aid use shifts preference to the 
more conservative option, but we did not know the active ingredients or type of 
information that is valued or causes this shift. Our findings in chapter two and three fill this 
gap in the literature. 
 
Furthermore, we know that the use of web-based patient decision aids, including Option 
Grid, improve patient outcomes such as knowledge, mitigate decision anxiety, and shift 
preference; but there is also evidence that patients genuinely appreciate these tools. 
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Feldman-Stewart et al. evaluated a web-based patient decision aid for early-stage prostate 
cancer treatments and concluded that the internet “was an effective medium” to support 
patients in their decision-making process [27]. This sentiment is shared by users of tools 
regardless of the screening test or health condition being discussed. Users typically like the 
content of patient decision aids; but, older users especially, suggest improving the ease of 
navigation and the layout [28-30]. This was the case in our study, and even more so for 
users with low health literacy skills – a population often omitted from samples who test 
online patient decision aids [31]. In addition, users across our sample (see chapter four for 
details) wanted personalized risk information. Evidence suggests that providing 
individualized risk information to men on ‘active surveillance’ helps them better 
understand their risk of getting cancer [32]. Future research should focus on making web-
based interventions accessible and usable by all audiences and tailoring interventions to 
individual needs.   
 
According to the most recent national health interview survey, “nearly 90% of PSA 
screenings for men over the age of 70 were suggested by physicians” – which does not 
comply with the USPSTF recommendations [33]. A cross-sectional study by Woods-
Burnham et al. found that there needs to be significant improvements made regarding how 
clinicians communicate the risk of prostate cancer screening, particularly with African-
American men [34]. The study found that “younger age, higher income and education” 
individuals who had a conversation with their clinician about the PSA test had more 
knowledge than other patient populations [34]. Furthermore, survey research finds that the 
majority of primary care providers in the US do not use patient decision aids but are open 
to learning how to operationalize these tools in practice [35]. These findings are part of a 
pattern regardless of healthcare topic – there is a need to improve healthcare 
communication and delivery. Chapters one to four show how encounter-based and web-
based patient decision aids can facilitate SDM and improve patient outcomes. The final 
two chapters focus on implementing these tools in clinical practice, an endeavor that 
remains challenging. 
 
Patient decision aid implementation requires support from various levels within an 
organization, as highlighted in the two final studies of this thesis. As described by Scholl et 
al. systems use different strategies to promote the implementation of decision aids to 
promote SDM [36]. As was the case within the CapitalCare organization in chapter six, 
some systems implement a payment model where clinicians receive financial 
compensation for using patient decision aids and documenting it in the electronic medical 
record. Other systems have tried to promote SDM as a way to improve quality of care by 
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crafting organizational guidelines. Ultimately, there’s a top-down effort by a system to 
guide the organization in the SDM direction. However, the lessons from the 
implementation studies indicate that guidelines or changing the payment model may not be 
enough to ensure the implementation of patient decision aids.  
 
At the organizational level, leadership is a key component for successful implementation of 
any intervention. The clinical ‘champion’ at HealthPartners led by example and 
encouraged her fellow colleagues to use patient decision aids. A grassroots effort led by a 
leader to carry out the system-level SDM mandate has also been supported in other 
writings assessing the mechanisms of decision aid implementation [37-39]. In a system 
that contains increasing time pressures, setting the implementation of an intervention as a 
priority by clearly defining how and why it is being implemented can help foster a sense of 
purpose. Unfortunately, the majority of medical schools do not include SDM training in 
their curriculum, so many clinicians falsely perceive that they are doing textbook SDM 
when in fact the opposite is true [40]. For this reason, organizational investment in 
education on the how and why is necessary for clinicians. Having leadership and education 
for a team guided by an organization that sets SDM as a priority is an important step in 
shifting the culture of the clinic to one that is conducive to implementing patient decision 
aids. Results from chapter five show that if a positive culture welcoming of patient 
decision aid implementation exists, practice can change.  
 
Moreover, collective action at the grassroots in order to work out the ‘when, who, how’ is a 
key component of May’s NPT, and in this case, for patient decision aid implementation 
[41]. Identifying roles within the clinic workflow and conducting a critical appraisal of 
details for executing implementation requires communication between the clinical actors. 
The communication and coordination of care are important organizational characteristics 
that can ease the tension that accompanies the integration of a new intervention. For 
instance, the nurses at HealthPartners were fundamental in identifying patients who could 
receive one of the available decision aids and providing them with the tool prior to their 
conversation with the clinician. Recent evidence suggests that integrating patient decision 
aids in the electronic medical record can support providers who wish to practice SDM [42]. 
 
A recent report published by Coulter et al. which summarized the barriers to patient 
decision aid implementation mentioned the importance of culture from both the clinician 
and patient perspective [43]. In chapter six we understood based on the project manager 
survey, that older clinicians did not view the implementation of Option Grid favorably. 
This is the case for many clinicians across locations. A recent exploratory investigation 
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with SDM experts in the Netherlands indicated that many Dutch clinicians also have a 
negative attitude toward adopting decision aids routinely and lack the knowledge and 
ability to apply SDM in their practice [44]. Based on the narrative synthesis of chapter one, 
one of the reasons for this negative attitude toward patient decision aids is the 
disagreement with the content of these tools and the fact that many believe they are not 
suitable for patients with lower health literacy skills. A strategy to combat these sentiments 
is to encourage clinicians to modify existing or create their new tools to provide intrinsic 
motivation to implement them. The clinical ‘champion’ at HealthPartners took on that role 
in part because she was involved in editing three Option Grid decision aids. A recent 
quantitative analysis by Cuypers et al. assessed uptake and usage of a web-based prostate 
cancer treatment decision aid by oncologists or nurses at the time of the consultation in 
nine Dutch hospitals [45]. Findings indicate that 35% of eligible patients received the web-
based encounter decision aid; however, that number rose to over 80% at sites who had 
professionals involved in the development of the tool [45]. 
 
Finally, it is important to consider the clinical culture from the perspective of clinicians 
and patients. In an Eastern European country such as Poland, patients may not be expected 
to take on a more prominent role in the clinical encounter. As Fisher et al. explained, 
“cultural factors may influence patient preferences” [46]. Redefining the patient role and 
expectations by helping them understand SDM can help spur clinicians to change the way 
they practice. Patients are essential organizational stakeholders and need to work in tandem 
with their clinician to set goals and priorities of care. After all, that is the essence of SDM. 
 
Implications and recommendations 
Researchers, clinicians, and policy-makers have identified SDM as a viable solution to 
promoting a patient-centered model of healthcare. As the paradigm continues to shift to 
SDM in clinical practice, patient decision aids can play a critical role in facilitating its 
practice. The following paragraphs will discuss implications and recommendations for 
future direction in four key areas: health policy, education, clinical practice and research.  
 
Health policy 
Patient-centered care has been at the heart of recent healthcare policy in various countries, 
particularly in the West [47]. A recent editorial described policy efforts in 22 countries 
regarding SDM, with concrete measures being taken in the US, Canada, United Kingdom, 
the Netherlands, Germany, and Australia [47]. Funding for SDM research has generally 
been positive in these countries, and research teams are devoted to developing patient 
decision aids and implementing them in clinical practice (with limited success) [47]. For 
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instance, in the US, the Affordable Care Act passed in 2010 includes the promotion of 
SDM; in Canada the province of Saskatchewan supports work in this area, and in 
Australia, ‘SDM is established within national clinical standards’ [47]. Unfortunately, we 
have yet to see a sustained implementation of patient decision aids in any clinical setting. 
In other areas of the globe like South America, Asia, and Africa, SDM is largely 
recognized but not advocated as an essential approach [47].  
 
In the Netherlands there is strong support from all stakeholders [47]. The Dutch Ministry 
of Health is committed to promoting SDM mainly for ethical purposes, and the most recent 
Dutch Act of Agreement on Medical Treatment requires health professionals to discuss the 
pros and cons of treatment or screening options with their patients [43]. Strong support 
also emanates from Dutch patients – the Dutch Federation of Patients’ Organizations is 
calling for more SDM in clinical practice [43]. Despite these political efforts from 
stakeholders, more work needs to be done to implement SDM training in medical 
education [43]. As mentioned in the discussion of chapter six, future research should assess 
the degree to which use of encounter patient decision aids cut costs. Cost-savings could 
lead to a more rigorous push for the implementation of tools in clinical practice.  
 
Education 
Researchers understand the effects of these tools on outcomes and patient practice, but 
clinicians have yet to catch up. A key barrier to implementing patient decision aids is the 
lack of training or education on how to operationalize these tools. Clinicians are seldom 
taught in their medical education about SDM and the potential value of using patient 
decision aids [40]. The final chapter in this thesis provides the evidence that encounter 
tools help practice SDM and improve patient outcomes. Medical education needs to 
expand to include the theoretical and practical nature of SDM, so clinicians can be familiar 
with the process early in their careers. We also recommend educating patients on their 
‘new’ role in the decision-making process. Decades of paternalistic medicine has subjected 
patients to a back-seat role. For expectations and behavior to change on the patient’s 
behalf, they need to be empowered through education to be more active in their exchange 
with their provider.  
 
Clinical practice 
In terms of clinical practice, our research has implications in the area of implementation of 
encounter patient decision aids. First, the literature indicates that time constraints are the 
primary barrier to routine adoption of decision aids (regardless of type) from the clinician 
perspective [48,49]. Qualitative studies in our narrative synthesis recognize that clinicians 
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believe the introduction of patient decision aids in their practice would increase wait-times. 
Our meta-analysis, however, disproves that theory. Encounter patient decision aids do not 
significantly increase the duration of consultations, and they do increase patient 
participation in the decision-making process.  
 
We recognize that there are many factors (organizational, clinical, cultural) that can 
influence the implementation of patient decision aids. It is important to note that patients 
also need to be prepared for a new role in the clinical encounter and to be more active in 
the decision-making process. This new role goes against traditional norms and one must 
consider the patient’s “knowledge, emotional state, and the power balance with their 
clinician” [46]. Ultimately, patients need to be primed to engage in discussions with their 
clinician [46]. Encounter patient decision aids could be the solution considering our study 
findings, but more research is needed to help clinicians find optimal solutions to engage 
patients in their healthcare. Further research is also needed to better understand how to 
create tools that are usable and accessible to patient with low health literacy skills.  
 
Research 
Many research questions remain in the area of patient decision aids and their 
implementation in practice. How do these tools impact healthcare decisions? Users of our 
web-based decision aid identified their preference leaning, but their final treatment or 
screening decision may have been different. Hence, we do not know the decision these 
users made in the real world. Does their use lead to cost-savings? A systematic review by 
Walsh et al. concluded that “there is insufficient evidence, as yet, to be confident that the 
implementation of patient decision support interventions leads to system-wide savings” 
[50]. More research is needed to understand if these tools lead to reduction in costs. What 
type of health system is conducive to their implementation? A paucity of implementation 
studies has been conducted with encounter patient decision aids. Research has identified 
important barriers, but we have little understanding of how to overcome these barriers or 
how to build a system that is suitable for implementation of encounter tools. It is known 
that individuals’ independent use of these tools lead to preference shifts, which suggests 
that implementation could be facilitated by making them searchable and available online to 
patients. How do these tools impact clinical outcomes? Randomized trials have shown that 
the use of encounter tools, generally, does not influence clinical outcomes. For example, 
the use of depression tools has not shown to significantly decrease depressive symptoms 
for patients. However, more data is needed for different health conditions for researchers to 
establish the extent to which the use of these tools impacts clinical outcomes. 
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Conclusion 
Our thesis contributes to a better understanding of the effects of patient decision aids in the 
online arena and within the clinical encounter. It also provides an in-depth look at the 
implementation of these tools across clinical and cultural settings. Overall, we conclude the 
following: 
 
1. As exemplified by Option Grid, web-based patient decision aids are valuable to 
individuals seeking evidence-based information; however, these tools need to be tailored 
to individual needs and designed to be usable by all.  
2. The risk information embedded in web-based Option Grid decision aids is not only 
highly valued but is associated with shifts in user preference. For example, users of the 
breast cancer treatment, PSA screening test, and statins for heart disease risk Option 
Grids all shifted their preference to the more risk-averse option. 
3. The web-based Option Grid decision aids, as exemplified by the PSA test tool, shift 
preference away from screening, increase knowledge, and reduce decisional conflict. 
4. Routine implementation is contingent on context. Using these tools as a means to an end 
to receive financial compensation from the healthcare organization without receiving the 
proper training on how to operationalize the tools prevents implementation success. 
Intrinsic motivation or an effort led at the grassroots level, with the cooperation of all 
actors in the clinical setting may be a better strategy. Overall, there needs to be 
agreement on the need to use encounter tools and a cooperative strategy to implement 
them in practice. 
5. Implementation of Option Grid encounter patient decision aids in a sample of clinics in 
Warsaw, Poland, did not have an impact on SDM for most clinicians. We can infer that 
the cultural expectations of clinicians and the role of the patient in the clinical exchange 
led to a level of resistance to routine use. Some clinicians had a negative attitude 
towards implementation and did not agree with the content embedded in Option Grid.  
6. Encounter patient decision aids increase patient knowledge, satisfaction, involvement in 
the decision-making process, a reduction in decisional conflict, and did not significantly 
increase duration of the consultation. A narrative synthesis of non-randomized studies 
indicates that patients and clinicians find these tools useful for information provision 
and structuring the clinical conversation. Acceptability is impacted by the belief that 
these tools will significantly prolong consultations, the lack of training on how to 
operationalize the tools in practice, and disagreement with the content of these tools. A 
coherent organizational strategy is needed for successful implementation of encounter 
tools to occur. 
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Summary 
 
The aim of this thesis was to determine: (i) the effects of encounter patient decision aids on 
patient outcomes; (ii) the impact of online, interactive patient decision aids on an 
unsolicited sample of users who spontaneously searched for, and used these tools; (iii) the 
usability, acceptability, and feasibility of an online, interactive patient decision aid; (iv) the 
barriers and facilitators to implementing encounter patient decision aids across a range of 
real-world clinical contexts. 
 
Chapter 1: General introduction 
Shared decision making is a clinical approach that promotes bilateral communication 
between patient and clinician, so that the patient can be informed of the risks and benefits 
associated with the treatment or screening options to enable a decision that aligns with 
their preference. It is widely considered the pinnacle of ethical, patient-centered care. Over 
the past few decades, interventions known as patient decision aids have been developed in 
various formats and modes of delivery to help facilitate the shared decision making 
process. Patient decision aids present evidence-based information on the treatment or 
screening options to empower patients to make decisions that align with their goals and 
preferences. Traditionally, patient decision aids have been delivered to patients outside the 
clinical encounter (pre- or post-encounter tools) and these tools have shown to increase 
knowledge, satisfaction, accuracy of risk perceptions, and reduce decisional conflict. These 
pre- or post-encounter tools, however, are long and complex. As an alternative to these 
traditional tools, shorter patient decision aids, such as the Option Grid encounter patient 
decision aids, have been developed to be used during the clinical encounter or online. It is 
still unclear if the positive outcomes associated with the use of traditional patient decision 
aids are replicated with encounter tools. We also know little about the effects online patient 
decision aids have on persons who choose to use these tools spontaneously while searching 
for information about their condition on the internet. Lastly, further investigation is needed 
to better understand the barriers and facilitators to implementing encounter patient decision 
aids across a range of real-world contexts. 
 
Chapter 2 
A meta-analysis of 23 encounter patient decision aids indicates that these tools reduce 
decisional conflict scores and increase knowledge, satisfaction, and shared decision 
making based on observational-based assessments without significantly increasing the 
duration of consultations. The results of a narrative synthesis of 30 non-randomized studies 
assessing encounter patient decision aids show that from the patient’s perspective, these 
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tools improve knowledge and awareness of treatment options thereby facilitating better 
communication with their clinician. Clinicians generally felt that encounter patient decision 
aids have high utility for structuring and facilitating conversations in a manner that is 
consistent with the tenets of shared decision making. However, their implementation is 
challenging for three primary reasons: perceived time constraints, lack of training on how 
to these tools in practice, and disagreement on the content or format that may be 
incompatible with patient populations with lower health literacy. Implementation of 
encounter patient decision aids can be feasible provided clinicians agree to their use to 
improve healthcare delivery, the clinical team agrees on the mechanisms to disseminate the 
tools to patients, and there is a critical appraisal process to identify and address barriers as 
a group. Overall, despite the barriers to their implementation, encounter patient decision 
aids are considered useful by patients and clinicians for structuring clinical conversations, 
they increase shared decision making, patient knowledge and satisfaction, and reduce 
decisional conflict scores. 
 
Chapter 3  
A cross-sectional analysis of 626 online, interactive Option Grid users was conducted to 
determine if treatment or screening preferences shifted as users were presented with new 
information. After viewing the risk information embedded in the tools their preference 
shifted to the more risk averse treatment or screening option. Analysis of the five most-
used interactive tools – (i) amniocentesis test: yes or no?; ii) angina: treatment options; iii) 
breast cancer: surgical options; iv) Prostate Specific Antigen (PSA) test: yes or no?; v) 
statins for heart disease risk: yes or no? – indicated that the latter 3 tools significantly 
shifted user preference to the more conservative treatment or screening option. The tools 
for angina and amniocentesis were not associated with preference shift. Answers to FAQs 
that contained risk information shifted preference. For example, information about the area 
of tissue that will be removed with lumpectomy and mastectomy treatment options, the 
likelihood of radiotherapy or lymph gland removal, and the need for chemotherapy were 
active ingredients within the interactive breast cancer Option Grid associated with 
preference shift. Information regarding what the PSA test involves, the significance of an 
elevated PSA level, and the risks associated with a prostate biopsy were information 
elements associated with preference shift for users of the PSA Option Grid. Users of the 
interactive statins Option Grid saw their preferences significantly shift toward increasing 
levels of physical activity when they viewed information regarding the degree to which the 
treatment option would reduce the risk of getting other health problems, and the length of 
time they would have to abide by the treatment regimen. Not only did risk information 
shift treatment or screening preference, but it was also rated as the most valued information 
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across each Option Grid. In summary, the risk information embedded in the online, 
interactive Option Grid patient decision aids significantly shifted preference to the more 
risk averse treatment or screening option for three of the five most-used tools.  
 
Chapter 4 
To determine the evidence-based information that shifts user preference, as demonstrated 
in Chapter 3, we analyzed data from a sample of 164 users of the online, interactive 
prostate-specific antigen (PSA) test Option Grid. We also analyzed whether or not the 
information embedded in the tool affected knowledge and decisional conflict regarding the 
screening test. The online, interactive PSA test Option Grid significantly shifted user 
preference to the risk averse screening option (i.e. not having the test), increased 
knowledge about the test, and reduced decisional conflict. Three of the ten most frequently 
asked questions about the PSA test embedded in the tool were associated with this 
preference shift: (i) the PSA test is a blood test that measures the antigen level from the 
prostate gland; (ii) the fact that 30% of men with a high PSA level have prostate cancer, 
but that inflammation and infection can also increase PSA levels; and (iii) the fact that it is 
not possible to know if a cancer is aggressive with the PSA test alone (a high PSA level 
means that one would need more tests like biopsies, and biopsies carry risks all shifted 
preference). The interactive PSA Option Grid also significantly increased user knowledge 
of the screening test and reduced decisional conflict. In conclusion, the online, interactive 
PSA Option Grid, increased user knowledge and reduced decisional conflict, and the risk 
information shifted preference to not having the test.  
 
Chapter 5 
Twenty men volunteered to user-test the online, interactive prostate-specific antigen (PSA) 
Option Grid. The men were asked to ‘think-aloud’ as they proceeded through the PSA 
Option Grid and were then asked a series of questions based on the Morville Framework 
(questions on the usability (including design and navigation); usefulness (including 
questions on content); desirability (positive or negative features); value; and credibility of 
information). The men indicated that the tool was useful despite the challenges those with 
limited health literacy skills faced engaging with the tool, the information acceptable with 
an emphasis to add more risk information associated with age and family history, and 
potentially feasible to implement prior to a clinical consultation. A total of eight men had 
low health literacy skills which affected their ability to navigate the tool. They felt 
intimidated with having to use a laptop independent of any help and preferred the use of a 
paper-based decision aid instead. Navigating digital interfaces was not an issue for the 
twelve other men who user-tested the Option Grid. Regardless of health literacy levels, 
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users stated their desire for changes related to the layout (i.e. moving the icon array) and 
organization of the information for each frequently asked question of the interactive tool. 
The risk information provided by the Option Grid was found to be highly valuable with 
most hoping to see content tailored to their specific attributes like age and family history in 
a future version of the tool. The PSA Option Grid also represented a credible source of 
information, and users envisioned using this tool prior to the clinical encounter to facilitate 
an improved discussion with their physician. Ultimately, the interactive PSA Option Grid 
was only usable for those with higher levels of health literacy which emphasizes the 
importance of user-centered design when developing online patient decision aids in order 
to make them usable and accessible for men with lower educational attainment or health 
literacy. 
 
Chapter 6 
The implementation of Option Grid patient decision aids was explored in a pre-post study 
at three clinics in Warsaw, Poland with thirteen clinicians. Of the thirteen clinicians who 
used a trio of Option Grid patient decision aids in the intervention phase, only five received 
a significant increase in their collaboRATE scores - a validated, three-item patient-reported 
measure to assess how well clinicians do shared decision making – compared to the 
baseline phase where no patient decision aids were used. The five clinicians that received 
the significant increase were all located at the same clinic in Warsaw (three had a minimal 
clinically important difference), one clinician had a statistically significant decrease in their 
collaboRATE scores, and eight clinicians did not have a statistically significant difference 
when comparing the two phases of the study. An interview with the project manager 
indicated that older, experienced clinicians were concerned about time constraints in 
workflow, and disagreed with some of the content embedded in the tool. Lack of training 
on how to use Option Grid decision aids in practice was also cited as a barrier. As far as 
can be determined, this was the first time that patient decision aids were implemented in a 
sample of clinics in an Eastern European country like Poland, and we can infer based on 
our results that the role of patient and clinician expectations and culture on the effects of 
decision aid implementation warrant further investigation.  
 
Chapter 7 
Two American health organizations (CapitalCare and HealthPartners) implemented Option 
Grid patient decision aids independent of any study context. We assessed their 
implementation process by interviewing 23 health professionals at various levels of both 
organizations. The analysis was based on the Normalization Process Theory (NPT), which 
helps assess implementation of interventions in workflow. The study showed that routine 
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Option Grid patient decision aid adoption was influenced by the motivation to use them in 
practice, the level of education on shared decision making and how to operationalize the 
tools, and the actions taken by various members of the clinical team. In terms of the 
coherence mechanism of NPT, the implementation of Option Grid at CapitalCare was 
externally motivated – the organization wanted to benefit from financial incentives offered 
by a new initiative. Using the Option Grid was a means to an end (a workable solution) to 
receive financial compensation at CapitalCare, whereas at HealthPartners there was a 
‘champion’ clinician who motivated colleagues to use these tools in practice. The 
collective action taken by nurses at both sites to provide the tools to patients prior to the 
clinical discussion alleviated the burden for clinicians who did not have to identify patient 
eligibility or the appropriate tool to use in practice. Clinicians at both sites eventually saw 
the utility of these tools despite the lack of awareness or understanding of shared decision 
making. The critical appraisal indicated that some clinicians appreciated the improved 
communication with the patient when the tool was present in the encounter. Routine 
adoption of encounter patient decision aids is possible provided there is agreement about 
the need to use them, that the team members are willing to work together to make sure that 
such tools can be integrated in existing work patterns and understood as making a positive 
overall contribution to the work that has to be performed.  
 
Chapter 8: General discussion 
The studies presented in this thesis indicate that encounter patient decision aids increase 
knowledge, satisfaction, patient involvement (based on observational-based assessment), 
reduce decisional conflict, and their use does not significantly prolong the duration of 
clinical encounters. The spontaneous and independent use of online patient decision aids 
shift preference to more conservative treatment or screening options, and also increase 
knowledge and reduce decisional conflict. Users with high and low health literacy skills 
considered the evidence-based risk information embedded in the encounter patient decision 
aid helpful regardless of the usability issues for those with lower health literacy. Patients 
and clinicians find the use of encounter tools helpful in structuring the conversation and 
raising awareness of the treatment options. Despite the positive patient outcomes 
associated with using encounter patient decision aids (online or paper-based), their 
implementation faces significant barriers across real-world clinical contexts. Our research 
found that, from the clinician’s perspective, time constraints, disagreement with the content 
of the tools, and lack of training on how to use them in practice are key barriers to 
implementation. It is recommended that organizations promote shared decision making at 
the policy level and collaborate with clinical stakeholders to develop strategies to 
implement tools in clinic workflow. This includes providing healthcare professionals with 
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education on the purpose of shared decision making and how patient decision aids facilitate 
its practice.  
 
Samenvatting
Het doel van dit proefschrift was om het volgende te bepalen: (i) de effecten van 
keuzehulpen voor patiënten, ingezet in de spreekkamer, op patiëntgerelateerde uitkomsten; 
(ii) de impact van online, interactieve keuzehulpen voor patiënten onder een steekproef van 
gebruikers die deze keuzehulpen zochten en gebruikten; (iii) de bruikbaarheid, acceptatie 
en haalbaarheid van een online, interactieve keuzehulp voor patiënten; (iv) de 
belemmerende en bevorderende factoren voor het implementeren van keuzehulpen voor 
patiënten, ingezet in de spreekkamer, in meerdere reguliere zorg settings. 
Hoofdstuk 1: Algemene introductie 
Gedeelde besluitvorming is een klinische benadering die de bilaterale communicatie tussen 
patiënt en arts bevordert, zodat de patiënt kan worden geïnformeerd over de risico's en 
voordelen van de behandeling of screeningopties, om een beslissing mogelijk te maken die 
in overeenstemming is met hun voorkeur. Het wordt algemeen beschouwd als het toppunt 
van ethische, patiëntgerichte zorg. In de afgelopen decennia zijn interventies die bekend 
staan als keuzehulpen voor patiënten ontwikkeld in verschillende vormen en manieren van 
aanbieden, om het gedeelde besluitvormingsproces te vergemakkelijken. Keuzehulpen 
voor patiënten presenteren evidence-based informatie over de behandeling of 
screeningopties om patiënten in staat te stellen beslissingen te nemen die overeenkomen 
met hun doelen en voorkeuren. Traditioneel werden keuzehulpen voor patiënten buiten het 
consult (voor of na) aan de patiënt gegeven. Deze keuzemiddelen vergroten aantoonbaar de 
kennis, tevredenheid, nauwkeurigheid van risicopercepties en verminderen onzekerheid 
over de genomen beslissing. Deze keuzehulpen zijn echter lang en complex. Als een 
alternatief voor deze traditionele keuzehulpen zijn kortere keuzehulpen ontwikkeld, zoals 
het Option Grid, om te gebruiken tijdens het consult of online. Het is nog steeds 
onduidelijk of de positieve resultaten die zijn geassocieerd met het gebruik van traditionele
keuzehulpen ook gelden voor de keuzehulpen die tijdens het consult of online worden 
ingezet. We weten ook weinig over de gevolgen van online keuzehulpen voor patiënten die 
deze keuzehulpen spontaan gebruiken tijdens het zoeken naar informatie over hun 
aandoening op internet. Tenslotte is onderzoek nodig om de belemmerende en 
bevorderende factoren beter te begrijpen voor het implementeren van keuzehulpen voor 
patiënten in verschillende klinische contexten in de echte wereld. 
Hoofdstuk 2 
Een meta-analyse van 23 keuzehulpen voor de patiënt laat zien dat deze hulpmiddelen de 
onzekerheid over de genomen beslissing verminderen en de kennis, tevredenheid en mate 
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van gedeelde besluitvorming verhogen (op basis van op beoordeelde observaties van 
consulten), zonder de duur van het consult aanzienlijk te verlengen. De resultaten van de 
narratieve synthese van 30 niet-gerandomiseerde studies naar keuzehulpen voor patiënten 
laat zien dat deze instrumenten vanuit het perspectief van de patiënt de kennis en het 
bewustzijn van de behandelingsopties verbeteren, wat de communicatie met hun arts 
vergemakkelijkt. Artsen waren over het algemeen van mening dat keuzehulpen voor 
patiënten tijdens het consult heel nuttig zijn voor het structureren en faciliteren van 
gesprekken, op een manier die consistent is met de principes van gedeelde besluitvorming. 
De implementatie ervan is echter uitdagend om drie hoofdredenen: ervaren gebrek aan tijd, 
gebrek aan training over hoe deze keuzehulpen in de praktijk werken en oneens zijn met de 
inhoud of het formaat die mogelijk onverenigbaar is met patiëntenpopulaties met een 
lagere gezondheidsvaardigheden. Implementatie van keuzehulpen voor patiënten tijdens 
het consult kan haalbaar zijn, mits artsen akkoord gaan met het gebruik ervan om de 
gezondheidszorg te verbeteren, het klinische team het eens is over de mechanismen om de 
keuzehulpen aan patiënten aan te bieden, en er is een kritisch beoordelingsproces om 
belemmeringen tijdig te identificeren en aan te pakken. Over het algemeen worden 
ondanks de belemmeringen voor de implementatie ervan, de keuzehulpen door patiënten 
en clinici als nuttig beschouwd voor het structureren van klinische gesprekken, verhogen 
ze gedeelde besluitvorming, patiëntkennis en -tevredenheid, en verlagen ze de scores voor 
onzekerheid over de genomen beslissing. 
Hoofdstuk 3 
Een cross-sectionele analyse van 626 gebruikers van online, interactieve Option Grid 
keuzehulpen werd uitgevoerd om te bepalen of de voorkeursoptie voor een behandeling of 
screening verschoof nadat gebruikers nieuwe informatie kregen. Na het bekijken van de 
risico-informatie die was ingebed in de keuzehulpen verschoof de voorkeur naar de meer 
risicomijdende behandeling of screeningoptie. Analyse van de vijf meest gebruikte 
interactieve keuzehulpen - (i) vruchtwaterpunctietest: ja of nee?; ii) angina: 
behandelingsopties; iii) borstkanker: chirurgische opties; iv) Prostaat Specifiek Antigeen 
(PSA)-test: ja of nee?; v) statines voor het risico op hart- en vaatziekten: ja of nee? - gaf 
aan dat de laatste drie keuzehulpen de voorkeuren van de gebruikers aanzienlijk 
verschoven naar de meer conservatieve behandeling of screeningoptie. De keuzehulpen 
voor angina en vruchtwaterpunctie waren niet geassocieerd met de verandering van 
keuzevoorkeur. Antwoorden op veelgestelde vragen met risicogegevens beïnvloedden de 
voorkeur. Bijvoorbeeld informatie over het weefselgebied dat zal worden verwijderd met 
borstbesparende en borstamputatie behandelingsopties, de waarschijnlijkheid van 
radiotherapie of lymfeklierverwijdering, en de noodzaak van chemotherapie waren actieve 
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ingrediënten binnen de interactieve borstkanker Option Grid, geassocieerd met een 
verschuiving in de voorkeursbehandeling. Informatie over wat de PSA-test inhoudt, het 
belang van een verhoogd PSA-niveau en de risico's die gepaard gaan met een 
prostaatbiopsie, waren informatie-elementen die verband hielden met de verschuiving in de 
keuzevoorkeur onder gebruikers van het PSA Option Grid. Gebruikers van de interactieve 
statines Option Grid zagen hun voorkeuren aanzienlijk verschuiven naar toenemende 
niveaus van fysieke activiteit toen ze informatie zagen over de mate waarin de 
behandelingsoptie het risico zou verminderen om andere gezondheidsproblemen te krijgen, 
en de tijd die ze de behandeling zouden moeten ondergaan. Risico-informatie verschuift 
niet alleen de behandeling of screeningvoorkeur, maar het werd ook beoordeeld als de 
meest gewaardeerde informatie in alle onderzochte Option Grids. Samenvattend kan 
gesteld worden dat de risico-informatie die is ingebed in de online, interactieve 
keuzehulpen van de Option Grid significant de voorkeur verschuift naar een meer 
risicomijdende behandeling of screeningoptie voor drie van de vijf meest gebruikte 
hulpmiddelen. 
Hoofdstuk 4 
Om te bepalen welke informatie bijdraagt aan het verschuiven van voorkeursopties, zoals 
aangetoond in Hoofdstuk 3, zijn data geanalyseerd van 164 gebruikers van de online, 
interactieve prostaatspecifieke antigeen (PSA) Option Grid nader geanalyseerd. Tevens is 
gekeken wat de invloed van de informatie was op het kennisniveau over de PSA test en 
hoe zeker men was over de gemaakte keuze. De online, interactieve PSA Option Grid 
keuzehulp voor patiënten stuurde de gebruikersvoorkeur aanzienlijk naar de risicomijdende 
screeningoptie (m.a.w. afzien van het laten uitvoeren van de test), verhoogde het 
kennisniveau over de test en verminderde beslissingsonzekerheid. Drie van de tien meest 
gestelde vragen over de PSA-test in de keuzehulp waren geassocieerd met deze 
voorkeursverschuiving: (i) de PSA-test is een bloedtest die het antigeenniveau uit de 
prostaat meet; (ii) het feit dat 30% van mannen met een hoog PSA-niveau prostaatkanker 
heeft, maar dat ontsteking en infectie ook PSA-niveaus kunnen verhogen; en (iii) het feit 
dat het niet mogelijk is om te weten of een kanker agressief is met de PSA-test alleen (een 
hoog PSA-niveau betekent dat men meer testen zoals biopsieën nodig zou hebben, en 
biopsieën dragen risico's). De interactieve PSA Option Grid verhoogde het kennisniveau 
van de gebruikers over de screeningstest aanzienlijk en verminderde het 
beslissingsonzekerheid. Kortom, het online, interactieve PSA Option Grid verhoogde 
gebruikerskennis en verminderde de onzekerheid over de genomen beslissing, en de risico-
informatie verlegde de voorkeur naar het niet doen van de test. 
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Hoofdstuk 5 
Twintig mannen, de helft met lage gezondheidsvaardigheden, meldden zich vrijwillig aan 
om de online, interactieve prostaatspecifieke antigeen (PSA) Option Grid te testen. De 
mannen werd gevraagd om 'hardop te denken' toen ze door het PSA Option Grid gingen en 
werden vervolgens een reeks vragen gesteld op basis van het Morville Framework (vragen 
over de bruikbaarheid (inclusief ontwerp en navigatie); bruikbaarheid (inclusief vragen 
over inhoud); wenselijkheid (positieve of negatieve kenmerken), waarde en 
geloofwaardigheid van informatie). De mannen gaven aan dat (1) de keuzehulp nuttig was, 
ondanks de uitdagingen die mensen met beperkte gezondheidsvaardigheden hadden om 
met de keuzehulp om te gaan; (2) de informatie acceptabel was, met de nadruk op het 
toevoegen van meer risico-informatie geassocieerd met leeftijd en familiegeschiedenis; en 
(3) het mogelijk haalbaar was om te implementeren voorafgaand aan een klinisch consult. 
In totaal hadden acht mannen lage gezondheidsvaardigheden, wat hun vermogen om door 
de keuzehulp te navigeren beïnvloedde. Ze voelden zich geïntimideerd door het zelfstandig 
moeten gebruiken van een laptop en gaven de voorkeur aan het gebruik van een papieren 
keuzehulp. Het navigeren door digitale interfaces was geen probleem voor de twaalf andere 
mannen die het Option Grid hadden getest. Ongeacht het niveau van 
gezondheidsvaardigheden, gaven gebruikers aan dat ze behoefte hadden aan veranderingen 
met betrekking tot de lay-out (dat wil zeggen het verplaatsen van de pictogramreeks) en de 
organisatie van de informatie voor elke veelgestelde vraag van de interactieve keuzehulp. 
De risico-informatie die door het Option Grid wordt geboden, bleek zeer waardevol, in de 
hoop in een toekomstige versie van de keuzehulp de inhoud is afgestemd op hun specifieke 
kenmerken, zoals leeftijd en familiegeschiedenis. Het PSA Option Grid was ook een 
geloofwaardige bron van informatie en gebruikers hadden het voornemen om dit 
hulpmiddel voorafgaand aan de klinische ontmoeting te gebruiken om een betere discussie 
met hun arts mogelijk te maken. Uiteindelijk was het interactieve PSA Option Grid alleen 
bruikbaar voor mensen met een hoger niveau van gezondheidsvaardigheden, wat het 
belang benadrukt van user centered design bij het ontwikkelen van online keuzehulpen, om 
ze ook bruikbaar en toegankelijk te maken voor mannen met een lager opleidingsniveau of 
lagere gezondheidsvaardigheden. 
Hoofdstuk 6 
De implementatie van Option Grid keuzehulpen werd onderzocht in een pre-post studie bij 
drie klinieken in Warschau (Polen), met 13 deelnemende artsen. De artsen gebruikten, na 
een korte training, gedurende vier maanden drie Option Grid keuzehulpen. Voor de 
evaluatie vulden 2048 patiënten in de voormeting en 1889 patiënten in de nameting de 
collaboRATE in – een gevalideerd meetinstrument met drie items die de patiënt scoort om 
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te beoordelen hoe goed artsen gedeelde besluitvorming toepassen. Na de interventieperiode 
lieten vijf van de 13 artsen een aanzienlijke toename zien in de collaboRATE score, 
vergeleken met de situatie waarin geen keuzehulpen werden gebruikt. Deze vijf artsen 
waren allemaal werkzaam in dezelfde kliniek. Een korte vragenlijst, verspreid onder 
deelnemende artsen, waarin de houding van de arts werd beoordeeld, liet zien dat oudere, 
ervaren artsen zich zorgen maakten over de tijdsdruk en ze waren het oneens met een deel 
van de inhoud van de keuzehulp. Gebrek aan training over het gebruik van Option Grid 
keuzehulpen in de praktijk werd ook aangehaald als een barrière in een interview met de 
projectmanager van de studie. Voor zover kan worden vastgesteld, was dit de eerste keer 
dat keuzehulpen voor patiënten werden geïmplementeerd in een aantal klinieken in een 
Oost-Europees land als Polen, en we kunnen op basis van onze resultaten concluderen dat 
er nader onderzoek nodig is naar de rol van verwachtingen van patiënten en artsen en de 
cultuur op de effecten van de implementatie van keuzehulpen. 
Hoofdstuk 7 
Twee Amerikaanse gezondheidsorganisaties (CapitalCare en HealthPartners) 
implementeerden Option Grid keuzehulpen in hun reguliere zorg. Het implementatieproces 
werd geëvalueerd aan de hand van interviews met 23 professionals, werkzaam op 
verschillende niveaus binnen beide organisaties. De analyse was gebaseerd op de 
Normalisatie Proces Theorie (NPT), die helpt de implementatie van interventies in de 
workflow te beoordelen. Het onderzoek liet zien dat de routineuze adoptie door Option 
Grid keuzehulpen wordt beïnvloed door de motivatie om ze in de praktijk te gebruiken, het 
opleidingsniveau over gedeelde besluitvorming en hoe de keuzehulpen te operationaliseren 
en de acties die door verschillende leden van het klinische team zijn ondernomen. Wat 
betreft het coherentiemechanisme van NPT, was de implementatie van Option Grid bij 
CapitalCare extern gemotiveerd - de organisatie wilde profiteren van financiële prikkels 
die door een nieuw initiatief werden geboden. Het gebruik van de Option Grid was een 
middel om een doel te bereiken (een werkbare oplossing) om financiële compensatie te 
ontvangen bij CapitalCare, terwijl er bij HealthPartners een ‘kampioen’-clinicus was die 
collega's motiveerde om deze keuzehulpen in de praktijk te gebruiken. De collectieve actie 
die door verpleegkundigen op beide locaties werd ondernomen om de keuzehulpen aan 
patiënten aan te bieden voorafgaand aan het consult, verlichtte de last voor artsen die de 
geschiktheid van de patiënt niet hoefden te beoordelen of de geschikte tool om in de 
praktijk te gebruiken. Artsen op beide locaties zagen uiteindelijk het nut van deze 
keuzehulpen ondanks het gebrek aan bewustzijn of begrip van gedeelde besluitvorming. 
De kritische beoordeling gaf aan dat sommige artsen de verbeterde communicatie met de 
patiënt op prijs stelden toen de keuzehulp tijdens het consult aanwezig was. Routineuze 
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adoptie van keuzehulpen voor patiënten is mogelijk, mits er overeenstemming bestaat over 
de noodzaak om ze te gebruiken, dat de teamleden bereid zijn samen te werken om ervoor 
te zorgen dat dergelijke hulpmiddelen kunnen worden geïntegreerd in bestaande 
werkpatronen en worden gezien als een positieve algemene bijdrage aan het werk dat moet 
worden uitgevoerd. 
Hoofdstuk 8: Algemene discussie 
De in dit proefschrift gepresenteerde onderzoeken laten zien dat Option Grid keuzehulpen 
voor patiënten de kennis, de tevredenheid en de betrokkenheid van de patiënt verhogen, de 
onzekerheid over de genomen beslissing vermindert en het gebruik ervan de duur van 
klinische ontmoetingen niet significant verlengt. Het spontane en onafhankelijke gebruik 
van online keuzehulpen door patiënten verlegt de voorkeur naar conservatievere 
behandelingen of screeningopties, en vergroot tevens de kennis en vermindert het de 
onzekerheid over de genomen beslissing. Gebruikers met hoge en lage 
gezondheidsvaardigheden beschouwden de evidence-based risico-informatie die is ingebed 
in de keuzehulpen als nuttig, ongeacht de bruikbaarheidsproblemen voor mensen met een 
lagere gezondheidsvaardigheden. Patiënten en artsen vinden het gebruik van keuzehulpen 
tijdens consulten nuttig bij het structureren van het gesprek en het vergroten van het 
bewustzijn over de behandelingsopties. Ondanks de positieve resultaten van patiënten die 
worden geassocieerd met het gebruik van keuzehulpen voor het nemen van beslissingen 
(online of op papier), staat hun implementatie voor aanzienlijke obstakels in de echte 
klinische setting. Uit ons onderzoek bleek dat, vanuit het perspectief van de arts, 
tijdsbeperkingen, oneens zijn met de inhoud van de keuzehulpen en gebrek aan training 
over hoe deze in de praktijk te gebruiken, belangrijke belemmeringen zijn voor de 
implementatie. Het wordt aanbevolen dat organisaties gedeelde besluitvorming op 
beleidsniveau bevorderen en samenwerken met klinische belanghebbenden om strategieën 
te ontwikkelen voor het implementeren van keuzehulpen in de workflow van de kliniek. Dit 
omvat het bieden van voorlichting aan zorgprofessionals over het doel van gedeelde 
besluitvorming en over hoe keuzehulpen voor patiënten de toepassing ervan kunnen 
bevorderen.
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